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Abstract 
 
Introduction 
It is expected that the number of patients with cardiac implantable electronic devices 
(CIEDs) presenting to Radiation Oncology departments per year will increase. This 
is due to the increasing longevity of the human lifespan, increasing number of 
implantations of CIEDs, the aim to increase the use of radiation therapy for cancer 
patients in Australia and the multiple overlapping risk factors for both cardiac 
disease and cancer. 
 
The possibility of CIED malfunction during radiation therapy is poorly understood, 
and there is a need for further investigation into the efficacy of current departmental 
protocols. No structured evidence based guidelines have been published since 1994, 
which are now severely outdated due to advances in both radiation therapy and 
CIED technology design. Previous literature has focussed on examining the 
accumulated dose to CIEDs, with recent studies suggesting a correlation between 
high photon energy treatments and severe soft errors for implantable cardioverter 
defibrillators (ICDs). These assumptions are often based on non-clinical radiation 
therapy regimes and have not been compared to a control group to assess the real 
risk to the patient of failures. These studies have also not assessed the effect of 
accumulated dose to the CIED leads or heart, treatment fractionation, intent or 
technique, or the use of a magnet in ICD treatments. Research into the risk of 
pacemaker (PM) failure during radiation therapy has been limited in the last decade. 
This research has been developed to fill vital gaps in the literature, particularly aimed 
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at roles of a radiation therapy department in reducing the risk to CIED patients 
undergoing treatment.  
 
Method 
The overall aim of this research was to assess the risks associated with radiation 
therapy when treating CIED patients, and whether these may be managed by the use 
of a treatment protocol. This research posed six research questions: (1) what is the 
risk of severe soft errors during high energy radiation therapy (18MV) for patients 
with ICDs; (2) is an increased rate of failure observed in both PMs and ICDs during 
radiation therapy at high photon energy when compared to a lower photon energy 
(6MV); (3) does removing the CIED from the direct treatment beam eliminate the 
risk associated with radiation therapy at both high and low photon energies; (4) does 
the accumulated dose to the CIED affect the risk of failure; (5) do other radiation 
therapy considerations, such as treatment technique, previous treatment, treatment 
intent, and heart and lead doses affect the risk of CIED failure (6) is the risk of 
failure in both PMs and ICDs effectively managed when using a current 
departmental protocol for treatment of CIED patients based on current literature.   
 
Results  
The results of the research questions concluded that: (1) severe soft errors may be 
associated with up to a 22.2% failure rate of implantable cardioverter defibrillators 
(ICDs) treated at 18MV in a clinical environment when not exposed to the direct 
beam; when exposed to the direct radiation beam the risk is increased; (2) The 
severity of errors increased at 18MV when compared to 6MV in both PMs and ICDs; 
The use of a magnet during ICD treatments appeared to limit severe soft errors; (3) 
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Removal of the CIED from the treatment field did not eliminate the risk associated 
with both low and high photon energy treatment, however did decrease the risk of 
failure; this risk was greater in ICDs than PMs; (4) A direct irradiation study of 
donated CIEDs suggested that failures were not a dose driven effect, with failures 
occurring at doses equivalent to scatter radiation; (5) Maximum heart doses greater 
than 20Gy were associated with changes in PMs that may indicate early failure; 
doses greater than 40Gy were associated with 87.5% of PM leads recording changes 
that could result in the loss of pacing capture; previous treatment, treatment 
technique and treatment intent did not affect the risk of failure; (6) The 
implementation of management protocols during radiation therapy proved to be 
effective however did not eliminate the risk of failures.  
 
Conclusion 
CIED patients may be safely treated using radiation therapy when there is a 
departmental protocol followed with adequate cardiac monitoring during and after 
treatment. This research suggests limiting the treatment energy used in both ICD and 
PM irradiation to less than 10MV, and reducing the maximum accumulated heart 
dose to 40Gy.  The routine use of a magnet during ICD treatments should be 
considered in consultation with a cardiologist. A number of radiation therapy 
treatment recommendations are included as a vital update to current protocols.  
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Chapter One: Introduction 
 
It is expected that the number of patients with cardiac implantable electronic devices 
(CIEDs) presenting to Radiation Oncology departments will increase due to the 
multiple overlapping risk factors shared between cancer and cardiovascular disease 
(CVD), such as age, obesity, smoking, alcohol consumption and physical inactivity. 
Between 2010 and 2056 it is expected that the percentage of the Australian 
population over 65 will increase from 13.6% to 25% (AIHW, 2014b). In Australia, 
new pacemaker (PM) and implantable cardioverter defibrillator (ICD) implantations 
have increased from 1997 to 2009, by 95.5% and 691.8% respectively (Mond, 2001; 
Mond & Proclemer, 2011).  
 
The possibility of CIED malfunction during radiation therapy is poorly understood.  
There is evidence to suggest that exposure of PMs and ICDs to radiation therapy 
may cause temporary or permanent malfunction. There is limited data available on 
the risk of malfunction of PMs and ICDs exposed to radiation therapy. What data is 
available is based on limited information, non-clinical dose regimes and individual 
case studies, and lacks active involvement from cardiac device companies. Failures 
that have been observed have not been compared to a control population. These 
studies have also not assessed the effect of accumulated dose to the CIED leads or 
heart, treatment fractionation, intent or technique, or the use of a magnet in ICD 
treatments. 
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1.1 Aim  
 
 
The overall aim of this research was to assess the risks associated with radiation 
therapy when treating CIED patients, and whether these may be managed by the use 
of a treatment protocol. The following questions were devised to investigate this 
aim: 
1. What is the risk of severe soft errors during high energy radiation therapy 
(18MV) for patients with ICDs? 
2. Is an increased rate of failure observed in both PMs and ICDs during 
radiation therapy at high photon energy when compared to a lower photon 
energy (6MV)? 
3. Does removing the CIED from the direct treatment beam eliminate the risk 
associated with radiation therapy at both high and low photon energies? 
4. Does the accumulated dose to the CIED affect the risk of failure? 
5. Do other radiation therapy considerations, such as treatment technique, 
previous treatment, treatment intent, and heart and lead doses affect the risk 
of CIED failure? 
6. Is the risk of failure in both PMs and ICDs effectively managed when using a 
current departmental protocol for treatment of CIED patients based on 
current literature? 
 
  
-3- 
1.2 Scope of Research 
 
This research focused on the effect of high photon energy external beam radiation 
therapy (EBRT) in Australia on CIEDs. Betatron, Cobalt-60, Neutron and Proton 
therapy are not currently practiced in Australia; these modalities were beyond the 
scope of the research. As no centre that participated in this research had access to 
flattening filter free (FFF) technology or tomotherapy equipment, these were also 
beyond the scope of this research. Areas of further research in this topic are 
highlighted in future recommendations in later chapters of the thesis.  
 
1.3 Thesis Design and Overview 
 
The research was conducted in three main steps to answer the research questions 
presented. Figure 1.1 presents a flow chart outlining each step of this research.  
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Figure 1.1: Flowchart of research study design 
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Background 
Chapter Two is a review of the technology and principles relevant to CIEDs and 
radiation therapy.  
 
Literature Review 
Chapter Three is a literature review of research relevant to irradiation of CIEDs 
during radiation therapy. 
 
Research Study One: Power on Resets - ICDs 
Study one of the research, presented in Chapter Four, involved identification of ICD 
patients who had suffered a power on reset of their device during radiation therapy 
treatments in three Sydney hospitals between 2008 and 2011. The types of 
treatments delivered during these events were assessed, and common risk factors 
identified. This study aimed to answer research question one.  
 
Research Study Two (a) and (b): Irradiation of CIEDs using direct (a) and indirect 
(b) irradiation; 6MV vs. 18MV 
The second study of the research, presented in Chapters Five and Six, exposed 
twenty CIEDs of various manufacturers and models to both direct (15 CIEDS, 
Chapter Five) and indirect or scatter (five ICDs, Chapter Six) external beam 
radiation therapy (EBRT). A comparison of the effects of high (18MV) and low 
(6MV) photon energy was made. Comparison of dose rate, through direct and 
indirect exposure, as well as accumulated dose to the CIEDs was also made. The 
sensitivity of PM and ICDs to radiation therapy was also compared. These studies 
aimed to investigate research questions two, three and four.  
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Research Study Three (a) and (b): Case control observational studies of CIEDs 
undergoing radiation therapy 
The third research study, presented in Chapters Seven and Eight, observed the effect 
of radiation therapy on both PM (study 3a, Chapter Seven) and ICD (study 3b, 
Chapter Eight) patients treated at the Royal Prince Alfred Hospital, Camperdown, 
between 2005 and 2012. All patients were treated using an evidence based protocol 
employed at the centre at the beginning of the study. These patients were compared 
to a control group who had not had previous exposure to radiation therapy. A 
comparison of CIED battery life, signal amplitude, lead impedance, capture 
threshold, output, lead type and notable events were made between the groups. The 
effect of radiation therapy exposure, including treatment energy, maximum dose to 
the CIED, leads and heart, treatment intent, technique, and previous radiation 
therapy treatments, were assessed. The effect of magnet use during treatment for 
ICDs was also assessed.  These studies aimed to investigate research questions one, 
two, four, five and six in a clinical environment.  
 
Summary and recommendations 
Chapter Nine presents a summary of the findings from the three research studies to 
investigate the research aims. Future research recommendations that arose from this 
study are also discussed. A list of treatment recommendations for use within 
radiation oncology departments is also presented in this chapter.  
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Chapter Two: Background 
 
2.1 Introduction 
 
It is likely that the number of patients with implanted cardiac pacemakers (PMs) and 
cardioverter defibrillators (ICD) presenting to radiation oncology departments is on 
the rise. This is due to the rising incidence of cancer in Australia (AIHW, 2012), 
increasing cardiac device implantation rates (Mond & Proclemer, 2011), the 
increasing longevity of the human lifespan (Australian Bureau of Statistics, 2013a) 
and overlapping risk factors between cardiovascular disease (CVD) and cancer. 
There is increasing evidence to suggest that exposure of PMs and ICDs to radiation 
may cause temporary or permanent device malfunction (Hurkmans et al., 2012), 
however, there is limited data available on the real risk faced by patients with PMs 
and ICDs who are required to undergo radiation therapy. What data is available is 
based on limited information, non-clinical dose regimes and individual case studies, 
and lacks active involvement from cardiac device companies.  
 
This chapter will present a review of the technology and principles of CIEDs and 
radiation therapy relevant to this thesis. 
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2.2 Ageing Population 
 
Like most advanced countries, the median age of the Australian population is 
increasing due to sustained low fertility, at 1.9 births  per female population 
compared to world fertility rate of 2.5 births per female population (Australian 
Bureau of Statistics, 2011), and increasing life expectancy. Between 1990 and 2012, 
the median population age has increased from 32.1 years to 37.3 years (Australian 
Bureau of Statistics, 2013b). Australian life expectancy currently sits high in world 
standards, at approximately 79 years for males and 84 years for females, 6th and 7th 
respectively (AIHW, 2014b).  In 2010, 13.6% of the population was aged 65 years or 
over. By 2015 this is predicted to increase to 16.4%, and to approximately 25% by 
2056 (Australian Bureau of Statistics, 2013a). An ageing population has a significant 
impact on incidence of cancer and cardiovascular disease (CVD). The AIHW has 
recognised ageing as the greatest risk factor for CVD (AIHW, 2011), and in 2007, 
68% of all cancers (excluding non-reportable cancers including basal and squamous 
cell cancers) were diagnosed in people aged 60 years and older (AIHW, 2010).  
 
2.3 Cardiovascular Disease (CVD) 
 
CVD is defined as any disease or condition encompassing the heart or blood vessels. 
These may include coronary heart disease, cardiomyopathy, stroke, hypertension, 
and cardiac arrhythmias. CVD is the leading cause of death in Australia for both men 
and women, accounting for approximately 32% of all national deaths in 2010. It is 
considered to be Australia’s most costly disease in terms of both health expenditure 
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and cost of lives. The burden of disease caused by CVD in terms of disability and 
premature death is second only to cancer (AIHW, 2011). 
 
Modifiable risk factors for CVD include high blood pressure, high cholesterol, 
physical inactivity, obesity, smoking, alcohol consumption and poor diet. Non-
modifiable risk factors include age, deemed by the World Health Organisation 
(WHO) as the highest non-modifiable risk factor for CVD, along with sex, family 
history of CVD and ethnicity (World Health Organisation, 2011). 
 
2.3.1 Heart anatomy and function 
 
The heart consists of four chambers: right and left atria (RA and LA) and right and 
left ventricles (RV and LV). 
 
Figure 2.1: Anatomical view of the heart and conduction system 
(Washington Heart Rhythm Association, 2014). 
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The superior vena cava (SVC) and the inferior vena cava (IVC) carry blood from the 
body to the RA. Four pulmonary veins carry the blood from the lungs to the LA. The 
aorta and the pulmonary trunk carry the blood from the LV to the body and RV to 
the lungs respectively. The sinoatrial (SA) node is located in the superior aspect of 
the RA, near the junction with the SVC. The SA node is the hearts natural PM; as it 
depolarises it sends an electrical signal to the atria, causing both atria to contract. 
The atrioventricular node (AV) is the electrical connection between the atria and the 
ventricles. It is located in the lower portion of the RA, delaying the cardiac impulse 
from the SA node to allow atria to contract and empty their contents. The signal is 
then relayed rapidly through the His-Purkinje system to the ventricles, allowing them 
to contract almost simultaneously. This may be graphically represented on an 
electrocardiogram (ECG). An ECG is a relatively cheap and reproducible test that is 
available in most medical centres (Davies & Scott, 2013). ECGs may assist in the 
diagnosis of cardiac disease and structural issues through the visualisation of the 
QRS complex shown in figure 2.2, which indicates ventricular contraction of the 
heart. A detailed definition of the QRS complex is given in table 2.1, showing how 
the electrical activity of the heart is related to function. This pattern may be severely 
disrupted in patients with CVD, as described in the following section. 
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Figure 2.2: QRS complex as shown on an ECG (Ashley & Niebauer, 2004) 
 
Table 2.1: Definition of the QRS complex represented in figure 2.2. (Davies 
& Scott, 2013) 
ECG  Definition 
P wave Represents the electrical activation of both atria (atrial depolarisation); 
the first half of the P wave represents the right atrial depolarisation; 
the second half represents the left atrial depolarisation. 
PR 
interval 
The time taken for the electrical signal to travel from the atrial 
depolarisation to travel the AV node and through the His-Purkinje 
system.  
QRS 
complex 
Represents the depolarisation of the ventricles. Formed by three waves 
(Q, R and S) 
Q wave Depolarization of the interventricular septum 
R wave Depolarization of the main mass of the ventricles 
S wave Final depolarization of the ventricles 
ST 
segment 
Time between the final depolarisation and repolarisation of the 
ventricles. 
T wave Ventricular repolarisation (atrial repolarisation obscured by QRS) 
QT 
interval 
Time between the depolarisation and repolarisation of the ventricles. 
U wave Not always visualised on the ECG; may represent either repolarisation 
of the ventricular septum or Perkinje fibres. 
Key: ECG = Electrocardiogram; AV = atrial-ventricular 
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2.3.2 Use of CIEDs for treatment of CVD 
 
CVD may be treated by medication, medical procedures and dietary and lifestyle 
changes. Permanent PM and ICD implantations are used to treat cardiac arrhythmias, 
where the heart beats either too fast (tachycardia), too slow (bradycardia) or 
irregularly. 
 
Common indications for artificial pacing include, but are not limited to: 
• Chronic second or third degree AV block, also known as heart block.  This 
occurs when there is a failure of electrical conduction through the AV node 
and/or the His-Purkinje system, visualised on an ECG through a delayed or 
missing QRS. 
• Chronic atrial or ventricular fibrillation (AF or VF). In chronic AF or VF, 
the chambers of the heart beat chaotically, visualised on an ECG by irregular 
QRS intervals. 
• Chronic atrial or ventricular tachycardia (AT or VT). In chronic AT or VT, 
the chambers of the heart beat rapidly, visualised on an ECG by short QRS 
intervals and missing P waves. 
• Sinus node disease (sick sinus syndrome) with symptomatic bradycardia. In 
this instance the heart beats too slowly, visualised on an ECG through 
lengthened RR intervals and a heart rate of <50bpm. 
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Artificial pacing is indicated in patients to alleviate symptoms such as fatigue, 
dizziness and fainting,  and prevent subsequent morbidity and mortality resulting 
from arrhythmias (Brignole et al., 2014). 
 
 2.4 Cardiac implantable electronic devices  
 
Cardiac implantable electronic devices (CIEDs) consist of both artificial PMs and 
ICDs. There are multiple cardiac device manufacturers, including but not limited to 
Biotronik (Berlin, Germany), Boston Scientific/Guidant (Marlborough, MA), 
Medtronic (Minneapolis, MN), St Jude Medical (St Paul, MN) and Sorin (Milan, 
Italy). Each company has multiple devices, with hundreds of different PM and ICD 
models in circulation at any point in time. An example of a Biotronik PM and ICD 
are shown in figure 2.3. 
 
Figure 2.3: A Biotronik Evia Pacemaker (left) and Biotronik Lumax ICD 
(right).  
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2.4.1 Artificial Pacemakers 
 
An artificial PM is an electrical device which is able to pace the heart when it is no 
longer able to maintain a nominal heart rate due to damage in the SA or AV node. 
This damage causes bradycardia or tachycardia (Epstein et al., 2008). The first 
internal device was implanted in 1959, made possible only by the invention of new 
small silicone transistors in 1956. These devices were short-lived and unreliable until 
the invention of the lithium ion battery in the 1970s (Sundar, Symonds, & Deehan, 
2005). 
 
A modern PM is hermetically sealed, and comprises of a generator approximately 
4cm – 5cm wide and 0.8cm thick. It incorporates both a lithium battery and 
computer circuitry, and one or more leads, encompassing electrodes which are 
positioned against the heart muscle. PMs may be either single or dual chamber; a 
single chamber PM has a single lead which is placed in either the atrium or ventricle 
of the heart, while a dual chamber PM has both an atrial and ventricular lead. Dual 
chamber pacing has been shown to have greater advantages than single chamber 
devices, as they resemble clinical pacing more closely by maintaining AV synchrony 
(Dretzke et al., 2004), however there is a higher complication rate associated with 
dual chamber PMs due to the presence of the additional leads (Ellenbogen & Wood, 
2005). There are also significant cost reductions associated with single lead devices 
(Wiegand et al., 2001). A third lead may be incorporated into the left ventricle as a 
part of a cardiac resynchronization PM (CRT-P). In CRT-Ps, an electrical signal is 
sent to both ventricles to help them beat together in a more synchronous pattern, and 
may include anti-tachycardia pacing like ICDs (see section 2.4.2) (Medtronic, 2014).  
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Due to the multiple configurations and models of PMs available, a lettered code for 
describing the mode of pacing delivery has been devised by the North American 
Society of Pacing and Electrophysiology (NASPE) and British Pacing and 
Electrophysiology Group (BPEG), shown in table 2.2 (Bernstein et al., 2002).   The 
columns in the table refer to: 
I - number of heart chambers paced; A PM will send an electrical pulse to the 
appropriate chamber when the heart rhythm is sensed to be too slow or has 
been interrupted 
 
II – number of heart chambers sensed: The PM will also sense the chamber 
that when a normal heart rhythm is detected an electrical pulse will not be 
delivered 
 
III – Response to sensing: The response to detection in heart rhythm is set to 
either trigger pacing, inhibit pacing or no response. 
 
IV – Ability for rate modulation: Rate modulation allows the PM to alter the 
heart rate to meet patient needs, such as in physical activity. 
 
V – Multisite pacing: Multisite pacing allows for more than one site within a 
heart chamber to be paced.     
Table 2.2: The revised NASPE/BPEG generic code for anti-bradycardia 
pacing 2002 (Bernstein et al., 2002) 
I II III IV V 
Chamber(s) 
paced 
Chamber(s) 
sensed 
Response to 
Sensing 
Rate 
Modulation 
Multisite 
Pacing 
A = Atrium O = 
None/when 
PM function is 
not dependant 
on sensing 
electrical 
signal 
O = None/no 
response to 
underlying 
electrical 
signal 
O = None O = None 
V = Ventricle A = Atrium T = Triggering 
of PM 
function 
R = Rate 
Modulation 
A = Atrium 
D = Dual 
(A+V) 
V = Ventricle I = Inhibition 
of pacing 
function 
 V = Ventricle 
 D = Dual 
(A+V) 
D = Dual 
(T+I) 
 D = Dual 
(A+V) 
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For example, a simple single chamber PM may be programmed to VVI, where the 
right ventricle is both paced (I) and sensed (II), with inhibition of pacing function 
when a rate is sensed (III). In VVIR, the above is true with the added ability for the 
device to modulate the pacing rate (IV). A PM battery will last between five to ten 
years, depending on mode selected and degree in which it paces the heart, as well as 
frequency of monitoring and other device specific parameters. When the battery is 
depleted the generator is replaced, however the leads may be reused. Unused leads 
may be capped and left in the patient’s body. 
 
2.4.2 Implantable Cardioverter Defibrillators (ICDs) 
 
An ICD is able to perform the same functions as a PM, with the added ability to 
deliver shock therapy to return the heart back into normal rhythm when ventricular 
fibrillation (VF) or ventricular tachycardia (VT) occurs by simultaneously 
depolarizing the entire myocardium and interrupting the chaotic heart rhythm 
patterns (Bradley & Normand, 1998). Supraventricular tachycardia (SVT) occurs 
when fast heart rhythms occur above the ventricles, including atrial flutters and atrial 
fibrillation (AF). SVT is not life threatening, and in some cases may be chronic. 
Shocks are not designed to treat SVT, but may be triggered if inappropriate sensing 
rates are programmed (see figure 2.4). 
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Figure 2.4: Example of an SVT (AF) (Boston Scientific, 2014a). 
 
VT occurs when one point in the ventricle signals too fast, leading to heart rates of 
150 to 250 beats per minute (bpm; shown in figure 2.5(a). VF occurs when multiple 
sites within the ventricle attempt to signal the heart to beat, causing the heart to 
quiver rather than beat and leading to heart rates up to or over 300bpm (shown in 
figure 2.5(b). In both cases, the heart fails to pump enough blood and oxygen 
through the body, leading to dizziness, blackouts, and in extreme cases, sudden 
cardiac death. 
(a)  (b)  
Figure 2.5: Examples of (a) VT (b) VF (Boston Scientific, 2014b).  
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An ICD is implanted when a patient is at risk of sudden death due to VF or VT. 
ICDs are larger than PMs, approximately 5-7cm wide and 1.5cm thick. The earliest 
recorded use in humans was in 1980, 21 years after the invention of the PM, and 
required a thoracotomy for implantation until the late 1980’s (Deyell, Tung, & 
Ignaszewski, 2010). An ICD will last between three to eight years, depending on 
factors such as pacing frequency, mode, monitoring frequency and number of 
therapeutic shocks delivered.  
 
Shock therapy (defibrillation) is delivered through one (single coil) or two (dual coil)  
additional high voltage leads. Single coil high voltage leads allow the current to pass 
from the right ventricle to the generator unit, also referred to as a “hot can”. Dual 
coil high voltage leads allow the current for defibrillation to be passed from one coil 
in the right ventricle and one in the SVC (Ellenbogen & Wood, 2005). Historically, 
dual coil leads are more commonly used than single coil leads, used in 85-95% of 
ICD patients. Recent studies have shown single coil leads may be as effective in 
VT/VF termination on first shock, improve extractability and reduce costs (Ellis & 
Hurt, 2012). 
 
2.4.3 Composition of CIEDs 
 
Until the late 1970s, CIEDs incorporated simple circuitry and bipolar transistors. 
These early models had limited programming capabilities, with limited susceptibility 
to radiation damage (Hildner, Linhart, & Poole, 1969; Walz, Reder, Pastore, 
Littman, & Johnson, 1975). Modern PMs and ICDs incorporate complementary 
metal oxide semiconductor (CMOS) circuitry. The introduction of CMOS circuitry 
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has increased device reliability due to the limited power dissipation compared to its 
predecessor. However, a number of authors had reported an increase in the 
sensitivity of CMOS devices to radiation therapy (Elders, Kunze-Busch, Jan 
Smeenk, & Smeets, 2013; Hurkmans et al., 2012; Makkar et al., 2012; 
Wadasadawala et al., 2011).  
 
CMOS circuitry refers to the use of complementary and symmetrical  p and n-type 
metal oxide semiconductor field effect transistors (MOSFET). The direction of the 
current flow is dependant on the impurities added to various regions of the silicon 
(Si) to create either a p-type material where a large number of ‘holes’ predominate, 
or n-type material where a larger number of electrons move freely (Hambley, 2002). 
 
A MOSFET is a (relatively) simple device capable of amplification. The terminals in 
a MOS transistor are composed of Si,  and silicon dioxide (SiO2) serves as an 
insulator between the various parts of the circuitry. They contain (Hambley, 2002): 
 Gate – electronic cuircuit that passes a pulse only when a signal is present at 
a  second input 
 
 Source 
 
 Drain – terminals connected by a channel that provide electron or hole 
carriers that flow to the other terminal to be drained if a current is present.  
 
2.4.4 Pacing Leads 
 
2.4.4.1 Unipolar and Bipolar Leads 
Pacing leads may be either unipolar or bipolar. While all electrical circuits must have 
an anode (positive pole) and a cathode (negative pole), the difference between a 
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unipolar and bipolar lead is how many of these are located on the lead itself. 
Unipolar leads contain one electrode located at the tip as the cathode and uses the 
metal casing of the CIED as the anode; bipolar leads contain two isolated electrodes 
– one distally at the tip of the lead, with a second 1-2cm proximally from the first 
electrode – to act as the anode and the cathode respectively. This is shown in figure 
2.6.  
(a)  
(b)  
Figure 2.6: (a) A unipolar lead containing one lead coil and (b) a bipolar 
lead containing an outer coil and inner lead coil (Kenny, 2005) 
 
Since a unipolar lead uses the metal casing of the CIED, the electrical circuit created 
is relatively large and may create artefact on an ECG, as well as stimulation of 
pectoral muscles. However, they are extremely reliable due to their flexibility and 
relatively small size. This is due to only one coil being required for the lead. Bipolar 
leads create relatively small electrical circuits, virtually eliminating these issues, but 
were traditionally bulkier and less flexible than unipolar leads due to number of coils 
required in a lead. However new bipolar leads have become smaller and more 
flexible, with increased reliability. Bipolar leads are also less likely to pick up 
myopotentials, a type of muscle noise that could interfere with correct pacing 
(Kenny, 2005). 
-21- 
2.4.4.2 Active and Passive Fixation of Leads 
Lead fixation may be active or passive. Active lead fixation requires a helix at the 
end of the lead to be screwed into the myocardium to provide lead stability. Passive 
fixation is easier to insert, incorporating tines that are lodged into the thickened 
muscle of the atrium or ventricle (Hayes, Asirvatham, & Friedman, 2013). Active 
fixation of leads allows for the placement of leads at any desirable location and is 
easier to remove than passive fixation leads due to the development of scar tissue 
over the latter (Ellenbogen & Wood, 2005). A comparison of the leads is shown in 
figure 2.7. 
 
Figure 2.7: (a) A passive fixation lead with tines at the tip and (b) an active 
fixation lead with helix at the end for insertion into the myocardium 
(Hayes et al., 2013) 
2.4.4.3 Left Ventricular Lead insertion and Cardiac Resynchronisation Therapy 
Cardiac resynchronisation therapy (CRT) is required when the heart has become 
damaged, associated with congestive heart failure and weakening of the heart 
muscle. This damage may result in the asynchronous pacing of the heart’s electrical 
system, In these cases, a lead is inserted into the left ventricle, allowing a CRT 
device to stimulate both the left and right ventricles simultaneously, restoring 
synchronous heart action (Shea & Sweeney, 2003). CRT devices may have the 
functions of either a PM (CRT-P) or defibrillator (CRT-D). 
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2.4.5 CIED implantation site 
 
A CIED is most commonly implanted via an endocardial technique performed under 
local anaesthetic. The CIED is generally inserted in the infra clavicular region for 
lead insertion via the cephalic, axillary or subclavian vein and the SVC. A CIED 
may be implanted in the groin via the femoral vein or in the inguinal region via the 
SVC, for patients with contraindications for pacing, such as venous obstruction, 
previous SVC lead or cavity infections, abnormal anatomy, or in paediatric cases 
(Mathur, Stables, Heaven, Ingram, & Sutton, 2001). Less commonly, an epicardial 
technique may be used, which requires surgery under general anaesthetic. Pacing 
leads are placed directly on the epicardium, and is generally used when heart surgery 
is already being performed, or when structural abnormalities prevent the use of an 
endocardial implantation technique (Ellenbogen & Wood, 2005). A comparison of 
the two techniques is shown in figure 2.8.  
 
 
Figure 2.8: Image of (a) endocardial and (b) epicardial lead insertion 
technique (Cleveland Clinic, 2015).  
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2.4.6 Australian CIED Implantation Rates 
 
Worldwide, PM and ICD implantation rates are continually increasing. Since 1997, 
quadrennial surveys on yearly implantation rates have been published by the World 
Society of Arrhythmias (WSA), formerly the International Cardiac Pacing and 
Electrophysiology Society (ICPES). From 1997 to 2009, new PM and ICD 
implantations rose by 95.5% and 691.8% respectively (Mond, 2001; Mond & 
Proclemer, 2011). New implants per million population has risen from 345 to 565 
for PMs, and 24 to 160 for ICDs. Between the 2005 and 2009 surveys, Australia was 
one of only four nations to register a decrease in PM implants per million 
population, however this was suggested to reflect the greater rise in Australia’s 
population during these years rather than a decreasing implantation trend (Mond, 
Irwin, Ector, & Proclemer, 2008; Mond & Proclemer, 2011). PM and ICD 
replacement procedures, as each cardiac device reaches its end of life, were also on 
the rise. PM insertions and replacements are more common in males (59%) than 
females (41%). Similarly ICD insertions and replacements are more common in 
males (79%) than females (21%) (AIHW, 2011). The rates of CIED implantation are 
shown in figures 2.9.  
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(a)   
(b)    
Figure 2.9: Australian (a) new and replacement CIED imlpantations 
visualised separately per year; (b) new CIED implantations per million 
population; as described in the WSA quadriennial cardiac surveys (Mond, 
2001; Mond et al., 2008; Mond, Irwin, Morillo, & Ector, 2004; Mond & 
Proclemer, 2011). 
 
2.4.7 Routine CIED checks 
 
After CIED implantation, routine cardiac device checks are undertaken every six to 
12 months to check device stability and programming features. The most commonly 
checked parameters are included in table 2.3. Analysis of these functions allows 
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cardiac technicians and oncologists to monitor the effectiveness of the CIED, as well 
as indicate any malfunctions occurring in the device.  
Table 2.3: Common CIED check parameters 
Key: V = Volts, % = percentage; BOL = Beginning of life; EOL = End of life; PM = 
pacemaker; ICD = implantable cardioverter defibrillator; ms = milliseconds; mV = 
millivolts; Ω = ohms; CIED = combined implantable electronic devices. 
 
 
Check 
Type 
Function Measurement 
Battery 
Voltage/ 
Longevity 
The remaining life of the battery. Once a 
battery is depleted the entire device must be 
replaced.  
V, % or Longevity e.g. 
BOL, EOL  
Pacing 
Percentage 
The amount that the device paces the heart. 
Each chamber may be paced between 0 and 
100%.  
% 
PM or ICD 
Dependenc
e 
Patients are deemed dependant if there is an 
absence of underlying intrinsic rhythm at 40 
bpm when the pacing functions are turned 
off. 
Dependent/Non-
Dependent 
Capture or 
Pacing 
threshold 
Minimum energy needed to pace the heart; 
measured by voltage and pulse width 
V and ms 
Signal 
Amplitude 
How much energy the device puts out 
through the leads with every pulse 
mV 
Lead 
impedance 
Measures lead integrity Ω 
High 
Voltage 
lead 
impedance 
(ICD only) 
Measures high voltage lead integrity Ω 
Sensitivity/
Sensing 
threshold 
Threshold that the activity of the heart must 
meet to be registered by the device 
mV 
Output Related to capture threshold; set by 
technician based on results threshold results 
(either 2 x voltage or 3 x pulse width; may 
differ from this to conserve battery 
V and ms 
CIED 
Alerts 
CIED records historical instances of SVT, 
VF/VT, arrhythmia episodes, devices resets, 
shocks delivered or terminated before 
delivery (ICD only) etc. for further analysis 
Time, date and length of 
occurrence 
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2.5 Cancer  
 
Cancer is defined as the uncontrolled proliferation of abnormal cells, shown in figure 
2.10. These cells can invade surrounding tissue causing damage, and may eventually 
metastasise to other areas of the body. Cancer is defined by the site in which the 
disease originated, also known as the primary site – e.g. breast or lung cancer - 
and/or the histology of the cells involved – e.g. squamous cell (SCC) or basal cell 
(BCC) carcinomas of the skin, sarcomas. Cancer may form in the bloodstream 
without the presence of a solid tumour – e.g. leukaemia.  
(a) (b)  
Figure 2.10: A comparison of (a) normal cell division to (b) cancer cell 
division (University of Virginia Health System, 2014) 
 
Risk factors for a variety of cancers include lifestyle (e.g. smoking, alcohol 
consumption, poor diet, obesity, physical inactivity), demographic (e.g. age, gender), 
genetic (e.g. family history, hormonal factors), occupational exposures (e.g. dust, 
asbestos, sunlight, radiation), and environmental factors (e.g. pollution). Many of 
these risk factors are shared with CVD. 
 
Cancer is the second leading cause of death in Australia, accounting for 
approximately 3 in 10 deaths in Australia in 2012 (AIHW, 2012). Cancer was 
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estimated to be the leading cause of burden of disease in Australia (19%) in 2010, 
and an expected 1 in 2 Australian  men and 1 in 3 women will develop cancer, and 1 
in 5 Australians will die from cancer before the age of 85 (AIHW, 2012). The 
incidence of cancer in Australia is on the rise, with new cases diagnosed doubling 
between 1982 and 2007. In addition there was a 3% increase in new cases diagnosed 
between 2006 and 2007. Rates of cancer incidence between 1997 and 2008 are 
shown in figure 2.11.  
 
Figure 2.11: Australian Cancer Incidence 1997 to 2008 (AIHW, 2014a) 
 
When taking into account the increasing and ageing population, there was still a 27% 
increase in new cases between 1982 and 2007. This suggests that only part of the 
increase in cancer incidence may be explained by the ageing and increasing 
population, with modifiable risk factors such as smoking, diet, and obesity likely 
contributing to this rise (AIHW, 2010).  
 
The most commonly diagnosed cancers in Australia include prostate, bowel, breast, 
melanoma of the skin and lung cancers (AIHW, 2012).   
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2.6 Radiation Therapy 
 
Radiation therapy is one of the main treatment options for cancer, estimated to 
contribute to 40% of cancer cures, compared with 49% by surgery and 11% by 
systemic treatments (Einhorn et al., 1996). Radiation therapy is a non-invasive local 
treatment using precise doses of ionizing radiation delivered to either a malignanct 
or non malignant tumour, while sparing healthy tissue. Benefits of radiation therapy 
include confinement of treatment side effects, preservation of function, and better 
cosmetic results than surgery (Washington & Leaver, 2010). Radiation therapy is 
also widely used in palliative treatments, with approximately 40-50% of treatments 
administered with a palliative intent (Kirkbridge, 1999). 
 
Various forms of radiation therapy have existed since the discovery of x-rays by 
Wilhelm Roentgen in 1895.  It may be delivered from an external source, commonly 
referred to as External Beam Radiation Therapy (EBRT), or internally known as 
Brachytherapy (BT), which incorporates needles or catheters inserted into tumours at 
a high or low dose rate (HDR BT and LDR BT respectively),  for either part or all of 
treatment. HDR BT and LDR BT were available in 42% and 27% respectively of 
radiation oncology departments in Australia in 2010 (Radiation Oncology Tripartite 
Committee, 2012). For the purpose of this thesis, only EBRT treatments are 
discussed.  
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 2.6.1 External Beam Radiation Therapy 
 
EBRT may be administered using low or high energy equipment. The depth at which 
a tumour may be treated is directly linked to the energy of the beam – i.e. the higher 
the energy the deeper the beam penetration into the body. Low energy EBRT, 
including orthovoltage and superficial (kilovoltage) treatments,  has previously 
shown no link to CIED malfunction when not directly irradiated, and is therefore not 
discussed in this thesis (Hurkmans et al., 2012).  
 
High energy EBRT refers to equipment producing x-ray, or photon, beams of 1 
megavolt (MV) or more, as well as a range of electron (MeV) energies. Modern 
treatments are commonly delivered using a linear accelerator (LINAC). For the 
purpose of this thesis, low and high photon energies refer to 10MV or less and more 
than 10MV respectively. In some cases during this research, electron energies were 
included alongside low photon energy.  
 
While both Betatron and Cobalt-60 (Co-60) units are no longer used in Australia 
(Wigg & Morgan, 2001), they are still used in limited capacity overseas and are 
referenced in the literature pertaining to CIEDs. For the purpose of this thesis, 
Betatron and Co-60 treatments are beyond the scope of this research.  
 
2.6.2 Linear Accelerators (LINAC) 
 
A LINAC refers to radiation therapy equipment where the charged particles travel in 
a straight line as they gain energy from an alternating electromagnetic field, and is 
the most common form of radiation therapy in Australia (Wigg & Morgan, 2001). 
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An example of a modern LINAC is shown in figure 2.12. In  December 2011, there 
were 168 LINACS in Australia, with 74% located within the public health sector 
(Radiation Oncology Tripartite Committee, 2012).  
 
Figure 2.12: An Elekta Synergy linear accelerator (Elekta Inc, 2014).  
 
A LINAC uses high frequency electromagnetic waves to accelerate electrons to high 
energies through a linear tube. The high energy electrons may be used for treatment 
of shallow malignancies such as skin (MeV) or aligned to strike a target in the 
LINAC head to produce photon energies (MV) to treat tumours deep within the 
body, as shown in figure 2.13. 
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Figure 2.13: Example of a LINAC treatment head during the administration 
of (a) a photon beam and (b) and electron beam (Khan, 2010). 
 
A LINAC is comprised of a drive stand, gantry (including treatment head) and 
treatment couch. The drive stand allows the gantry to move on a horizontal axis 
around a central point, known as the isocentre, a point in space where the rotation 
axis of the gantry, couch and collimator intersect (Washington & Leaver, 2010). In 
newer model LINACs the drive stand is hidden behind the wall of the treatment 
room. It contains the major electrical components of the LINAC including the 
klyston, waveguide, circulator and cooling system. The gantry primarily directs the 
photon or electron beam to the planning target, housing the electron gun, accelerator 
and treatment head. The LINAC treatment head contains a thick shell of high density 
shielding material to prevent radiation leakage. The LINAC head, or collimator, also 
rotates around a central axis. The treatment head houses the bending magnet, x-ray 
target, flattening filter, scattering foil, collimators and jaws to shape the final beam. 
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Components in the treatment head  directly contribute to scatter within and outside 
the treatment field. The treatment couch allows up to six degrees of motion to allow 
patients to be positioned so that the isocentre is (generally) positioned in the middle 
of the planned treatment volume. Additional imaging panels may also be included. 
Further descriptions are provided in table 2.4. 
Table 2.4: LINAC components (Washington & Leaver, 2010). 
LINAC 
component 
Component Description Modalities 
Drive Stand Magnetron 
or Klystron 
Produces and amplifies microwaves to 
accelerate electrons  
MeV and 
MV 
Waveguide Hollow tube conveying the microwaves 
through the drive stand 
MeV and 
MV 
 
Circulator Prevents any reflected microwaves returning 
to the klystron 
MeV and 
MV 
Cooling 
System 
Water cooling, allows many components of 
the LINAC to operate at a stable temperature 
MeV and 
MV 
Gantry Electron Gun Produces electrons MeV and 
MV 
Accelerator 
Guide 
Slows microwaves to to be synchronous with 
the electrons 
MeV and 
MV 
Treatment 
Head 
Bending 
Magnet 
Redirects electrons through the treatment 
head 
MeV and 
MV 
X-Ray 
Target 
Metal target, generally tungsten, produces 
Bremsstrahlung x-rays into a wide beam 
MV only 
Primary 
Collimator 
Shape the primary beam MV  
Scattering 
foil 
Scatters the electrons into a wide beam MeV 
Ion Chamber Monitors the beam for symmetry, assists in 
the calculation of monitor units 
MeV and 
MV 
Secondary 
Collimators/J
aws 
Set using LINAC controls to shape the final 
beam parameters; include level of internal 
shielding (MLCs) where available. 
MV 
Accessory 
Mount 
Electron applicator, available in various 
sizes, contains multiple colliamtors to reduce 
lateral scatter; includes slot for personalised 
electron beam shileidng cutout 
MeV 
Accessory 
Mount 
Slot for manual beam shaping devices MV 
Key: Mev = megaelectron Volts/electrons; MV = megavolts/photon; LINAC = linear 
accelerator; MLC = multi-leaf collimator. 
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A variety of energies may be produced using a LINAC. LINACs are capable of 
producing photon energies between 4-20MV and electron energies between 4MeV 
and 25MeV. Scattered radiation is created in interactions within the treatment head 
and patient (Washington & Leaver, 2010). Not all energies are available at each 
department, as energies available are those that have been callibrated by 
departmental physicists, as well as those made available by the LINAC vendor. The 
depth in which the beam will penetrate the patient is directly related to the strength 
of the beam energy, as shown in figure 2.14. 
 (a)    (b)  
Figure 2.14: Isodose charts representing PDD and distribution of (a) a 
6MV beam and (b) an 18MV beam in water (Khan, 2010). Central axis 
depth is represented in cm. 
 
The level at which 100% of the prescribed dose is deposited under the skin is 
referred to as the depth of maximum dose (dmax). The dose received at depth is 
determined through percentage depth dose calculations (PDD). Primary dose created 
through the treatment head is paired with scatter radiation to calculate dose. Higher 
energy photon therapy creates heavy particle scatter in the form of neutron particles, 
with the number of neutrons created relative to the energy used; for example there 
was a measured six fold increase in neutron scatter created  when treatment energy 
was increased on a Siemens (Concord, CA) LINAC from 15MV to 18MV 
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(Followill, Stovall, Kry, & Ibbott, 2003). The amount of scatter created during 
treatment is also dependant upon the model of LINAC. 
 
Heavy particle beams, including neutrons and protons, may also be used in the 
delivery of EBRT. These types of therapy are currently not available in Australia and 
are therefore not included for analysis in this thesis. 
2.6.3 Radiation Therapy Planning and Treatment Process 
 
The absorbed dose of radiation therapy is measured in Gray (Gy), and calculated as 
one joule (J) of energy absorbed per kilogram of absorbing material. One Gy is 
equivalent to 100 centigray (cGy). Treatments may be administered  in as little as 
one day, or up to five to eight weeks of daily treatments, or fractions. Conventional 
fractionation comprises of daily doses of 1.8Gy to 2Gy for radically, or curatively, 
treated patients (Ling, Gerweck, Zaider, & Yorke, 2010). Hyperfractionation, or 
increased daily doses at decreased overall fractionation, are used in palliative cases, 
to decrease treatment time for non-local patients, and in newer treatment techniques 
such as stereotactic treatments (see section 2.7.4).  
 
Prior to treatment, simulation is required to determine the size and shape of the 
treatment volume relative to normal tissue (Washington & Leaver, 2010). Patients 
are often simulated in the weeks prior to treatment using one or more scanning 
methods. Patients are most commonly simulated using computed tomography (CT), 
with the addition of magnetic resonance imaging (MRI) and positron emission 
tomography (PET) where better visualisation of tissue or pre-operative tumour 
localisation is required. These scans are transferred to the treatment planning system 
(TPS) and used by the radiation oncologists to create  gross, clinical and planning 
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target volumes (GTV, CTV and PTV respectively). The dose and fractionation are 
also determined by the radiation oncologist. Critical planning avoidance structures, 
also known as organs at risk (OARs), may also be determined by either radiation 
oncologists or departmental protocol based on reports by the International 
Commission of Radiation Units (ICRU) which specify acceptable dose limits for 
treatment volumes to limit treatment side effects (International Commission on 
Radiation Units and Measurements, 1999). Radiation therapists use this information 
to optimise treatment plans to individual patient anatomy whilst limiting dose to 
OARs. The TPS determines the number of monitor units (MU) required to deliver 
the dose prescribed by the radiation oncologist. One hundred MU is equivalent to 
100cGy (or 1Gy) for a 10x10cm field at dmax. Treatment is delivered at a variety of 
dose rates, up to 1000MU/min (or 10Gy/min-1) for new LINACs (Varian Medical 
Systems, 2014a).  
 
Patients may be treated either curatively (radically) or palliatively. Curative 
treatments often use doses between 50Gy to 80Gy over five to eight weeks to deliver 
enough dose to the tumour to enable permanent cell death. Palliative cases are often 
lower in total dose (≤30Gy) given either as single treatments, or in fractions over a 
number of weeks in order to provide palliation of symptoms. Dose is determined by 
a number of factors, including OARs,  concurrent treatments (such as chemotherapy 
or surgery), and treatment technique (Washington & Leaver, 2010). 
 
The dose delivered to the OARs may be estimated via two different methods. For 
OARs that are close to the tumour volume and contained within the simulation CT 
scan, an OAR is outlined on the CT scan alongside planning volumes. The planning 
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algorithms within the TPS calculate the estimated dose received to an outlined OAR 
and display the dose in the form of a dose volume histogram, shown in figure 2.15. 
The received dose to the organ is visualised on the horizontal axis while the 
normalised volume of the organ receiving the dose is visualised on the vertical axis. 
The coloured lines correspond to individual outlined OAR and planning volumes.  
 
Figure 2.15: example of a dose volume histogram  
 
 
External measurements may be performed during treatment to confirm estimated 
doses calculated from the TPS using thermoluminescent dosimetry (TLDs).  TLDs 
are appropriate for OARs close to the surface of the body, such as lenses of the eye 
or a CIED. TLDs are made up of a crystalline material, most commonly Lithium 
Fluoride (LiF); when exposed to radiation they absorb a small portion of the energy 
created which may be measured by heating the LiF and measuring the light emitted 
(Khan, 2010).  
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2.7 Types of radiation therapy 
 
There are a number of radiation therapy techniques that are currently used in 
Australia. A description of these is found below.  
 
2.7.1 Conformal radiation therapy 
Conformal radiation therapy (CRT) has been used since the implementation of 
LINACS. Originally, conformal radiation therapy relied on hand drawn patient 
outlines and calculations. Presently, 3D and 4D CT, MRI, PET or a combination of 
multiple scans of individuals are transferred to a 3D-TPS assist in the planning of 
patient treatments (3D-CRT). Treatments are planned using departmental protocols, 
with dose limits and planning volumes based upon international guidelines 
(International Commission on Radiation Units and Measurements, 1999). 
3D-CRT uses static gantry and field settings. Treatment may be delivered in 
multiple, sequential phases to increase the dose to the original tumour whilst 
delivering adequate dose to surrounding tissue which may include microscopic 
disease. Ancillary equipment, such as physical wedges and shielding blocks could be 
inserted into the treatment head to assist in shaping the treatment beam. As 
technology has developed, shielding blocks have been replaced with multi-leaf 
collimators (MLC) after their invention in approximately 1984, consisting of a series 
of tungsten “leaves” that may move independantly and allow for more accurate 
shaping of beams without heavy shielding blocks, shown in figure 2.16. MLCs have 
also allowed the development of intensity modulated radiation therapy (IMRT) by 
allowing the leaves to move continuously whilst the beam is on.  
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Figure 2.16: MLC leaves in a LINAC treatment head (Varian Medical 
Systems, 2014b).  
 
2.7.2 Intensity Modulated Radiation Therapy  
 
 
IMRT is an advanced form of radiation therapy, allowing for the better conformity 
of treatment to complex 3D volumes by allowing the intensity of radiation to be 
shaped in small segments. IMRT allows for tighter margins to treatment volumes, 
sparing dose to healthy tissue and OARs. IMRT also allows escalated dose to be 
delivered to the PTV with the same or smaller OARs dose compared to 3D-CRT 
(International Commission on Radiation Units and Measurements, 2010).  
The modulation of the beams may also limit the necessity of higher energies to be 
used in areas such as the pelvis. IMRT is delivered using two to three times the 
number of treatment beams than 3D-CRT, and may result in an overall increase in 
low dose areas and MUs.  
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A comparison of these treatment techniques is shown in figure 2.17. The IMRT plan 
in figure 2.17(b) allows the high dose to be shaped to the tumour volume (red 
outline) with reduced high dose to the spinal cord and lungs. A slightly larger 
portion of the right lung receives radiation in the IMRT plan to achieve this dose 
shaping.  
(a)  
(b)  
Figure 2.17: Planning comparison of a mediastinal Hodgkins Lymphoma 
(a) 3D-CRT to (b) IMRT (Ricardi, Filippi, Piva, & Franco, 2014) 
IMRT has many advantages over 3D-CRT, however is typically time and resource 
heavy (Moran et al., 2011). Decreasing tumour margins also leads to a need in 
increasing level of accuracy in treatment reproducibility, requiring either more x-
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rays and electronic portal imaging (EPIs), or greater use of image guided radiation 
therapy (IGRT). The additional imaging requirements also lead to a small increase in 
radiation exposure to the patient, and any ancillary devices such as CIEDs. IMRT 
performed with high photon energies is associated with similar in-field neutron 
scatter doses to CRT, but may  see doses up to two times greater outside the 
treatment field, mainly due to the increased beam on time required for IMRT 
treatments (Ipe, Roesler, Jiang, & Ma, 2000; Schneider et al., 2006). In countries 
where radiation therapy is not subsidised, this treatment can lead to great personal 
expense (Smith et al., 2011). 
 
2.7.3 Volumetric Modulated Arc Therapy 
 
 
Volumetric modulated arc therapy (VMAT) is an extension of dynamic IMRT, 
where the gantry of the LINAC revolves around the patient in one or more arcs while 
the beam segments continously change. VMAT greatly decreases the time in which 
treatment is given as the gantry and beam shielding are in constant motion (Li, Wu, 
Peng, Zhang, & Bai, 2014). Low dose 3D imaging may also be carried out 
concurrently with treatment, allowing real time monitoring of organ motion. Like 
IMRT, a higher proportion of tissue receiving low dose is created using VMAT, 
which may result in increased long term side effects such as radiation pneumonitis or 
radiation induced malignancies (Teoh, Clark, Wood, Whitaker, & Nisbet, 2011).   
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2.7.4 Stereoteactic Radiosurgery and Stereotactic Body Radiation 
Therapy 
 
 
Stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) uses 
small beams to accurately treat small tumours or benign malignancies in difficult 
areas. SRS is commonly used in the treatment of brain or spinal tumours, wheras 
SBRT is used in other areas of the body (Washington & Leaver, 2010). 
Hypofractionation, where high doses in a smaller amount of treatments, is one of the 
principle factors in SBRT and SRS. SRS is usually carried out over one treatment, 
whereas SBRT may be carried out over four or more treatments. Beam modulation 
may also be used. SBRT and SRS require high levels of accuracy, assisted by 
specialised immobilisation devices and increased imaging requirements. SRS is only 
available in a handful of centres in Australia and is not analysed further in this thesis.  
 
2.7.5 Emerging radiation therapy techniques 
 
Advancements in radiation therapy techniques are allowing for increased treatment 
accuracy, decreased side effects and reduced treatment volumes while decreasing 
treatment time. The following techniques have been described as their use may 
impact the appropriate function of a CIED, and require consideration in any 
treatment guideline. 
 
 Image guided radiation therapy (IGRT) has incorporated both 2D and 3D MV and 
KV imaging to increase the accuracy of treatment delivery. IGRT has led to the 
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development of adaptive planning for tumours are affected by variable organ motion 
such as the bladder, or in cases where tumours may shrink over time (Heijkoop et al., 
2014). IGRT is associated with an increased dose to the patient due to the daily 
imaging, with imaging field borders which may extend beyond treatment borders.  
 
Respiratory gating has recently been incorporated into treatments which may be 
affected by respiratory motion, such as lung, breast and liver tumours. In these cases, 
treatment is only delivered when the patients lung volume is at a desired level to 
reduce the amount of functional lung and heart irradiated during treatement. 
Respiratory gating requires the use of a four dimensional (4D) CT scan during the 
planning stage. 4D CT scans take multiple images at each level through the patient at 
each point in the breathing cycle, with an increased time required for the scan 
(Giraud & Houle, 2013). 
 
Modulation of treatment beams through IMRT, VMAT and SBRT has lead to the 
introduction of flattening filter free (FFF) treatment beams. Historically flattening 
filters were used in LINACS to create the tradiaitonal beam profile required in CRT. 
With the increasing use of modulated beams to shape treatments, the flattening filter 
is no longer necessary in IMRT and VMAT treatments. By removing the flattening 
filter, treatment times may be decreased as the dose rate is increased up to 4.2 times 
faster than with the flattening filter in place. As the flattening filter is also a large 
contributer to neutron scatter during treatment,  its removal decreases the stray 
neutrons measured outside the beam, decreasing out of field doses (Georg, Knoos, & 
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McClean, 2011). FFF beams are relatively new to Australia and their place in 
Radiation Therapy departments is yet to be determined. 
2.8 External Beam Radiation Therapy in Australia 
 
 The most commonly treated sites using radiation therapy in NSW  include lung, 
breast, rectal, prostate and head and neck cancers (NSW Health, 2008). The 
collaboration for cancer outcomes, research and evaluation (CCORE) group 
estimated the optimal radiation therapy utilisation rate in Australia should be 52.3% 
when an analysis of individual treatment sites was undertaken, shown in table 2.5. 
 
Table 2.5: Optimal radiotherapy utilisation rate by cancer type (Delaney, 
Jacob, Featherstone, & Barton, 2003)  
Tumour type Patients receiving 
radiation therapy 
(% of all cancers) 
Tumour type Patients receiving 
radiation therapy 
(% of all cancers) 
Breast 10.8 Colon 1.3 
Lung 7.6 Pancreas 1.1 
Prostate 7.2 Other 1.0 
Rectum 3.1 Oesophagus 0.8 
Head and Neck 3.1 Renal 0.8 
Lymphoma 2.6 Testis 0.5 
Melanoma 2.5 Myeloma 0.4 
Unknown 
Primary 
2.4 Gall Bladder 0.1 
Gynaecological 1.8 Leukaemia 0.1 
Central Nervous 
System 
1.8 Thyroid 0.1 
Bladder 1.7 Liver 0.0 
Stomach 1.4 TOTAL 52.3 
 
The current radiation therapy utilisation rate in Australia is 38% (Barton & Delaney, 
2011). When optimal radiation therapy target utilisation is combined with a 
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retreatment rate of 25% and an additional 10% for non-notifiable and non-malignant 
disease (CCORE, 2003), an estimated 57,242 patients should have received radiation 
therapy in Australia in 1997, increasing to 79,292 in 2008, shown in figure 2.18.  
 
Figure 2.18: Estimated radiation therapy rates between 1997-2008, 
including new cases, retreatments and non-malignant and non-notifiable 
disease (AIHW, 2014a; CCORE, 2003; Radiation Oncology Tripartite 
Committee, 2012). 
 
Given the overlap in risk factors, the ageing population, increasing incidence of 
CIED implantations and cancer rates, and the aim to increase radiation therapy loads 
in Australia, it is reasonable to assume that the number of cardiac device patients 
presenting to radiation therapy departments for treatment will increase. 
 
2.9 Proximity of CIEDs to a radiation therapy field 
 
Radiation therapy may be delivered to any part of the body so long as the dose given 
is constrained by the dose limits of the OARs. Common treatments to the upper 
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chest, such as lung, breast, head and neck,  or any primary or secondary cancers of 
the lymph nodes, could potentially see a CIED in, or close to, the required treatment 
field, as shown in figure 2.19. In less common cases where a CIED is implanted in 
the groin or abdomen, prostate, rectal, liver and bladder treatments may also present 
a problem. 
 
(a)  
(b)  
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(c)  
Figure 2.19: Examples of digitally reconstructed radiographs (DRRs) 
showing treatment fields close to CIEDs including (a) Anterior setup field 
for mediastinal treatment, (b) supraclavicular field for breast treatment 
and (c) Anterior field for head and neck treatment.  
 
Traditionally the dose received by the device was believed to directly impact the 
correct functioning of a CIED during treatment. As a result it is not recommended to 
directly irradiate a CIED (Hurkmans et al., 2012). Often the CIED is surgically 
relocated  to the contralateral side before treatment planning begins to avoid direct 
irradiation, as shown in figure 2.20. In some cases, radiation therapy is avoided 
altogether as a result of the CIED implant (Croshaw, Kim, Lappinen, Julian, & 
Trombetta, 2011). This is discussed further in section 3.7.  
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Figure 2.20: DRR of a patient at RPAH who has had their device relocated 
from the right supraclavicular region to the left supraclavicular region 
due to the right axilla being treated. The original lead (outlined in blue) 
remains within part of the treatment field.  
 
2.10 Radiation Therapy damage to CIEDs 
 
Damage to CIEDs during radiation therapy may be caused by exposure to either 
direct or scatter radiation, or electromagnetic interference (EMI) caused by the linear 
accelerator.  
 
Exposure to ionising radiation leads to the formation of excess electron hole pairs in 
the SiO2, resulting in ‘holes’ being created in the valence band, and excess electron 
energy being dispersed from the device as shown in figure 2.21. The holes created in 
the valence band are slow to move and are generally attracted to any structural 
defects (Last, 1998). This results in the formation of aberrant electrical pathways in 
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the insulator, which may be short lived or more permanent, resulting in a variety of 
minor or significant malfunctions (Little, 1994). 
 
 
 
 
 
 
Figure 2.21: Example of electron holes created in the SiO2 when exposed 
to radiation. 
 
Failures have historically been attributed to either total dose effects (TDE) or single 
event upset (SEU). A SEU may occur when a high energy neutron strikes the 
reversed biased p-n junction of a memory cell and deposits enough charge to cause a 
change in the memory. The most sensistive circuit structure in CIEDs is the random 
access memory (RAM), due to the small amount of charge used to store device 
programming code and data (Bradley & Normand, 1998). A disruption to the RAM 
circuitry may cause the RAM to lose the stored programming, altering individual 
programming or leading to an electrical reset of the device, commonly referred to as 
a power on reset (POR). 
 
CIED reaction to interference may be either transient or permanent.  Transient 
interference is more likely to be attributed to EMI rather than radiation, as the 
interference is often only present during ‘beam on’ times. Interference caused by 
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radiation is more likely to require reprogramming to resolve malfunctions. Higher 
doses of radiation are more likely to cause significant damage, which may not be 
repaired by reprogramming (Tondato et al., 2009). 
 
Malfunctions may be minor, with minimal safety implications, or may lead to 
severe, irreversable errors. In CIED dependant patients, hard and severe soft errors 
have the potential to result in lethal consequences. 
 
2.10.1 CIED errors assessed during radiation therapy 
 
Errors assessed in this thesis have been grouped into table 2.6 by the author as a 
summary of device failure criteria used in current literature (Elders et al., 2013; 
Hashii et al., 2012; Hurkmans, Scheepers, Springorum, & Uiterwaal, 2005a; 
Mouton, Haug, Bridier, Dodinot, & Eschwege, 2002). Using these criteria, multiple 
failures may be observed concurrently. For example partial resets may also present 
through amplitude modifications; missed pulses or pacing silence may be associated 
with detectable VT or VF, or oversensing. 
-50- 
Table 2.6: CIED failure criteria during exposure to Radiation Therapy 
Error Type Severity Definition Examples 
Hard Error 
Unable to 
be 
recovered 
 
A permanent loss of therapeutic function 
or communication which cannot be 
repaired by the programming computer; 
potentially lethal errors. 
 Loss of telemetry with the programming wand/computer 
 Permanent undetectable electrical signal/pacing silence 
 Runaway PM/ICD 
Soft Error 
Able to be 
recovered 
by the 
programmer 
or company 
Severe 
Accidental overwriting of protected 
RAM causing the device to enter a safety 
back-up mode with a fixed pacing rate; 
potentially lethal errors. 
 Power on Reset  
 Complete pacing silence during irradiation - pacing silence may indicate an 
important and incompatible arrhythmia during irradiation and may result in 
fatality in pacing dependant patients. 
  
Moderate 
Partial electrical reset indicative of 
interference with protected RAM that 
does not interfere with the settings of 
pacing mode or detection of arrhythmias. 
 Output pulse amplitude changes >25% - Amplitude changes may cause 
insufficient charge to be delivered to the heart in order to pace.  
 Battery voltage changes >5% or unmatched decrease in battery longevity if 
voltage is unavailable. Battery depletion may cause changes in mode or pacing 
frequency as a form of battery conservation.  
Minor 
An error that results in transient issues 
and does not require reprogramming to 
maintain adequate function.  
 Missed pacing pulse at the start or end of irradiation - likely due to a sudden 
change in dose rate causing photocurrents (EMI) which disturb the internal device 
clock.  
 Missed pulse/s during irradiaton 
 Increase pacing frequency during irradiation 
 Pacing Impedance changes >50% - disruption of the lead conductor is 
traditionally associated with a sudden rise in pacing lead impedance. Lead 
insulation failure is indicated by a sudden reduction in impedance  
 Partial reset – loss of historical data, temporary altered sensitivity, amplitude 
changes <25%, telemetry and programming defects preventing CIED 
reprogramming.  
Key: ICD = implantable cardioverer defibrillator; RAM = random access memory; VT = ventricular tachycardia; EMI = electromagnetic 
interference; VF = ventricular fibrillation; CIED = combined implantable electronic device 
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2.11 Current treatment protocols 
 
There are currently numerous accepted treatment protcols for CIED patients 
receiving radiation therapy worldwide. Multiple manufacturers have 
acknowledged the risk of CIEDs exposure to radiation therapy, often reporting 
“no safe dose” may be given to the devices due to the variability in device 
circuitry (Boston Scientific, 2012; St. Jude Medical, 2011). Until recently, St 
Jude Medical suggested dose limits of up to 20-30Gy (St. Jude Medical, 2005). 
In peer-reviewed journals, a range of dose limits are suggested from ‘no safe 
dose’ (Sundar et al., 2005), to between 2 and 10Gy for PMs (Hurkmans et al., 
2005a; Wadasadawala et al., 2011), and from 1Gy for ICDs (Hurkmans et al., 
2012; Hurkmans, Scheepers, Springorum, & Uiterwaal, 2005b). More recently, 
manufacturers such as Biotronik have acknowledged a potential risk in using 
dose energies greater than 10MV. A literature review has been undertaken in 
Chapter Three to assess these recommendations further.  
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Chapter Three: Literature Review 
 
 
3.1 Introduction 
 
This literature review was conducted to examine current evidence that is 
available, documenting the effect of radiation therapy on cardiac implanted 
electronic devices (CIEDs). Specifically it details the effect of external beam 
radiation therapy (EBRT) produced through linear accelerators (LINACs). The 
available research has been analysed in two timeframes - pre 1994 and 1994 
onwards - due to the publication of internationally recognised guidelines on 
pacemaker (PM) irradiation in 1994. These groups are each analysed by 
research type, including in vitro studies, in vivo case studies, observational and 
planning or physics studies, as well as CIED type - either PM or ICD. The 
guidelines published by manufacturers have also been reviewed. A breakdown 
of the studies has been conducted due to the range of treatment exposures to the 
CIEDs during the varying types of research. Changes have also occurred in 
CIED treatment protocols over the past decade, with these changes reflected in 
the current literature.  
 
A systematic review was published by this author in the Journal of Medical 
Imaging and Radiation Oncology prior to the commencement of this thesis in 
2010, found in Appendix A. This article proposed a time limit of 1994-2008 to 
assess changes in literature between the release of the American Association of 
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Physicists in Medicine Task Group 34 (AAPM TG34) protocol release in 1994 
and the time of the articles commencement. There was no discrimination in the 
type of material composing the CIEDs analysed in the previous article. This 
chapter uses a similar methodology to the article, incorporating all known 
literature available which incorporates modern complementary metal oxide 
semiconductor (CMOS) CIEDs. This chapter does not include critical analysis 
of letters to the editor or review articles, accounting for the discrepancy in 
articles which have met the search criteria. 
  
3.2 Method 
 
Electronic databases Medline and Scopus were searched using the following 
keywords: Pacemaker (pacemaker, artificial; cardiac pacing, artificial) OR 
implantable cardioverter defibrillator (defibrillators, implantable) AND 
radiotherapy. Articles were excluded if their primary focus was not on photon 
EBRT (such as proton therapy, brachytherapy or Cobalt-60). Studies were also 
excluded if they were concerning CIEDs that were implanted after the course of 
RT was completed. The initial search for articles was conducted between 1965 
and 2014. Papers published in the 1960s and early-mid 1970s dealt with older 
generations of PMs incorporating bipolar semiconductors, and were excluded 
as these studies showed little to no effect of radiation on PM function, even at 
extreme doses (Walz et al., 1975). As a result the first included article was 
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published in 1975. Complementary metal oxide semiconductor (CMOS) 
circuitry was introduced into PMs in the late 1970s. While increasing 
functionality, reliability and decreasing size, it also appeared to correspond with 
an increase in the radiosensitivity of CIEDs (Calfee, 1982), and hence device 
design including CMOS circuitry  is another focus of this review. 
 
Only articles published in, or translated to English were included. The reference 
lists of selected articles were searched for other relevant articles that did not 
appear in the database search.  
 
One hundred and eight articles were identified in the initial database search. Of 
these, 60 articles met the inclusion criteria. These articles dated between 1975 
and 2013 inclusive. Forty eight articles were of original research, with the 
remaining twelve as review articles. Review articles were included where 
applicable for additional information as they often suggested new CIED 
treatment protocols, but they were not analysed as a separate category.  
 
3.3 Development of American Association of Physicists in 
Medicine Task Group 34 (AAPM TG34) Protocol, 1994 
 
 
In 1994, the AAPM TG-34 (Marbach, Sontag, Van Dyk, & Wolbarst, 1994) 
released the first RT treatment guidelines for patients with implanted PMs 
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(Marbach et al., 1994). These guidelines were widely adopted internationally as 
shown by their citation in subsequent articles, as well as their prevalence in 
Australian protocols. Development of these guidelines was primarily based on 
the PM studies detailed below. ICDs were uncommon at this time, as they 
required thoracotomies for implantation until the late 1980s. Only one article 
incorporated ICDs prior to 1994 (Rodriguez, Filimonov, Henning, Coughlin, & 
Greenberg, 1991), with failures occurring above 76Gy. 
 
3.3.1 In vitro PM studies (1975-1994) 
 
 
Eight in vitro PM studies were published between 1975 and 1994. Many of 
these studies contained exposure to Cobalt-60 (Co-60) or Betatron treatment 
machines, as well as Linear Accelerators (LINACs); for the purpose of this 
study, only the exposure to the LINACs was observed. Failures that were 
recorded prior to 1994 were generally associated with high accumulated doses 
to the PM, with none failing below 10Gy. A variety of low photon (MV) 
energies, between 4MV to 10MV, and varying electron (MeV) energies were 
used. Large doses were often given in single fractions, limiting critical 
evaluation of dose related failure. These studies originally found that the direct 
irradiation of PMs resulted in a higher risk of failure, and formed the basis of 
irradiation guidelines still in use (Adamec, Haefliger, Killisch, Niederer, & 
Jaquet, 1982). EMI was deemed to be a cause of failure when irradiating PMs 
(Walz et al., 1975). A summary of these studies is given in table 3.1. 
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Marbach, Meoz-Mendez, Huffman, Hudgins, and Almond (1978) were the first 
to note the potential failures of PMs incorporating CMOS circuitry when 
exposed to direct irradiation. They reported a transient failure of a single device 
using 8MeV when placed in the direct beam. This was  similar to findings 
previously reported  by Walz et al. (1975) when irradiating PMs with 4MV, 
although the PM was placed outside the treatment beam. Both studies used a 
variety of treatment machines to conduct the research. Both authors concluded 
that although EMI produced by the LINAC was sufficient to cause PM 
malfunction, treatment of patients with cardiac PMs was acceptable, since 
failures observed were only temporary. Walz et al. (1975) noted extended 
pacing silences, up to one minute, when irradiated with electrons at 10Gy/min-1. 
The authors associated these silences with the characteristics of the beam pulse 
being translated as R-waves by the PM. The authors concluded that this was not 
harmful.  Marbach et al. (1978) noted that while some concern was warranted, 
permanent failures were only observed in doses exceeding current therapeutic 
guidelines.  
 
Adamec et al. (1982) irradiated 13 programmable PMs with a single LINAC, 
eliminating the potential bias of multiple LINACs of the previous studies. Nine 
of the 13 programmable PMs failed at doses ranging from 10-70Gy, with 
failures preceded by rapid changes in the pulse width which lasted several 
seconds, often accompanied by large changes in pulse frequency. Adamec et al. 
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(1982) concluded that direct irradiation of programmable PMs at therapeutic 
levels should be avoided.  
 
Failures were not observed at doses below 39Gy by Maxted (1984), and no 
failures observed below 160Gy by Salmi, Eskola, Pitkanen, and Malmivuo 
(1990). Rodriguez et al. (1991) observed signs of failure in nine PMs treated 
with photons between 14-50Gy; four PMs treated with 18MeV failed before 
70Gy. Wilm, Kronholz, Schutz, and Koch (1994) irradiated 20 PMs, with no 
minor disturbances in function or complete failures observed before 10Gy. 
Decreased pulse amplitude observed at around 10Gy was believed to be an 
early signal of irreversible damage to the PM. Souliman and Christie (1994) 
also noted a large dose range at which PMs failed, with three below 28Gy and 
an additional eight at less than 70Gy. 
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Table 3.1: In vitro irradiation studies to 1994 
Author(s) Year No. of PMs Energy Max. Dose Outcome 
Walz, B. J. 
Reder, R. E. 
Pastore, J. O. 
Littman, P. 
Johnson, R. 
1975 5 MeV and 
MV 
> 300Gy One PM failed at 4MV. 
Failure observed consistent with the effect EMI, rather than 
radiation.  
Variation in dose rate did not affect PM function.  
PM under 8MeV showed extensive pacing silences, up to one 
minute. 
Marbach, J. R. 
Meoz-Mendez, R. T. 
Huffman, J. K. 
Hudgins, P. T. 
Almond, P. R. 
1978 4 MeV and 
MV 
 >120Gy One PM failed at 8MeV (LINAC). 
Failed PM given 120Gy in single fraction 
 
Adamec, R. 
Haefliger, J. M. 
Killisch, J. P. 
Niederer, J. 
Jaquet, P. 
1982 13  10MV 70Gy Nine of the 13 programmable PMs failed at doses ranging from 10-
70Gy. 
Avoidance of direct irradiation to programmable PMs was 
suggested. 
Maxted, K.J. 1984 19 4MV >54Gy Treatments given in 3-15Gy fractions. 
Three failures occurred in PMs irradiated at 15Gy/#.  
Total failure was observed at 54Gy for two PMs. 
Pacing rate doubled at 39Gy for one PM; total failure did not occur 
until 69Gy. 
None of the PMs irradiated at fractions closer to a traditional 
treatment regime failed. 
Salmi, J. 
Eskola, H. J. 
Pitkanen, M. A. 
Malmivuo, J. A. 
1990 6 unknown 200Gy No malfunctions before 160Gy. 
Two PMs programmed to DDD observed complete failure at 160Gy 
and 190Gy. 
No complete failure observed in PM programmed to VVI, although 
exposed to >200Gy.  
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Author Year No. of PMs Energy Max. Dose Outcome 
Rodriguez, F. 
Filimonov, A. 
Henning, A. 
Coughlin, C. 
Greenberg, M. 
1991 23  6 MV 
and 18 
MeV 
14 to 
>76Gy 
Eight of 17 PMs treated with MV showed signs of failure between 
14-50Gy. 
Four of six PMs treated with 18MeV failed before 70Gy. 
Wilm, M. 
Kronholz, H. L. 
Schutz, J. 
Koch, T. 
1994 20  10 MV 
and 12 
MeV 
>50Gy No complete failures occurred before 10Gy. 
No minor disturbances in function before 10Gy.  
Decreasing pulse amplitude was observed at approximately 10Gy; 
deemed to be an early precursor to irreversible damage of the PM.   
No significant difference in response to MV and MeV irradiation. 
Souliman, S. K. 
Christie, J. 
1994 18 8MV 70Gy Three PMs failed below 28Gy. 
Eight additional PMs failed at doses below 70Gy. 
Key: PM = Pacemaker; MV = photon; MeV = electron; Gy = Gray; EMI = electromagnetic interference; LINAC = Linear 
Accelerator; # = fraction.
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3.3.2 In vivo PM studies (1982 - 1994) 
 
Eight in vivo PM studies reported in the literature between 1982 and 1994. These 
studies assessed individual PM patients response to radiation therapy, with the 
exception of (Lee, Huang, Mechling, & Bazgan, 1986) which contained two 
patients.  Runaway PM, where the pacing rate increases to erratic, non-physiological 
pacing rates with the potential to cause patient harm, was reported three times. 
Unspecified PM tachycardia, which was unresponsive to reprogramming, also 
occurred three times. Three patients were treated without failure. Doses to the PMs 
ranged from 0.5Gy to 60Gy, with the lowest reported failure at 15Gy. A summary of 
these studies are given in table 3.2.  
 
Clinical failures were reported by Katzenberg, Marcus, Heusinkveld, and Mammana 
(1982) when a PM patient received a dose of more than 30Gy, with the PM exposed 
to one treatment beam. Atrial tachycardia developed without sensed intrinsic 
ventricular beats, necessitating ventricular pacing. Subsequently the PM required 
replacement. Pourhamidi (1983) observed PM failure at 15Gy, resulting in 
permanent malfunction.  
 
A runaway PM was recorded by Quertermous, Megahy, Das Gupta, and Griem 
(1983) after direct irradiation of 20.8Gy, with potentially fatal accelerations of both 
the atrial and ventricular discharge rate. Lewin, Serago, Schwade, Abitbol, and 
Margolis (1984) observed a pacing rate change to 110bpm from the programmed 
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rate of 72bpm after 19.8Gy. Lee et al. (1986) also reported runaway PMs occurring 
in two separate patients undergoing radiation therapy. One patient received a second 
course of treatment adjacent to the PM, which resulted in a high pacing rate of both 
the atrium and ventricle; the time and dose at which this occurred is unknown as it 
was discovered one month post treatment. In the second patient, failure was 
observed between 30 and 36Gy.  
 
Muller-Runkel, Orsolini, and Kalokhe (1990) and Teskey, Whelan, Akyurekli, 
Eapen, and Green (1991) reported no malfunction at doses of 6.2Gy and >60Gy 
respectively. Ngu, O'Meley, Johnson, and Collins (1993) observed no effect on a 
single PM when located close to the treatment field, but have been criticised for their 
less than  stringent testing methods (Last, 1998).
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Table 3.2: In vivo irradiation studies to 1994  
Author Year Treatment 
site 
Dose to 
PM 
Outcome 
Katzenberg, C. A. 
Marcus, F. I. 
Heusinkveld, R. S. 
Mammana, R. B. 
1982 Breast >30Gy 4MV treatment. 
Atrial tachycardia developed without sensed ventricular beats. 
The PM required replacement. 
Pourhamidi, A. H. 1983 Oesophagus 15Gy 4MV treatment. 
Patient reported feeling dizzy, requiring an ECG and hospital admittance. 
PM malfunction was observed with increased pacing frequency. 
PM could not be reprogrammed and resulted in a PM change. 
Quertermous, T. 
Megahy, M. S. 
Das Gupta, D. S. 
Griem, M. L. 
1983 Lung >20Gy Previous treatment – 1.27Gy to PM. 
PM within the partial radiation field. 
Runaway rhythm developed at 20.8Gy, with potentially fatal accelerations of both 
the atrial and ventricular discharge rate. 
Attempted reprogramming failed; subsequent PM placed in the abdomen. 
Authors proposed the use of ECG throughout treatment to alert for any transient or 
permanent malfunctions that may develop. 
Lewin, A. A. 
Serago, C. F. 
Schwade, J. G. 
Abitbol, A. A. 
Margolis, S. C. 
1984 Axilla >19Gy PM partially within the treatment field.  
Pacing rate change to 100bpm from the programmed rate of 72bpm.  
Reprogramming of PM failed; new PM placed away from treatment site.  
No further incident recorded. 
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Key: PM = Pacemaker; MV = photon; Gy = Gray; ECG = electrocardiogram; bpm = beats per minute; 
Author Year Treatment 
site 
Dose to PM Outcome 
Lee, R. W. 
Huang, S. K. 
Mechling, E. 
Bazgan, I. 
1986 Mid 
Abdominal 
Area 
unknown Patient 1: Runaway PM. 
Previous course away from PM recorded no malfunction. 
Second course adjacent to the PM resulted in high pacing rate of both the atrium 
and ventricle. 
Time and dose unknown as this was discovered one month post treatment. 
Chest Wall 30-36Gy Patient 2: Runaway PM.  
Muller-Runkel, R. 
Orsolini, G. 
Kalokhe, U. P. 
1990 Lung 6.2Gy No malfunction. 
Teskey, R. J. 
Whelan, I. 
Akyurekli, Y. 
Eapen, L. 
Green, M. S. 
1991 Lung 60Gy No malfunction. 
Backup external PM was inserted through the femoral vein for the duration of 
treatment, it was not required. 
Ngu, S. L. 
O'Meley, P. 
Johnson, N. 
Collins, C. 
1993 Mediastinum 0.5Gy No malfunction, PM located 1cm inferior to treatment fields.  
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3.4 AAPM TG-34 Guidelines for PM irradiation. 
 
In 1994, the AAPM TG-34 released the first radiation therapy treatment guidelines for 
patients with implanted PMs (Marbach et al., 1994). These guidelines were widely 
adopted internationally as shown by their citation in subsequent articles, as well as their 
prevalence in Australian protocols. The protocol suggested by the AAPM TG34 is as 
follows (Marbach et.al., 1994, pp88-89): 
“(1) Pacemaker implanted patients should not be treated with a betatron. 
(2) Pacemakers should not be placed in the direct (unshielded) therapy beam. 
Some accelerator beams can cause transient malfunction.  
(3) The absorbed dose to be received by the pacemaker should be estimated 
before treatment. 
(4) If the total estimated dose to the pacemaker might exceed 2Gy, the 
pacemaker function should be checked prior to therapy…early changes in 
pacemaker parameters could signal a failure in the 2-10Gy region.  
(5) Although transient malfunction from EMI is unlikely from contemporary 
LINACS… the patient should be closely observed during the first treatment with 
a  LINAC and during subsequent treatments if magnetron or klystron misfiring 
(sparking) occurs.. 
(6) Studies to date have dealt with LINACs, Betatrons and cobalt irradiators 
only. Use of other radiation therapy machines should be evaluated on an 
individual basis and approached with caution.” 
 
3.4.1 Limitations of the AAPM TG-34 Guidelines 
 
As technology has rapidly changed in both cardiology and radiation oncology over the 
past 20 years, these guidelines are now considered out of date (Sundar et al., 2005), 
however they still form the basis of many current protocols. In some cases these 
protocols have been adopted completely without revision using data from current 
research, even when the technology, such as Co-60, is no longer in use in the centre 
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(Hogle, 2001; Solan, Solan, Bednarz, & Goodkin, 2004).These guidelines do not give 
advice on the treatment of patients with implanted ICDs, and only include  the first 
generation of CMOS circuitry (Sundar et al., 2005). There has also been significant 
change in LINAC technology and radiation therapy planning with the advent of 
modulated treatments.  
 
3.5 Irradiation studies post AAPM guidelines 
 
Since 1994 there has been no published revision of the AAPM guidelines. Radiation 
Oncology departments are required to base treatment protocols for patients with CIEDs 
on current literature. The available literature varies in regard to the risks and frequency 
of malfunction. In vitro studies for PM have not been performed since 2005, with a 
changing focus to the impact of radiation therapy on ICDs. Malfunctions are rarely 
reported for PM, but make up the largest portion of literature on ICDs. Whether this is 
due to an over-reporting of failures in ICDs or a genuine issue is yet to be discussed. 
  
3.5.1 In vitro studies using PMs  
 
Three PM in vitro studies have been performed since 1994, with the most recent 
occurring in 2005. A higher proportion of failures were recorded when the PMs were 
irradiated using 18MV, as opposed to 6MV and 8MV. A detailed summary of the results 
of the in vitro PM studies carried out since 1994 are given in Table 3.3.  
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Souliman and Christie (1994) irradiated 18 explanted single and dual chamber PMs with 
8MV in 2.8Gy fractions to a total dose of 70Gy, or until device failure. Eleven of 18 
PMs failed, with first failure shown at 16.8Gy with complete loss of function. Souliman 
and Christie (1994) concluded that patients with PMs should be closely monitored due 
to the possibility of fatal PM failure.  
 
Mouton et al. (2002) conducted the largest study to date on the impact of radiation 
therapy on PM operation, incorporating 96 explanted PMs irradiated with 18MV. It was 
also the first study to consider the importance of the effect of dose rate on PM function. 
The first failures occurred when exposed to scatter radiation (0.15Gy). Seventy per cent 
of PMs failed when radiation was delivered at high dose rates   (8Gy min-1), however 
the effect of dose rate on irradiated devices was not tested independently of accumulated 
dose. Mouton et.al. (2002) proposed that there was no safe accumulated dose due to 
important failures occurring at doses equivalent to scatter radiation, and that 
manufacturers should redesign devices with radiation ‘hardened’ circuitry. They also 
suggested that ECG monitoring should be carried out on PM-dependent patients so that 
treatment may be stopped if anomalies occur.  
 
Hurkmans et al. (2005a) conducted their study using a lower treatment energy than 
Mouton et al. (2002). Nineteen new PMs were irradiated to doses of 20Gy in seven 
fractions of increasing dose using 6MV, with two to five days between each fraction 
simulating an irradiation period of five weeks. The PMs were analysed, then irradiated 
to 120Gy or point of failure, whichever occurred first. The earliest failure occurred at 
10Gy with poor telemetry. All but one important failure occurred at ≥90Gy, with five 
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PMs showing no error. Hurkmans et.al. (2005a) proposed that the AAPM TG-34 
guidelines were still valid, but more studies were needed to ascertain ‘when and how 
new protocols’ should be introduced (p97).  
 
Neither Hurkmans et al. (2005a) or Souliman and Christie (1994) could match the 
frequency of failures that were shown in the study conducted by Mouton et al. (2002). 
The dose at which the failures occurred was also notably higher in the former two 
studies. This may be attributed to the dose energies at which these studies were 
conducted (8MV, 6MV and 18MV respectively), rather than the number of PMs 
included.  
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Table 3.3: In vitro irradiation studies post 1994 - PM 
Author Year No. of 
PMs 
Energy Max. 
Dose 
Outcome 
Souliman, 
S. K. 
Christie, J. 
1994 18 8MV 70Gy 2.8Gy fractions given to explanted single and dual chamber PM.  
First failure observed at 16.8Gy (complete failure).  
EMI was concluded to have no impact on PM function.  
Eleven of 18 PMs failed between 16.8 and 70Gy, with no device recovery observed. Loss of 
the ability to inhibit output shown by fixed rate pacing in interference mode preceded 
complete failure.  
Other malfunctions included loss of atrial pacing in conjunction with a decrease in pulse 
rate (3), and increased pulse interval and corresponding pulse rate reduction (5), both 
indicative of battery depletion.  
Mouton, J. 
Haug, R. 
Bridier, A. 
Dodinot, B. 
Eschwege, 
F. 
2002 96 18MV 120Gy Largest study to date of PM irradiation. 
First study to consider dose rate as a risk of PM malfunction. 
70% of PMs failed at dose rate 8Gymin-1; no failures at ≤0.2Gymin-1.  
Three failures deemed important/potentially harmful: amplitude changes >10% (A10), 
silences in electrical signal >10 seconds (S10) and permanent silence (PS). 
Minimum dose at which important failures occurred was 2, 0.5 and 0.15Gy respectively. 
Failures observed throughout treatment - 66% A10, 50% PS, 48% slowed down rate, 41% 
S10, 30% accelerated rate, 27% missing pulse at start of irradiation, 23% signal compatible 
modification, 17% shape deformation. 
5% of all PM observed multiple short silences, which are considered harmful.  
16.7% of PMs showed an important failure at 5Gy, dropping to 11.5% for ≤2Gy.  
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Author Year No. of 
PMs 
Energy Max. 
Dose 
Outcome 
Hurkmans, C.W. 
Scheepers, E. 
Springorum, B.G. 
Uiterwaal, H. 
2005 19 6MV 120 Treatment given in 7# of increasing dose, with 2-5 day intervals between each 
fraction to simulate treatment over five weeks. 
First failure at 10Gy. 
All important failures occurred at ≥90Gy except for one at 20Gy. 
Five of 19 PM showed a battery replacement warning.  
Loss of output was the most commonly observed point of failure. 
Complete loss of signal was observed in 7 PM with all but one recovering one week 
after the final fraction.  
Pacing frequency inhibition during irradiation was observed in 8 PM, but stopped 
immediately as the radiation was switched off.  
Temporary or permanent loss of telemetry capability was seen in 3 PM, one occurring 
at 20Gy. This device had the earliest malfunction (poor telemetry) at 10Gy. 
Five devices showed no errors.  
Key: PM = Pacemaker; MV = photon; Gy = Gray; EMI = electromagnetic interference; # = fraction; A10 = amplitude changes greater 
than 10%; S10 = pacing silences greater than 10 seconds; PS = permanent silence.
-70- 
3.5.2 In vitro studies using ICDs 
 
Four in vitro ICD studies have been published since 1994, with the most recent in 2013. 
All studies found that direct irradiation of ICDs was likely to cause a higher incidence of 
error, including pacing inhibition or rapid pacing rate including VT and VF. Only one 
study included the use of high photon energy (18MV) treatments; failures were found to 
occur more frequently at 18MV than 10MV, even when located distally to the treatment 
beam. A summary of these studies is found in table 3.4. 
 
Hurkmans et al. (2005b) also conducted the first in vitro ICD study, incorporating 
eleven new ICDs following a similar regime to a previously conducted PM study 
(Hurkmans et al., 2005a). Four ICDs from the same manufacturer reached their point of 
failure at a dose less than or equal to 2.5Gy, with the first malfunction occurring at 
0.5Gy. A fifth ICD, of the same model and type as the previous four, withstood 
irradiation to 120Gy, displaying great variability within the models themselves. In four 
cases, VT or VF (see section 2.4.2) detection occurred, which would have resulted in the 
inappropriate delivery of a shock. Rigorous protocols were proposed for the 
management of ICD patients undergoing radiation therapy due to the inability to predict 
or detect ICD failure and the potential for the ICD to inappropriately deliver a shock to 
the patient.  
 
Uiterwaal, Springorum, Scheepers, de Ruiter, and Hurkmans (2006) observed the effect 
on ICDs of direct and indirect exposure to a radiation therapy field. All ICDs showed 
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interference detection, resulting in pacing inhibition or rapid ventricular rate when 
placed within the field. Four ICDs indicated VT/VF detection which could result in the 
inappropriate delivery of a shock. Due to the risk of ICD malfunction resulting from 
interference detection, Uiterwaal et al. (2006) proposed a conservative recommendation 
list, including the need to reprogram ICDs to ‘monitor only’ to avoid inappropriate 
delivery of a shock, careful monitoring of patients undergoing radiation therapy,  and 
the necessity of emergency resuscitation equipment with external pacing capability, 
including an external defibrillator, being available. Kapa et al. (2008) expanded on the 
observation of the effect of scatter radiation with CIEDs placed outside the radiation 
beam to limit the dose received to 4Gy. No malfunction was recorded, with no changes 
in PM function one week post treatment.    
 
Hashii et al. (2012) assessed the impact  of neutron contamination on ICDs from 10MV 
and 18MV beams on older and newer ICD models, with ICDs placed 7cm outside the 
field edge. A control ICD was placed 140cm from the isocentre. Errors occurred more 
frequently in the 18MV group, in both the test and control ICDs. Chan et al. (2012) 
noted that an ICD exposed to radiation with 5mm bolus, equivalent to the depth of skin,  
is exposed to lower levels of scatter than without bolus. Only Hurkmans et al. (2005a) 
and Hurkmans et al. (2005b) incorporated bolus on top of the CIEDs in their study, 
potentially decreasing the incidence of failure in these studies when compared to others.   
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Table 3.4: In vitro irradiation studies post 1994 - ICD 
Author Year No. 
of 
ICDs 
Energy Max. 
Dose 
Outcome 
Hurkmans, C.W. 
Scheepers, E. 
Springorum, 
B.G.F. 
Uiterwaal, H. 
2005 11 6MV 120Gy Followed similar regimen to PM study, with shock delivery also assessed. 
First malfunction observed at 0.5Gy.  
Sensing threshold changes often seen as first malfunctions.  
Four ICDs of same model and manufacturer failed ≤2.5Gy; a fifth ICD withstood 
irradiation to 120Gy.  
No other failures were observed ≤20Gy.  
Four ICDs showed VT or VF detection.  
No significant changes in pulse amplitude or pulse frequency were observed.  
No telemetry problems occurred.  
Uiterwaal, G. 
Springorum, 
B.G.F. 
Scheepers, E. 
de Ruiter, G.S. 
Hurkmans, C.W. 
2006 11 6MV 20Gy ICDs irradiated within irradiation field, out of field and leads in field only. 
Aimed to assess interference detection which may result in inhibition or triggering 
of pacing pulses and in the incorrect delivery of a shock.  
All ICDs showed interference detection from the first fraction when placed inside 
the field. 
Four ICDs showed VT/VF detection.  
When placed outside the field, no interference was detected.  
Kapa, S. 
Fong, L. 
Blackwell, C. R. 
Herman, M. G. 
Schomberg, P. J. 
Hayes, D. L. 
2008 20 6MV 4Gy to 
ICDs/ 
80Gy to 
isocentre 
Expanded on the observation of ICDs failing at the dose rate of scatter radiation. 
All ICDs were placed on the outside beam edge to ensure only 4Gy of scatter 
radiation was accumulated by the ICDs. VT/VF therapies were programmed to 
“off” to avoid inappropriate shock delivery.  
No device demonstrated changes in programmed parameters or device reset after 
any fraction.  
Reprogramming was carried out one week post treatment to check for limitations 
to programming ability, with no limitations. 
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Author Year No. 
of 
ICDs 
Energy Max. Dose Outcome 
Hashii, H. 
Hashimoto, T. 
Okawa, A. 
Shida, K. 
Isobe, T. 
Hanmura, M. 
Nishimura, T. 
Aonuma, K. 
Sakae, T. 
Sakurai, H. 
2013 - 10 and 
18MV 
1600Gy 
(10MV)/ 
600Gy 
(18MV) 
isocentre 
Large in field doses, with ICDs placed 7cm outside the beam portal.  
A control ICD was placed 140cm from isocentre. 
Hard errors, or permanent loss of therapeutic function, were not observed.  
Incidence of severe, moderate and minor soft errors: 
   -Older ICDS:  
       -18MV - 0.75, 0.5 and 0.83/50Gy respectively 
       -10MV 0.094, 0.063 and 0/50Gy.  
   -Newer ICD:  
       -18MV - 0.083, 2.3 and 5.8/50Gy.  
Moderate and minor errors occurred at 18MV in the control ICD with an 
incidence of 0, 1 and 0/600Gy for the newer model and 0, 1, and 6/600Gy for the 
older model.  
At 10MV, no failure was observed in the control model.  
ICD errors occurred more frequently at 18MV when compared to 10MV, even 
when located 140cm from isocentre. 
Key: ICD = Implantable Cardioverter Defibrillator; MV = photon; Gy = Gray; VF = ventricular fibrillation; VT = ventricular 
tachycardia
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3.5.3 In vivo case studies of PMs 
 
There have been a total of eight case studies detailing radiation therapy exposure to 13 
PMs,  published since 2000, with the majority of case studies having reported no 
malfunction (Kirova, Menard, Chargari, Mazal, & Kirov, 2012; Mitra et al., 2006; 
Munshi et al., 2008; Nibhanupudy, de Jesus, Fujita, & Goldson, 2001; Santhanam, 
Bolton, Vasanthan, & Thomas, 2002; Tsekos, Momm, Brunner, & Guttenberger, 2000). 
The dose received by the PMs ranged from <0.5Gy to >50Gy. In most cases, the 
treatment energy given to the PM was not reported. While PM failure is shown to be 
rare, severe failure may result in serious patient consequences. A summary of these 
studies is given in table 3.5.  
 
One instance of undersensing in a PM has been reported, where the PM fails to sense the 
patients native cardiac rhythm, during treatment of a cardiac metastasis using 6MV 
IMRT (Dasgupta, Barani, & Roach, 2011) after an accumulated dose to the device of 
0.37Gy. As the cardiac tumour encased the PM leads, this may have attributed to the PM 
undersensing. This was remedied with reprogramming of the pacing output.  
 
Zweng, Schuster, Hawlicek, and Weber (2009) reported on the most serious 
malfunction, a runaway PM that developed after the ninth fraction of radiation therapy, 
resulting in the patient being admitted to the intensive care unit in a critical condition. 
Continuous monitoring with an ECG was undertaken by the department during all stages 
of treatment; the first indication of failure was seen when the patient complained of 
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sudden onset angina and shortness of breath. A magnet placed over the PM had no 
effect. The programmer was unable to reprogram the device; as a result the PM was 
immediately replaced. 
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Table 3.5: In vivo PM studies post 1994 
Author Year Tumour Prescribed 
dose/fractions 
Dose to 
PM 
Treatment 
Energy 
Outcome 
Tsekos, A. 
Momm, F. 
Brunner, M. 
Guttenberger, R. 
2000 Neuroendocrine 
carcinoma of right 
arm 
50.4Gy/28# >50Gy  Unknown 
 
Magnetic frequency of the PM began to 
decrease, returned to normal four months 
post treatment. 
No malfunctions occurred.  
Nibhanupudy, J. R. 
de Jesus, M. A. 
Fujita, M. 
Goldson, A. L. 
2001 Left Breast 50.4Gy breast, 
50Gy S.clav 
1.8Gy 6MV No malfunction 
Santhanam, S. 
Bolton, S. 
Vasanthan, S. 
Thomas, G. 
2002 Parotid tumour 
Lymphoma 
Myelofibrosis/Spleen 
Breast – axilla 
Lung 
Lung 
64Gy/32# 
15Gy/5# 
4.5Gy/9# 
26.7Gy/10# 
15Gy/10# 
30Gy/10# 
1.3Gy 
0.8Gy 
<0.5Gy 
26.7Gy 
0.8Gy 
0.6Gy 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
No malfunction 
No malfunction 
No malfunction 
No malfunction 
No malfunction 
No malfunction 
Mitra, D. 
Ghosh, K. 
Gupta, P. 
Jayanti, J. 
Dev, A.R. 
Sur, P.K. 
2004 NSCLC 40Gy 0.73Gy Unknown No malfunction 
Munshi, A. 
Wadasadawala, T. 
Sharma, P. K. 
Sharma, D. 
Budrukkar, A. 
Jalali, R. 
Dinshaw, K. A. 
2008 Left Breast 50.4Gy 4.3Gy 10MV No malfunction 
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Author Year Tumour Prescribed 
dose/fractions  
Dose to 
PM 
Treatment 
Energy 
Outcome 
Zweng, A. 
Schuster, R. 
Hawlicek, R. 
Weber, H. S. 
 
2009 Oesophagus 30Gy/10# 0.11Gy Unknown Runaway PM occurred after ninth 
fraction; patient presented with sudden 
angina and shortness of breath. 
Pacing mode switched from DDD to 
AAI with a fixed pacing rate of 185bpm.  
Placement of magnet over the PM did 
not affect the PM induced tachycardia.  
Patient required transfer to ICU in a 
critical condition. Replacement of the 
PM was conducted in emergency, with 
the patient showing rapid improvement 
after disconnection of the original PM.  
Dasgupta, T. 
Barani, I. J. 
Roach, M., 3rd 
2011 Cardiac Metastases 
(RA and RV) 
37.5Gy/15# 0.37Gy 6MV Cardiac tumour encased pacing leads.  
Single episode of ventricular 
undersensing – successfully remedied 
through reprogramming. 
Kirova, Y. M. 
Menard, J. 
Chargari, C. 
Mazal, A. 
Kirov, K. 
2012 Spine (T8-T9) 30Gy/10# 0.1Gy 20MV Partial pacing leads within whole field. 
No malfunction recorded.  
Key: PM = Pacemaker; MV = photon; Gy = Gray; # = fractions; s’clav = supraclavicular; RA = right atrium; RV = right ventricle; T8-
T9 = thoracic vertebrae eight to nine; ICU = intensive care unit; bpm = beats per minute.
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3.5.4 In vivo case studies of ICDs 
 
Five ICD case studies have been published post 1994.  Unlike the PMs, four of the five 
patients reported failures. Treatment energies were only reported for two patients, both 
of whom received high photon energies (18MV and 23MV), resulting in a power on 
reset (POR) of each device.  The dose to the ICD was also not commonly reported. The 
only patient to not show a failure of the ICD had the active functions of the device 
deactivated prior to each treatment. A summary of ICD in vivo studies is given in table 
3.6. 
 
In most case studies, the energy at which radiation therapy was given was not specified. 
Both Thomas, Becker, Katus, Schoels, and Karle (2004) and Lau et al. (2008) reported 
power-on resets occurring at high dose energies (18MV and 23MV respectively). In 
both cases patients remained asymptomatic.  
 
John and Kaye (2004) reported on shock coil failure, which was discovered during 
surgery to change an ICD after routine checks indicated the ICD battery was depleted,  
i.e. the failure was only discovered during the procedure for an unrelated event. 
Causation cannot be guaranteed, but was seen as the most likely explanation. 
 
Sepe, Schaffer, Krimmel, and Schaffer (2007) reported no malfunction after radiation 
therapy although the ICD was exposed to 2.5Gy. During each treatment the active 
functions of the ICD were deactivated. 
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Similar to PM devices, a runaway pacing rhythm was the most dangerous complication 
reported. One case study detailed the collapse of a patient during the third fraction of a 
radiation therapy course. The patient lost all cardiac function and required CPR and 
intubation (Nemec, 2007). The ICD could not be reset and was explanted in emergency. 
No replacement ICD was given as the patient was not dependant on the ICD, and 
treatment concluded without further incident. The dose to the ICD could not be 
estimated, however, as this was only the third fraction, it was deemed to be well below 
dose tolerance.  
 
In vivo case studies of ICDs may over report the incidence of failure as they have rarely 
reported the number of treatments given to ICD patients without incident. As many of 
these studies (as well as studies detailed in section 3.5.3) were written by cardiologists, 
they lack the relevant radiation therapy details required to assess the causes of CIED 
damage. Since 2009, observational studies have overtaken case reports in the literature 
and are found in section 3.6. 
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Table 3.6: In vivo ICD studies – post 1994 
Author Year Tumour Prescribed 
dose/ fractions 
Dose to 
PM 
Treatment 
Energy 
Outcome 
Thomas, D. 
Becker, R. 
Katus, H. A. 
Schoels, W. 
Karle, C. A 
2004 Bronchial 56Gy/28# Unknown 18MV Patient asymptomatic. 
POR detected nine days post treatment during routine ICD 
check. 
No other parameters were affected. 
John, J. 
Kaye, G. C. 
2004 Breast 50Gy/20# Unknown Unknown Partial exposure to ICD, full exposure to leads. 
Battery depletion at some point post RT led to ICD change. 
During ICD change, shock impedance >125Ω indicative of 
shock coil failure discovered. 
Lead required change at same time as ICD. 
Sepe, S. 
Schaffer, P. 
Krimmel, K. 
Schaffer, M. 
2007 Larynx 60Gy tumour/ 
50Gy lymph 
2.5Gy Unknown No malfunction. 
ICD externally deactivated during treatments.  
Nemec, J. 2007 Lung 59.4Gy/33# Unknown 
(low 
dose) 
Unknown 
 
Patient collapsed during fraction three due to runaway ICD 
and required CPR.  
ICD suggestive of RAM damage but no evidence was found  
during company interrogation. 
Patient required ICD explantation in emergency, with no 
replacement given. 
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Author Year Tumour Prescribed 
dose/ fractions 
Dose to 
PM 
Treatment 
Energy 
Outcome 
Lau, D. H. 
Wilson, L. 
Stiles, M. K. 
John, B. 
Shashidhar, 
Dimitri, H. 
Brooks, A. G. 
Young, G. D. 
Sanders, P. 
2008 Prostate 74Gy/37# 0.004Gy 23MV POR occurred during fractions two and nine. 
Lead shielding added to ICD for remaining treatments.  
No further incident occurred. 
Key: ICD = implantable cardioverter defibrillator; MV = photon; Gy = Gray; # = fractions; POR = power on reset; RT = radiation 
therapy; Ω = ohms; CPR = cardiopulmonary resuscitation; RAM = random access memory.
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3.6. Observational Studies – PM and ICDs (CIEDs) 
 
Seven observational studies were conducted between 2008 and 2013. Individual studies 
have spanned multiple years, observing 245 patients that were treated with various 
radiation therapy doses and energies. These studies have undertaken research into failure 
rates without employing unrealistic treatment practices – for example, high accumulated 
device doses, which were previously common, and enable the effectiveness of current 
protocols to be assessed. CIED failure was a rare complication, often occurring at high 
photon treatment energies, greater than 10MV. A detailed summary of these studies is 
given in table 3.7. 
 
Kapa et al. (2008) reported on the irradiation of 13 patients (eight PM, five ICDs) 
treated between 2002 and 2007 to support the in vitro study undertaken by the authors 
(described in section 3.5.2). In all cases, the CIED was located outside the treatment 
field and no failures were recorded. Gelblum and Amols (2009) observed 33 ICD 
patients treated over a two and a half year period at multiple sites between 2005 and 
2007, representing approximately 0.25% of their patient load. Two patients incurred a 
POR whilst undergoing 15MV prostate treatments. The dose received by these ICDs 
was negligible due to the distal location of the treatment site to the implant site. After 
the second failure, the departmental protocol was changed to limit treatment energy to 
6MV, with no further failures recorded. The authors noted that three ICDs received 
doses greater than 2Gy without malfunction, proposing that ICD damage is not a dose 
driven effect.   
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The longest observational study undertaken to date was conducted by Ferrara et al. 
(2010), which prospectively investigated CIED patients treated between 1999 and 2007. 
The study involved both PMs and ICDs, with a median follow up period of 26 months 
(range 6-87). Three patients suffered cardiac events, these being heart failure, angina 
and hypertension, during the course of treatment. Two further patients incurred late 
cardiac complications or heart failure. All five patients underwent neoadjuvent or 
concomitant chemotherapy. Whilst these cardiac events were not necessarily indicative 
of CIED damage from radiation, the authors could not rule out this possibility.  
 
Wadasadawala et al. (2011) observed eight PMs with accumulated doses ranging from 
0.14 to 60Gy. Two patients were treated with 15MV, three with Co-60 and three with 
6MV. Although receiving doses higher than general recommendations, no device failed, 
with follow up equalling or greater than five months in six cases.  
 
Soejima et al. (2011) assessed information from 62 patients across 29 centres in Japan 
between 2006 and 2008 (60 PM, 2 ICDs). As the study was conducted via a prospective 
survey with no standardised protocol used, the accumulated dose to the CIED was 
estimated in only 50% of devices. The accumulated dose received by the CIEDs ranged 
to 20.69Gy with the minimum dose not reported. One PM failed during 15MV IMRT 
prostate treatment at 46Gy and 56Gy. The observed failure was attributed to neutron 
contamination from the high energy beam.  
 
Makkar et al. (2012) analysed the results of 69 patients treated at the University of 
Michigan between 2005 and 2011 (50 PM and 19 ICDs). Two ICDs experienced 
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malfunctions during 16MV treatment. One patient incurred a partial electrical reset (loss 
of historical data only) after receiving 1.23Gy to the ICD during a combination 
6MV/16MV treatment. The ICD was located 1.5cm from the beam portal.  A total of 
2.01Gy was received without further incident. A second patient also recorded a partial 
reset of their ICD at 0.04Gy during a 16MV pelvic treatment. No further incidents were 
recorded during the completion of treatment. At 6 months, no battery depletion 
attributed to radiation therapy was recorded. Elders et al. (2013) recorded the irradiation 
of 15 ICD patients to 17 sites in The Netherlands. No device received greater than 1Gy 
due to the patient management protocol. Temporary malfunction was observed in four 
ICDs; all failures occurred at treatment energies greater than 10MV.   
 
The large number of patients observed across all of these studies, along with the 
cooperation of cardiology departments, allows the assessment of risk for these patients 
undergoing a realistic radiation therapy regime. The length of these studies also 
highlights the need for protocols to adapt to current research, namely the concern over 
using high energy (>10MV) irradiation to treat CIED patients. How these patients 
compare to a non- radiation therapy cohort remains to be investigated.  
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Table 3.7: Observational Studies – PM and ICDs 
Author Year CIED 
Type 
No. of 
CIEDs 
No of 
failures 
Outcome 
Kapa, S. 
Fong, L. 
Blackwell, C. R. 
Herman, M. G. 
Schomberg, P. J. 
Hayes, D. L. 
2008 PM & 
ICD 
8 PM/ 5 
ICD 
- All CIEDs located outside beam. 
No failures observed.  
Gelblum, D. Y. 
Amols, H. 
2009 ICD 33 2 Accumulated dose to the ICDs ranged from 0.01-2.99Gy;  
Two patients incurred POR during 15MV prostate treatments. 
Dose to POR ICDs was minimal; Three ICDs received >2Gy without error.  
Ferrara, T. 
Baiotto, B. 
Malinverni, G. 
Caria, N. 
Garibaldi, E. 
Barboni, G. 
Stasi, M. 
Gabriele, P. 
2010 PM & 
ICD 
37 PM / 
8 ICD  
5* Failures observed were cardiac events not definitively attributed to RT. All 
patients with failures treated with combine chemo/RT.  
The longest observational study conducted (1999-2007); follow up to 26 months. 
Three patients incurred cardiac events – heart failure, angina and hypertension – 
during the course of treatment.  
Two patients incurred late cardiac complications or heart failure.  
All five patients underwent neoadjuvent or concomitant chemotherapy.  
Wadasadawala, T. 
Pandey, A. 
Agarwal, J. P. 
Jalali, R. 
Laskar, S. G. 
Chowdhary, S. 
Budrukkar, A. 
Sarin, R. 
Deshpande, D. 
Munshi, A. 
2010 PM 8 - Accumulated dose received by the PM ranged from 0.14-60Gy.  
Two patients were treated with 15MV, three with Co-60 and three with 6MV.  
No failures recorded. 
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Author Year CIED 
Type 
No. of 
CIEDs 
No of 
failures 
Outcome 
Soejima, T. 
Yoden, E. 
N. Ishimura Y 
Ono, S. 
Yoshida, A. 
Fukuda, H. 
Fukuhara, N. 
Sasaki, R. 
Tsujino, K. 
Norihisa, Y. 
2011 PM & 
ICD 
60 PM/ 
2 ICD 
1 PM Accumulated dose ranged to 20.69Gy; second highest received 4.78Gy; only 
50% of devices had accumulated dose estimated.  
One PM failed during 15MV IMRT prostate treatment, attributed to neutron 
contamination.  
Preventative or precautionary measures included: ECG monitoring (47% of 
patients), cardiac device checks (84%), accumulated dose (50%) and 
cardiologist consultation (56%).   
No analysis of high vs. low energy failures possible.  
Makkar, A. 
Prisciandaro, J. 
Agarwal, S. 
Lusk, M. 
Horwood, L. 
Moran, J. 
Fox, C. 
Hayman, J. A. 
Ghanbari, H. 
Roberts, B. 
Belardi, D. 
Latchamsetty, R. 
Crawford, T. 
Good, E. 
Jongnarangsin, K. 
Bogun, F. 
Chugh, A. 
Oral, H. 
Morady, F. 
Pelosi, F., Jr. 
2012 PM & 
ICD 
50PM/ 
19 ICD 
2 ICD PMs accumulated dose ranged 0.009-5.06Gy; ICDs 0.04-1.69Gy.  
Five PM patients required device relocation before treatment.  
Two PM and three ICD patients were deemed too high risk to undergo 
device relocation, although the device was within 2.5cm of the beam portal; 
these patients received daily monitoring.  
24 PM and 12 ICDs were treated with high energy photons (16MV).  
Two ICD malfunctions - one partial electrical reset after 1.23Gy during 
6MV/16MV treatment.  A second patient recorded a partial reset of their 
ICD at 0.04Gy during a 16MV pelvic treatment.   
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Author Year CIED 
Type 
No. of 
CIEDs 
No of 
failures 
Outcome 
Elders, J. 
Kunze-Busch, M. 
Jan Smeenk, R. 
Smeets, J. L. 
2013 ICD 15 8 No device received >1Gy due to the patient management protocol.  
Failures occurred in 29% of treatments. 
During treatment, all ICDs were switched to “monitor only” mode to prevent 
inappropriate shock delivery.  
Two ICDs had a device reset. 
Two ICDs had invalid data retrieval.  
A second data error was observed in one patient 9 months post treatment, 
however it is unclear if this was RT related. 
All patients with device failures were treated with 10MV or greater. 
Key: CIED = cardiac implantable electronic device; PM = Pacemaker; ICD = implantable cardioverter defibrillator; MV = photon; 
POR = power on reset; RT = radiation therapy; Co-60 = Cobalt 60; IMRT = intensity modulated radiation therapy;  Gy = Gray; # = 
fractions.
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3.7 Treatment planning and protocols for CIED patients 
 
While the risk of damage from accumulated dose, direct irradiation and treatment 
energies greater than 10MV have been investigated, the clinical implications of any 
treatment recommendations proposed must be considered. Treatment planning for CIED 
patients has been investigated twice (Croshaw et al., 2011; Riley, Garcia, & Guerrero, 
2004), as well as the implications of the simulation of patients using CT scans 
(McCollough, Zhang, Primak, Clement, & Buysman, 2007).  
 
Riley et al. (2004) documented the utilisation of a 3D treatment planning system 
(3DTPS), incorporating coplanar, where the gantry and collimator move but the 
treatment couch remains at 0°, and non-coplanar beams, where the treatment couch 
moves off-axis. The treatment plan used a mix of 6MV and 18MV beams, some of 
which had an angled entry into the patient. This was to avoid the irradiation of the PM 
situated on the ipsilateral side during upper lobe radiation therapy of the lung. The 
accumulated dose to the PM was restricted to less than 5Gy. The study was used to 
prove optimum treatment could be provided while sparing the patient the high expense 
of a PM relocation.  More recent developments in CIED research has indicated that this 
type of treatment plan may be contraindicated due to the necessity of high energy beams 
to adequately deliver the required dose to the planning volume. Advances in treatment 
techniques, such as SBRT, may alleviate this issue.  
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Croshaw et al. (2011) observed the trend of breast cancer patients in America being 
referred for a mastectomy rather than breast conservation treatment due to the reluctance 
of cardiologists and electrophysiologists to move the CIED to the contralateral side, 
citing patient safety concerns and more difficult placement (Goldstein, Rabkin, & 
Spotnitz, 1999). Croshaw et al. (2011) suggested the implementation of an accelerated 
partial breast irradiation protocol (APBI) using 3D-CRT to limit radiation exposure to 
the CIED, whilst still allowing conservative surgical methods.  Between 2007 and 2010, 
5 patients were treated using this technique. The maximum dose received by the CIED 
was 1.68Gy. No CIED malfunctioned either during or after treatment.   
 
Limited clinical studies exist investigating the effect of CT scans on CIED function. 
McCollough et al. (2007) reported that although transient effects may occur, it was 
relatively safe for CIEDs to pass through a CT scanner, as the process is very short,  
lasting  less than three seconds in the case of sequential or spiral scans. Cardiologist 
assessment before CT scans is recommended.  
 
Current improvements to the stability and functionality of CIED design has led to more 
efficient battery power consumption. This increased stability  has led to further interest 
in raising the dose limit to CIEDs during radiation therapy to limits of 10Gy on a case 
by case basis (Hurkmans et al., 2012).  Increased dose limits may lead to CIEDs being 
within or close to the treatment beams, with the necessity for the dosimetric effect of the 
CIED on the treatment beam profile to be assessed. The results of the Gossman, Graves-
Calhoun, and Wilkinson (2010) study on the effect of CIEDs on beam profiles are 
summarised in table 3.8 
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Table 3.8: The effect of CIEDs on direct beam profiles (Gossman et al., 2010) 
 PM ICD Leads 
6MV 18MV 6MV 18MV 6MV and 18MV 
Attenuation -15.9% -9.4% -13.4% -6.1% 4% 
Backscatter 2.8% 3.4% 2.1% 3.1% - 
Lateral Scatter 2.5% 5.7% 1.5% 5.1% - 
Key: PM = pacemaker; ICD = implantable cardioverter defibrillator; MV = photons. 
 
Radial and transverse beams have been modelled on Medtronic CIEDs to assess the 
impact of the CIED components on beam profiles (Gossman, Nagra, Graves-Calhoun, & 
Wilkinson). Large changes (>10%) when exposed to radial and transverse beams led to 
isodose depth dose disagreement of up to 2.5cm, shown in figure 3.1. Direct irradiation 
of a CIED may lead to under dosing of PTVs if these changes are not taken into account. 
Extending the Hounsfield unit (HU) range when scanning with a CT was advised.   
 
Figure 3.1: Radiation therapy beam isodose profiles for Medtronic Inc. 
implantable PM Versa™ model VEDR01 for (a) 6MV axial plane and (b) 6MV 
transverse plane (Gossman et al., 2011). Grid units are in cm.  
 
-91- 
3.8 CIED radiation therapy guidelines: manufacturer 
recommendations 
 
Large variability exists between the recommendations of the cardiac device 
manufacturing companies. A summary of the recommendations from various 
manufacturers has been provided in table 3.9.  
 
The addition of an energy limitation for ICD irradiation is relatively new, based on the 
case studies currently available detailing power-on-resets (PORs) in ICDs located 
distally to the beam portal. Until 2011, St Jude recommended a dose limit of 20-30Gy 
(Hudson, Coulshed, D'Souza, & Baker, 2010; St. Jude Medical, 2005), but now 
reference “no safe dose”(St. Jude Medical, 2011).  
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Table 3.9: Manufacturer guidelines for the treatment of CIED patients with  
radiation therapy. 
 Boston Scientific 
(2012) 
Medtronic (2008) St. Jude Medical 
(2011) 
Treat with CIED 
generator inside field 
No No No 
Relocation of CIED Consider if in 
treatment field 
Consider if in 
treatment field 
Consider if in 
treatment field 
Maximum dose to be 
received by CIED 
No ‘safe’ dose PM - 5Gy 
ICD – 1Gy-5Gy 
No ‘safe’ dose 
Maximum energy used 
to deliver treatment 
- ≤10MV - 
Dose rate to CIEDs - 1cGy/min-1  unlikely 
to cause 
interference; limit 
dose rate by 
increasing distance 
of CIED to 
treatment field 
- 
Examination of CIED 
before treatment 
course begins 
Yes Yes Yes 
Examination of CIED 
during treatment 
course 
 Not required after 1st 
treatment if no 
interference occurs 
in #1. 
Consider if events 
or device related 
symptoms occur 
Consultation with 
patients cardiologist 
prior to planning 
Yes Yes Consider 
Monitor patient during 
irradiation  
Consider continuous 
monitoring for CIED 
dependant patients 
- ECG 1st fraction, 
clinician discretion 
thereafter 
Switch adaptive 
functions to passive (see 
section 2.4.1) 
Consider if inhibition 
of pacing or 
inappropriate shock 
therapy 
- Consider if 
inhibition of 
pacing occurs 
Program to 
asynchronous mode 
(e.g. AOO, DOO, see 
section 2.4.1) 
Consider if inhibition 
of pacing or 
inappropriate shock 
therapy 
Consider if 
inhibition of pacing 
occurs 
- 
Use of magnet to 
inhibit sensing 
Consider if inhibition 
of pacing or 
inappropriate shock 
therapy 
Consider Consider if 
inhibition or 
oversensing occurs  
Key: CIED = cardiac implantable electronic devices; PM = pacemaker; ICD = 
implantable cardioverter defibrillator; MV = photon; # = fraction; ECG = 
electrocardiogram.  
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3.9 CIED radiation therapy recommendations in the literature 
 
 
A number of small treatment recommendations have been presented in the literature, 
either with original studies or as a response to systematic reviews of the literature: 
common suggested dose limits to CIEDs ranged from “no safe dose” (Sundar et al., 
2005), to 1Gy (ICDs) and 2Gy (PM) (Solan et al., 2004), to 5Gy or more 
(Wadasadawala et al., 2011) with direct irradiation contraindicated. Hurkmans et al. 
(2012) released the most comprehensive protocol in recent literature which outline 
the Dutch guidelines based on the available literature, with suggestions that CIEDs 
may be treated up to 10Gy. The outline of the protocol is shown in figure 3.2. The 
current NSW Cancer Institute PM and ICD treatment protocol is based on these 
guidelines (Cancer Institute of NSW, 2014). Most recent recommendations suggest 
limiting the exposure of ICDs to treatment energies of 10MV or less (Hurkmans et 
al., 2012). There are currently no recommendations on the exposure of PMs to any 
treatment energy.  
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Figure 3.2: Outline of the Dutch CIED management protocol, reproduced 
from Hurkmans et al. (2012) 
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3.10 Conclusion 
 
While the risk of device failure is assumed during high energy radiation therapy, the 
role of accumulated dose has now become ambiguous. Due to the number of case 
studies presented in the literature of ICD failures, the risk of PM malfunction has 
also become less apparent. The prevalence of these failures may also be hyperbolised 
by the appearance of single case studies. The recent number of observational studies 
has allowed a broader view of the risk of CIED malfunction from varying treatment 
techniques and accumulated doses. However, limited inclusion of ICDs, as well as a 
focus on major malfunctions during treatment, without comparison to a control 
population has prevented the true risk of radiation therapy on CIEDs being assessed. 
 
 Limitations proposed in CIED treatments have inadequate considerations for their 
effect on radiation therapy planning. Limited information exists for cardiologists to 
adequately manage these patients.   Since 2009, this author has participated in the 
Cancer Institute of NSW EviQ protocol committee which has published updated 
guidelines for patient treatment based on emerging literature (Cancer Institute of 
NSW, 2014). A new revision of the AAPM guidelines is currently underway by the 
AAPM TG-203. While the investigation is approved until 31st December 2014, it is 
unknown when a published report will be available. Until then, it is important to 
review all current articles to create a comprehensive protocol which can be moulded 
to the needs of individual radiation oncology departments. It is also necessary for 
gaps in the published literature to be addressed.  
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Chapter Four: Implantable cardioverter defibrillator 
(ICD) resets during radiation therapy 
 
4.1 Introduction 
 
ICD power on resets (PORs) have been increasingly reported in the literature (see 
section 3.5.4). As a consequence, new protocols  have proposed limiting the photon 
beam energy used to treat patients with ICDs to less than 10MV (Hurkmans et al., 
2012) This is in order  to prevent neutron contamination (Hurkmans et al., 2012)  
(see section 2.10). A POR is caused by an accidental overwriting of the RAM 
contained within the ICD. This causes the device programming to be lost and a 
safety “backup” mode to be enabled (see section 2.9). 
 
High photon energy radiation therapy, defined within this thesis as being treatments 
undertaken with energies above 10MV, is performed where tumours are situated 
deep within the body, such as in pelvic treatments, or in patients with larger 
anatomy. The invention of beam modulated radiation therapy, such as intensity 
modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) 
and stereotactic body radiation therapy (SBRT), has allowed some traditionally high 
energy treatments to be replaced with lower energies. However, in some cases these 
advances may be prohibitively time consuming and expensive (Moran et al., 2011; 
Smith et al., 2011), or unavailable. The risk of POR during ICD irradiation needs to 
be assessed to see whether the risk posed outweighs the benefit of treatment using 
high photon energies.  
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4.2 Study Aims and Outcomes 
 
This study aimed to assess the risk of POR during high energy radiation therapy for 
patients who have ICDs. This aim was associated with the following outcomes: 
1. Identify patients with ICD PORs at participating hospitals between 2008 and 
2011. 
2. Document and analyse known ICD POR cases. 
3. Compare the risk of ICD failure during high photon energy treatments to 
ICDs which did not incur a failure during treatment. 
 This study served as the initial investigation into the topic of radiation therapy on 
PMs and ICDs and informed the studies presented in Chapters Five to Eight.   
 
4.3 Materials and Methods 
 
Hospitals which had ICD patients with recorded incidents of POR during radiation 
therapy were identified through conversations with department representatives at a 
NSW Cancer Institute EviQ meeting in 2010. Low and negligible risk (LNR) 
research ethics approval was given by the Human Resource Ethics Committee 
(HREC) at Royal Prince Alfred Hospital in 2011 (X11-0346 and 
LNR/11/RPAH/548). Site Specific Assessment (SSA) approval was given by RPA 
(LNRSSA/12/RPAH/129), St George (LNRSSA/12/STG/63) and Westmead 
(LNRSSA/12/WMEAD/118) hospitals in 2012. Copies of ethics approvals are found 
-98- 
in appendix B. SSA was also sought from Liverpool Hospital, but had not been 
assessed by 2013 and was thus abandoned.  
 
Patients were included if they were identified as having incurred a POR during 
radiation therapy at the participating hospitals between 2008 and 2011 inclusive. 
Five patients were identified: two patients from St George, one patient from 
Westmead and two patients from RPA. After data collection, a comparison was 
made between the RPA patients and ICD patients treated with 18MV between 2005 
and 2012 who were included on a subsequent study (see Chapter Eight; HREC 
approval LNR/11/RPAH/554, X11-0351 and LNRSSA/12/RPAH/130; found in 
appendix E).  
 
4.4 Case Studies 
 
Five ICD patients were identified during this study. A summary of these patients is 
given in table 4.1. Seven additional ICD patients were treated with 18MV at RPAH 
between 2005 and 2012 without incurring a POR. Accumulated doses to these seven 
devices ranged from 0.05Gy to 2.8Gy. 
 
4.4.1 Patient A – Centre A 
 
Patient A was an 80-year-old man with a previous history of mitral valve repair and 
concomitant minor coronary artery bypass grafting. Implantation of a Medtronic 
Consulta cardiac resynchronisation device (CRT-D), with leads in the right atrium 
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and both ventricles, was performed. Limited access to the patient’s cardiac history 
did not allow for further analysis, and it is unknown whether this ICD was a 
replacement for a previous CIED or for a recent cardiac complication.  
The patient presented with prostatic carcinoma, to be radically treated using a five 
field 18MV beam arrangement. A dose of 68Gy to the 95% isodose line in 35 
fractions was prescribed by the attending radiation oncologist. A maximum planned 
dose of 74.2Gy was located 2cm inferior to the isocentre. Thermoluminescent 
dosimeters (TLDs) were placed over the ICD site during the first treatment, 
estimating a total dose of 0.009Gy would be received by the ICD.  
 
During a routine CIED check after fraction 25, it was discovered that the ICD had 
experienced multiple electrical resets during the course of treatment. Six single byte 
memory corruptions were also identified during the devices regular parity checks, 
beginning from fraction one. The ICD was reprogrammed, and on advice from the 
manufacturers, the treatment was replanned to incorporate only 6MV for eight 
fractions. The final two fractions were administered again using 18MV after further 
advice from the manufacturers, with the final two fractions delivering 150% of daily 
dose to accommodate for the multiple changes in treatment regime. Treatment was 
completed with no further complications.  
 
4.4.2 Patient B – Centre A 
 
Patient B was an 81-year-old man with a dual chamber Boston Scientific ICD 
insertion due to an abnormal cardiac rhythm. He presented to the centre with an 
intermediate risk clinically localised prostatic carcinoma, and was treated with a five 
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field 18MV plan. A dose of 74Gy in 37 fractions was prescribed by the radiation 
oncologist to the prostate and seminal vesicles. No dose was estimated to the ICD.  
 
The day after treatment completion, a routine CIED check was undertaken by a 
cardiac technician from the manufacturer. The ICD was found to have gone into 
reset mode, in VVI mode with lower limit pacing at 65bpm. The device was 
reprogrammed to DDD mode, with lower and upper limit pacing at 60 to 130bpm 
respectively. All other checks were within normal range, including impedance and 
threshold. Leads and thresholds remained stable, with impedances within range. No 
adverse events were recorded, including no inappropriate therapy delivered to the 
patient, and treatment was completed without incident. The manufacturer associated 
the fault with the “build-up of radiation causing device to reset”.  
 
4.4.3 Patient C – Centre B 
 
Patient C, a 67 year old man, had a previous history of syncopal episodes and a 
cardiac arrest requiring the insertion of an ICD. The ICD was changed four years 
later due to normal battery depletion to a single chamber St Jude Medical Atlas Plus 
ICD.  
 
The patient presented for management of a prostate carcinoma. Treatment was 
performed using a two phase, six field 18MV treatment protocol. Forty-six gray was 
prescribed for treatment of the prostate and seminal vesicles, with a 28Gy phase two 
to a smaller PTV incorporating the prostate gland only. No accumulated dose was 
estimated to the ICD.  
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ICD interrogation performed before initial treatment began indicated no errors, with 
a battery voltage of 3.15V. At a routine CIED check one month post treatment, the 
ICD was unable to be interrogated. The patient was referred immediately to 
admission, however declined as he had no adverse symptoms. The device was 
explanted and sent to St Jude Medical for analysis. The investigation summary stated 
that the ICD was subject to a Hazard Alert.  
“A register in the device had a parity error, resulting in the inability 
to interrogate. It is believed that the parity error was induced during 
radiation therapy reported in the field. A parity error is a rare 
occurrence, but can happen when a device is exposed to a certain 
type of environment” (Associate manager of regulatory compliance, 
St Jude Medical).  
As the device was unable to be interrogated, the exact time at which this occurred 
was unable to be determined. The patient experienced symptoms around fraction 
twelve, with anorexia, nausea and abdominal discomfort. It is unknown if this was 
attributed to the ICD failure. Follow up of the new ICD to three years has shown no 
further device complications.   
 
4.4.4 Patient D – Centre C 
 
Patient D, a 76 year old man, had a previous history of coronary artery disease with 
inducible tachycardia. A Medtronic Maximo VR ICD was inserted with a single lead 
to the right ventricle.  
 
The patient presented with a rectal carcinoma, and was put forward for curative 
management using a single phase three field treatment, incorporating both 6MV and 
18MV dose energies; 25Gy was prescribed in five fractions to the PTV, with the 
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ICD receiving a total dose of 0.013Gy during treatment, estimated by TLD 
measurements during the first treatment.  
 
The ICD was checked prior to the first fraction and no issues were found. After the 
initial treatment, during the routine check of the device, the ICD indicated that a 
patient alert had been triggered for POR during treatment. The device was 
reprogrammed by the company technician and it was decided that daily monitoring 
was required for this patient. The ICD operated normally for fraction two, however 
incurred another POR after the delivery of fraction three. The ICD was again 
reprogrammed and functioned normally for the remaining two fractions. Follow up 
of the ICD has shown no further abnormalities.  
 
4.4.5 Patient E – Centre C 
 
A 69 year-old man presented to centre C for management of a metastatic rectal 
carcinoma. The patient had a Medtronic Maximo VR ICD implanted in the left upper 
chest for unknown reasons. Treatment was initially carried out with the patient 
laying prone using a three field treatment with a prescription of 25Gy in five 
fractions. A mix of 18MV and 6MV beam energies was planned for treatment. After 
delivery of the first fraction the patient received a week’s break in order for the 
treatment to be replanned with the patient position supine due to patient discomfort. 
A total dose of 0.023Gy was estimated by TLDs to be received by the device during 
the whole treatment.  
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The ICD was checked before the single prone treatment, the beginning of fraction 
one, two and five.  At the conclusion of the final fraction, the ICD indicated a POR 
had occurred.  
Table 4.1: Summary of ICD POR patients  
Pt Age Brand Model Treatment 
Area 
Tmt 
energy 
(MV) 
Dose 
(Gy) 
# Dose to 
Device 
(Gy) 
A 80 Medtronic Consulta 
CRT-D 
DF-1 
Prostate 18 71.6 35 0.009 
B 81 Boston 
Scientific 
Unknown Prostate 18 74 37 unknown 
C 67 St Jude 
Medical 
 Atlas 
Plus VR 
V-193 
ICD 
Prostate 18 74 37 unknown 
D 76 Medtronic Maximo 
VR 7232 
Rectal 6 and 
18 
25 5 0.013 
E 69 Medtronic Maximo 
VR 7232 
Rectal 6 and 
18 
25 5 0.023 
Key - Pt = patient; tmt = treatment; MV = megavoltage; Gy = Gray; # = fractions. 
 
4.5 Discussion  
 
The ICDs described above were out of the direct field, greater than 30cm from the 
nearest beam edge.  Accumulated doses to the ICDs were estimated to be well under 
1Gy, a previously accepted minimum dose for ICD exposure, and well under the 2-
5Gy limits more commonly suggested in current literature (Mouton et al., 2002).  
 
Previous articles (Thomas et al., 2004) have suggested that electromagnetic 
interference (EMI) created by the linear accelerator may cause power on resets, 
independent of scattered radiation. Wilkinson, Bounds, Brown, Gerbi, and Peltier 
(2005) assessed the susceptibility of soft errors occurring in electronic equipment 
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when exposed to radiation therapy. Ten static random access memory chips 
(sRAMs), a type of semiconductor memory, were exposed to radiation therapy at a 
distance of 50cm from beam isocentre. The devices were alternately not shielded, 
EMI shielded using a steel box, thermal neutron shielded using boric acid, and 10m 
outside treatment room.  Three errors occurred when the sRAMs were unshielded. 
Another error occurred when the sRAM was EMI shielded. No errors were recorded 
for the latter two setups. The authors concluded that errors likely resulted from 
neutron contamination, due to the lack of failures when neutron shielding was 
incorporated. 
 
Four patients were asymptomatic during and after the occurrence of the POR. A fifth 
patient experienced anorexia, nausea and abdominal discomfort around fraction 
twelve. It is possible that these symptoms were associated with side effects of the 
prostate treatment, such as diarrhoea, rather than the POR. It is also unknown at what 
point during treatment this patient experienced the POR due to loss of historical data. 
Within the literature presented (see section 3.5.4), POR were not associated with 
adverse symptoms, with emergent conditions a result of runaway CIED only. 
Whether those conditions were attributed to high energy treatments could not be 
ascertained. The lack of symptoms shown by the patients during these events 
highlights the need for regular device checks when ICD patients are exposed to 
18MV.  
 
More current published studies (Hurkmans et al., 2012; Lau et al., 2008; Tondato et 
al., 2009) have concluded that high photon energy radiation therapy (greater than 
10MV) should not be used in the treatment of ICD patients. This is due to the risk of 
POR through the creation of neutron particles in the scatter radiation (Hurkmans et 
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al., 2012). All ICDs in this study were exposed to scatter radiation with either partial 
or exclusive treatment using 18MV.  
A further seven ICD patients were treated at a participating hospital using either 
whole or partial treatment with 18MV between 2005 and 2012 without incident, with 
no further POR observed in the expanded date range. As two patients of the nine 
treated at this hospital incurred a POR of their ICD, 22.2% rate of POR has been 
observed at this hospital when ICDs are exposed to 18MV. At this hospital, 
treatment of ICD patient’s accounts for 0.26% of their patient load over an eight year 
period, with 28% of these treated using high photon energies. If these statistics are 
applied to the expected treatment rates published by the Radiation Oncology 
Tripartite Committee (2012), it is possible that in 2008, across Australia, up to 13 
ICD patients would have experienced a POR as a result of their radiation therapy. 
While failure is not absolute, a greater than one in five chance of POR during high 
photon energy radiation therapy is important to note. This result indicates that high 
photon energy treatments should be avoided; if not, the potential rate of failure 
should be communicated to the patient prior to treatment consent.  An assessment of 
the rate of POR could not be calculated at the remaining hospitals due to the lack of 
reporting by the department on treatments of ICD patients and limited 
communication between the cardiology and radiation oncology departments at these 
hospitals. Further investigation of high photon energy radiation therapy is required to 
assess the potential of ICD damage under radiation therapy in varying situations.  
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4.6 Limitations 
 
This study was limited in scope due to the lack of a centralised reporting of POR 
incidents that may occur during radiation therapy. While known PORs occurred 
within other departments, lack of detailed patient information prevented the 
incorporation of their cases into this study. Identification of patients required the 
staff at the treatment centre to be able to identify the patient in which a POR 
occurred; this was generally limited to those staff who had a particular interest in this 
issue. It is also feasible to assume that PORs that are identified after the patient has 
completed their radiation therapy may not be communicated to the radiation 
oncology department. Communication between cardiology and radiation oncology 
departments should be encouraged to help assess the risks associated with treatment. 
POR may also occur in PM patients; given the reputation of ICDs as being more 
radiosensitive than PMs, incidents may be overlooked. With the advent of cardiac 
resynchronisation PM (CRT-Ps), incorporating greater technological detail, these 
errors may begin to occur more frequently in PMs as well.  
 
As this study required the cooperation of multiple centres, multiple ethics forms 
were also required. At one point, a fourth and fifth centre were to be included in this 
study as well with three additional POR cases; in one centre the SSA ethics form was 
lost multiple times through the ethics process although approval had already been 
granted for a multiple site study at another HREC. Due to time constraints this centre 
was removed from the study. An ethics application was unable to be processed 
through a fifth centre, located interstate, due to lack of staff participation.  
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4.7. Recommendations 
 
Further research should be conducted to incorporate a wider range of patients and 
hospitals. It is encouraged that incidents during radiation therapy, such as POR, 
should be reported to a centralised database to better assess the risks associated with 
exposure to high and low energy radiation therapy over an extended period of time. 
In addition, treatments that did not result in incident should also be reported. Patient 
interviews should be conducted to assess any symptoms that may be associated with 
a POR occurring. New planning strategies to avoid the use of high photon energies 
should also be investigated. 
4.8 Conclusion 
 
It is assumed that neutron contamination is a cause of soft errors in ICDs when 
exposed to high photon energy radiation therapy. While treatment protocols have 
called for the limitation of high photon energy treatments to ICD patients, some 
centres may not have the technology required to properly treat these patients without 
energies greater than 10MV.  In cases where higher photon energy treatments are 
essential, increased monitoring protocols are suggested, including regular follow ups 
with cardiology. Informed consent must be obtained from the patient, including 
acknowledgement of the risk of POR. Continuous monitoring with an ECG during 
radiation therapy may be beneficial to identify changes in pacing patterns attributed 
to POR. 
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4.9 Further Research 
 
Further research directions were developed as a result of this study. A controlled 
study of CIED exposure to high and low photon energies and dose rate, associated 
with increasing accumulated dose was developed and conducted as a result of this 
study, described in Chapters Five and Six. Chapter Five assessed the impact of 6MV 
and 18MV on both PMs and ICDs when irradiated directly at small daily fractions, 
such as those associated with out of field doses, to assess the impact in both 
treatment energy and accumulated dose on CIED function. Chapter Six focussed on 
the exposure of ICDs to scatter radiation at both 6MV and 18MV, at daily doses 
similar to that observed in this study. These two studies were compared to assess the 
impact of dose rate on CIED function. An assessment of the rate of POR occurrence 
during radiation therapy was also made.  An observational case controlled study to 
assess risk of complications during radiation therapy was also conducted, detailed in 
Chapters Seven and Eight.  
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Chapter 5: A comparison of the effect of 6MV vs. 18MV 
on CIEDs using direct irradiation 
 
5.1 Introduction 
 
The hypothesis that the use of treatment energies greater than 10MV to irradiate a 
patient with an implanted ICD increases the risk of device failure has been 
increasingly documented in literature since 2004 (Hashii et al., 2012; Lau et al., 
2008; Thomas et al., 2004). This has led to the recommendation of protocols limiting 
photon treatment energies for the treatment of ICD patients to less than 10MV 
(Hurkmans et al., 2012). There are currently no recommendations for treatment 
energies to use when irradiating patients fitted with PMs. It is important to note that 
the largest in vitro study performed on PMs to date (Mouton et al., 2002) recorded a 
large number of failures at low accumulated doses when PMs were irradiated using 
18MV. The number of failures could not be matched in studies performed using 
energies less than 10MV (Hurkmans et al., 2005a; Souliman & Christie, 1994).  
 
There are a number of case studies detailing ICD failure at energies greater than 
10MV that have been published since 2009 (see section 3.5.4 and 3.6);  only limited 
PM failures have been reported, with only one recorded at energies greater than 
10MV (Soejima et al., 2011). The latest in-vitro study to be performed on PM was 
by Hurkmans et al. (2005a). A comparative study between high and low energies has 
not been performed using accumulated doses commonly seen in radiation therapy. 
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All other previous in vitro studies have been performed using high doses per fraction 
and accumulated doses well exceeding standard radiation therapy (see section 3.5.2) 
 
This chapter describes a comparative study between CIEDs irradiated at 6MV and 
18MV with daily doses similar to those that may be administered to patients during 
current radiation therapy practice. This study was designed to test both current 
protocols in accumulated dose used in radiation therapy, as well as the different 
response of CIEDs to 6MV and 18MV when irradiated under identical conditions. 
  
5.2 Study Aims and Outcomes 
 
The aim of this study was to establish if there was an increased rate of failure in both 
PMs and ICDs when irradiated at a higher photon energy (18MV) when compared to 
lower energy (6MV). This was associated with the following outcomes: 
1. Obtain CIEDs for irradiation. 
2. Develop a treatment protocol that would model acceptable radiation therapy. 
3. Develop a failure criteria based on current literature. 
4. Obtain programming and monitoring equipment for analysis of CIEDs pre 
and post exposure to radiation therapy. 
5. Modify monitoring equipment for review of CIEDs during exposure to 
radiation. 
6. Analyse failures observed in relation to 6MV and 18MV. 
7. Analyse failures observed in relation to current literature. 
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5.3 Materials and Methods 
 
This study was developed with the aid of cardiologists at Nepean Hospital Cardiac 
Services Department, representatives from CIED manufacturer Biotronik and 
radiation therapists and medical physicists at the Nepean Cancer Care Centre 
(NCCC; Kingswood, NSW). 
 
5.3.1 Donated CIEDs 
 
Eight PMs and seven ICDs were used in this study, as shown in figure 5.1. The 
CIEDs were donated by the biomedical device manufacturers Biotronik and 
Medtronic. The CIEDs were a combination of new devices, which had passed their 
sterility date, and explanted devices which were previously implanted but removed 
due to death or infection. The conditions of individual devices were not disclosed by 
the manufacturers, thus no further analysis of the condition or age of the device was 
undertaken. The devices were split into two treatment groups. As there were eight 
different models in the 15 donated CIEDs, shown in figure 5.1, groups were split by 
manufacturer and CIED type (ICD or PM).  Table 5.1 details the different groups by 
manufacturer, model and device type.  
  
-112- 
 
Figure 5.1: CIEDs donated for use in the study; Yellow tags indicate devices 
used in the 6MV group, red tags indicate devices in the 18MV group. 
Device numbers from left to right, top to bottom 6D05 to 6P11 and 18D05 
to 18P12 respectively.   
 
 Table 5.1: Irradiation groups  
Group Study ID Brand Model CIED type 
6MV 
#6D05 Biotronik Lumax ICD 
6D06 Medtronic Maximo II CRT-D ICD 
6D07 Medtronic Secura VR ICD 
6P08 Biotronik Evia DR PM 
6P09 Biotronik Evia DR PM 
6P10 Medtronic Adapta PM 
6P11 Medtronic Sensia PM 
18MV 
18D05 Biotronik Lumax ICD 
18D06 Biotronik Lumax ICD 
18D07 Medtronic Maximo II DR ICD 
18D08 Medtronic Secura DR ICD 
18P09 Biotronik Evia DR PM 
18P10 Medtronic Adapta PM 
18P11 Medtronic Adapta PM 
18P12 Medtronic Sensia PM 
#Device eliminated from study after one fraction due to mechanical fault. 
Key: ICD = implantable cardioverter defibrillator; PM = pacemaker; MV = photons. 
 
5.3.2 CIED Programming 
 
All CIEDs required programming before the start of treatment using a company 
specific programmer with attached wand. An example of the Medtronic programmer 
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is shown in figure 5.2. A programming wand communicates wirelessly with the 
cardiac device when placed directly over it, capturing current program conditions. It 
also allows additional programming to be communicated to the device (Ellenbogen 
& Wood, 2005). It is important to use the right programming wand for each device 
as the wrong wand will fail to communicate with the device. Additionally, there is a 
risk it may interfere with the implanted device (Kenny, 2005). The programming 
wand is connected to a table top computer which displays the captured data, and 
allows programming changes to be input and transferred back to the CIEDs.  
(a)  (b)  
Figure 5.2: Medtronic (a) programmer and (b) wand  
 
All CIEDs were programmed with the following parameters, summarised in table 
5.2. 
 
5.3.2.1 Mode 
All devices were programmed to VVI or VVIR mode (see section 2.4) as the leads 
were placed in the RV lead connection port enabling real time monitoring of pulse 
amplitude and pacing frequency 
-114- 
5.3.2.2. Pacing frequency 
A minimum heart rate of 60bpm was set to allow simple monitoring of any rate 
change that may occur during irradiation; i.e. 60 bpm was equal to one pulse per 
second. 
 
5.3.2.3. Output pulse width and amplitude  
A pulse width of 0.5ms and pulse amplitude of 2.5V was chosen, as it was a 
common value that could be set across all brands and models and limited variations 
that could lead to increased battery drain. Pulse amplitude and width were initially 
set to between 2.8 and 3.5V @ 0.4ms as these were the default pre-set values; this 
was rectified before treatment three and not deemed to impact the study results.  
 
5.3.2.4 Lead parameters 
All ventricular leads were set to ‘bipolar’, in order to monitor real time changes in 
the pulse amplitude and pacing frequency across both electrodes in the pacing lead. 
The atrial lead in dual chamber devices was plugged to prevent further interference.  
 
5.3.2.5 Ventricular tachycardia/ventricular fibrillation monitoring and anti-
tachycardia therapy 
Anti-tachycardia pacing for the ventricle was set to on in all CIED. Where available, 
anti-tachycardia pacing for the atrial chamber was switched to off as only single 
chamber pacing was being evaluated. Anti-tachycardia pacing would be reviewed 
through the oscilloscope as increased pacing rate (above 60 bpm). Anti-tachycardia 
therapy, including the delivery of shocks, was set to off in all ICDs for safety 
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reasons. If anti tachycardia therapy remained on, it was anticipated that the device 
would interpret the insertion or removal of the leads as a VT that required a shock to 
terminate. At the commencement of the second fraction, anti-tachycardia therapy 
was mistakenly left enabled in one PM (6D05). As a result when the leads were 
inserted the shock coils began to spark as the device delivered a strong shock 
through the leads. As this was not inserted into a patient the shock appeared to burn 
out the device with a loss of telemetry and 6D05 was excluded from further 
irradiation. Only the Medtronic ICDs had the ability to monitor VT and VF only 
without anti-tachycardia therapy being activated. As a result, both VT/VF detection 
and anti-tachycardia therapy was programmed to off in all other devices.  
Table 5.2: Programmed Parameters 
Parameter Settings 
Mode VVI or VVIR 
Pacing Frequency 60 bpm 
Pulse Amplitude 2.5V 
Pulse Duration 0.5ms 
Lead Parameters Bipolar 
VT/VF monitoring On (where possible) 
Anti-tachycardia pacing  On 
Anti-tachycardia therapy (shock), ICDs 
only 
Off 
Key: bpm = beats per minute; V = volts; ms = milliseconds; VT = ventricular 
tachycardia; VF = ventricular fibrillation; ICD = implantable cardioverter 
defibrillator. 
 
 
The following parameters were recorded during the study using the programming 
wand, but are not variables programmed by the user: 
 
5.3.2.6 Battery Voltage  
Battery voltage was recorded to identify any unmatched decrease in capacity which 
could not be explained by normal device functioning. 
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5.3.2.7 Pacing Impedance 
Pacing impedance was measured to ensure the integrity of the pacing leads. Session 
to session changes of 300 Ω can still be indicative of normal function. Abnormal 
lead impedance measurements may indicate a failure of the insulation when 
approximately 200 Ω or less, or a lead fracture if approximately 2000 – 3000 Ω 
(Ellenbogen & Wood, 2005). 
 
5.3.3 Fractionation  
 
 
Device irradiation was carried out after normal working hours at the NCCC 
Radiation Oncology department using Elekta (Elekta Pty. Ltd. Stockholm, Sweden) 
Synergy linear accelerators installed in 2011. The Elekta Synergy linear accelerator 
(LINAC) is capable of producing high energy photon beams (6, 10 and 18MV) and 
electron beams (6, 9, 12, 15 and 18MeV). 
 
A total of 24 fractions were delivered over a five week period. Irradiation was 
performed five days a week, with breaks over weekends to mimic normal radiation 
therapy fractionation and allow any device recovery that would normally occur. This 
regime was chosen due to the availability of the LINACs at NCCC. This 
fractionation schedule was only interrupted if a permanent telemetry failure was 
observed. Irradiation was carried out at room temperature, which was approximately 
23°C.  The irradiation was split into the following protocols, defined in table 5.3. 
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Table 5.3:  Fractionation Protocol 
Stage Fraction 
number  
Dose per 
fraction (Gy) 
Number of 
fractions  
Accumulated 
dose (Gy) 
1 1-10 0.2 10 2 
2 11-20 0.5 10 7 
3 21-23 1 3 10 
4 24 5 1 15 
 
The fractionation protocol was chosen due to the following considerations: 
 
5.3.3.1 Stage 1 
Irradiation carried out at 0.2Gy per fraction allowed observation of any changes in 
device function after limited exposure to radiation, up to the recommended AAPM 
guidelines for PMs of 2Gy, and above general recommendations for ICDs.  
 
5.3.3.2 Stage 2 
An increase in dose per fraction to 0.5Gy/fraction allowed analysis of device 
function beyond some 5Gy PM recommendations (Mouton et al., 2002) whilst still 
allowing for device recovery. In clinical practice, it is possible for CIEDs to receive 
greater than 5Gy when they are positioned outside the direct radiation fields but are 
relatively close to the treatment area and may be inside the exit beam (i.e. during 
head and neck treatments). 
 
5.3.3.3 Stage 3  
1Gy per fraction was used to quickly escalate the accumulated dose received by the 
device. This was to assess whether it is possible to irradiate devices to 10Gy without 
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adverse effects, as recommended by published protocols (Hurkmans et al., 2012; 
Last, 1998). 
 
5.3.3.4 Stage 4 
A single large 5Gy dose was delivered as the final fraction. This allowed the device 
to receive a cumulative dose above the proposed 10Gy limit, whilst delivering a 
single large fraction consistent with palliative treatments that may be unable to avoid 
irradiating a CIED. 
 
5.3.4 Equipment  
 
 
The following equipment was used in the treatment room: 
 
5.3.4.1 Leads 
In the treatment room, CIEDs were connected daily to the pacing leads through the 
RV lead connection port. Shock leads were also inserted into the SVC and RV 
connections in the ICDs to limit lead movement during irradiation. Only six 
compatible bipolar leads were donated to the study, requiring leads to be shared and 
inserted and removed from CIEDs daily. 
 
5.3.4.2 Cardiac Simulator 
Pacing leads were connected via the pacing electrode at the end of the lead to a HKP 
ARSI-4 arrhythmia simulator on loan from Biotronik. The cardiac simulator is used 
to mimic a beating heart. A 517 Ω resistance lead was created and placed between 
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the pacing leads and the simulator to simulate the implanted pacing load impedance 
(Mouton et al., 2002). The sensing electrode was grounded through a second wire 
connected to the simulator. The cardiac simulator comprised of two parts, a simple 
lead connection box and an electrical component, connected through a power cable. 
The electrical component was shielded daily using a lead box at the request of 
Biotronik. It was set to a slow heart rate (40bpm), mimicking a CIED dependant 
patient so the devices would be pacing 100% of the time. 
 
5.3.4.3 Oscilloscope 
The pacing signal from the CIED was detected and monitored with an oscilloscope 
connected across the resistors of the impedance lead. The oscilloscope allowed real 
time monitoring of the CIEDs by displaying the pulse amplitude and frequency of 
pacing during irradiation, as seen in figure 5.3. Division widths were set to 0.2 V per 
division and timing slowed to the minimum so that one beat was visualised on the 
oscilloscope every second. 
 
Figure 5.3: Daily equipment setup. The oscilloscope (left) and the heart 
simulator (middle and right) are connected to the pacing leads. A lead 
shielding box covers the electrical component of the simulator. 
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5.3.4.4 Video Camera 
As the oscilloscope had no recording function, a video camera was used in the 
treatment room to record the signal for later analysis.  
5.3.5 Bolus  
 
Before and after each session, a programming wand from each company was used to 
record basic device parameters and check normal telemetry function.   
 
The maximum dose depth (dmax) of a radiation beam is 3.6% higher in tissue than in 
air (Khan, 2010). As the percentage depth dose (PDD) calculations at NCCC are 
based on calculations using tissue equivalent materials, the use of bolus and solid 
water was necessary to ensure accurate LINAC output calculations, measured in 
monitor units (MU) and accurate dosing of the CIEDs. Solid water (sometimes 
known as plastic water), as shown in figure 5.4 is available through a number of 
manufacturers. It scatters and attenuates radiation in the same way that water does 
whilst being easier to use in a clinical department.  
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Figure 5.4: Plastic Water by Supertech (Elkhart, IN), available in various 
thicknesses. 
 
Devices were placed on top of 8cm of 30cm x 30cm solid water slabs in custom 
made bolus, to create adequate back scatter conditions. Three different methods of 
bolus were considered for the study.  
 
5.3.5.1 Water Tank 
 
Water tanks are commonly used in radiation therapy for LINAC commissioning and 
subsequent quality assurance checks (Das et al., 2008). To utilise a water tank for 
this study, the CIEDs would need to be placed on an acrylic arm and lowered into a 
tank filled with tepid water to the correct depth for maximum dose delivery. The 
water tank used at NCCC is shown in figure 5.5. 
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(a)  
(b)  
Figure 5.5: The Med-Tec, Inc (Orange City, IA) water tank that is used at 
NCCC (a) and (b) the winder that connects to the acrylic arm in order to 
lower the arm to a required depth, shown by the counter on the right hand 
side.   
 
This was considered to be the most accurate method in ensuring homogenous 
conditions surrounded the devices. As devices are hermetically sealed it was also 
originally deemed safe to submerge each device without damage. However as there 
were not enough leads for each device, leads would need to be changed daily which 
could compromise the integrity of the water tight seal. As a result it was concluded 
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that the water tank could potentially cause device damage and was eliminated as a 
potential bolus. 
 
5.3.5.2  Wax 
 
Wax is a common bolus material used in areas which have rapid changes in contour, 
such as around the scalp where traditional sheet bolus would create air gaps or 
unacceptable overlap. It can also be used to build up a small area within the larger 
treatment field. It was considered to be the most durable form of bolus available for 
this study, especially as the CIEDs would need to be removed from the bolus after 
each fraction with minimal damage. A prototype was created in which strips of wax 
were soaked in hot water and moulded around an ICD, as shown in figure 5.6. 
 
Figure 5.6: Wax bolus prototype that was developed to indicate the 
potential of the wax in providing a reproducible and homogenous bolus to 
the CIEDs.  
 
The wax provided reasonable conformity to the CIED, however the layering of wax 
strips introduced a number of air gaps into the bolus. It was also difficult to ensure 
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the devices would sit flat against the base of the bolus. The alternate option was to 
melt the wax and pour it around the device in a set mould. Unfortunately the melting 
point of wax was approximately 70°C, 15°C higher than the maximum 
recommended temperature for the CIEDs as indicated by the manufacturers. As a 
result this form of bolus was also eliminated. 
 
5.3.5.3 Superflab 
 
Superflab (CNMC Company Inc; Nashville, TN) is a flexible vinyl gel that closely 
simulates tissue, shown in figure 5.7. It is commonly used in radiation therapy as it 
conforms well to patient contours whilst maintaining uniformity of thickness.  
 
Figure 5.7: CNMC Company Inc. Superflab (CNMC Co., 2014) 
 
This product is relatively expensive and is sold in 30cm x 30cm sheets of varying 
thicknesses. Once damaged, they must be thrown away due to infection control 
considerations. A less durable version of superflab may be created inexpensively 
in-house using a combination of gelatine, water and glycerine, with preservatives 
added to prevent mould growth. The benefit of this version of Superflab is that it can 
be made with relative ease, poured around devices at a lower temperature than wax, 
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not require the devices to be water tight after the initial creation of the bolus and 
have minimal air gaps. The limitations revolve mainly around its fragility when cut 
and a tendency to shrink if not properly stored. Although it is more fragile than wax, 
it was considered that this form of bolus gave the greatest conformity and 
reproducibility, without introducing the possibility of device damage. The prototype 
is shown in figure 5.8. During the development of the superflab used in the study, bolus was created without the leads already connected to the devices as when the leads were removed from the bolus they left a deep cut which compromised the integrity of the bolus. 
 
Figure 5.8: Manufactured superflab prototype including lead insertion 
developed to investigate the efficacy of superflab as a bolus for this study 
 
Individual superflab bolus blocks were created for each device using a 23cm x 23cm 
mould. The CIEDs were placed in the middle of each mould, with specialised plugs 
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inserted into the lead connections to prevent liquid damage.  The water and gelatine 
were combined in a bowl over a water bath until the mixture was clear and free from 
lumps. The glycerine was added and the mixture was removed from the heat to cool 
slightly. The Superflab was poured into the moulds containing the devices, to ensure 
the bolus surrounded the sides and back of the devices. The front of the device was 
unobstructed by Superflab so that it could be removed for daily lead connection.   As 
the bolus would not be in contact with patients, and due to cost considerations, no 
preservatives were added. Each Superflab sheet was left to cool for six hours, until 
cold to touch and solid enough that it would not disintegrate when handled. The 
devices were removed from the Superflab blocks, which were labelled accordingly. 
A small slit was cut from the lead connections to the edge of the bolus to 
accommodate for the pacing leads during the study. Each sheet was wrapped in 
plastic wrap to limit shrinkage and mould growth.   
 
5.3.6 Treatment Beam 
 
 
A 10cm x 10cm field was used to irradiate the CIEDs, which were located in the 
central axis of the beam. A field to source distance (FSD) of 100cm to the centre of 
each of the CIEDs was set, to ensure 100% of the given dose was received at this 
point.  Solid water was placed on top of the CIEDS to ensure the dmax of each beam 
was delivered to the centre of each CIED. Dmax was determined to be 1.5cm for 6MV 
beams and 3cm for 18MV by the physicists at NCCC, with build-up depth shown in 
table 5.4. Figure 5.9 (a) and (b) demonstrate the final placement of the CIED in the 
study design. 
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Table 5.4:  CIED thickness and corresponding build-up required for dmax 
 Thickness of 
CIED (cm) 
Build-up required 
(cm) 
FSD to anterior 
surface of CIED 
6D05 1.3 0.7 99.35 
6D06 1.5 0.8 99.25 
6D07 1.5 0.8 99.25 
6P08 0.7 1.2 99.65 
6P09 0.7 1.2 99.65 
6P10 0.8 1.1 99.6 
6P11 0.7 1.2 99.65 
18D05 1.3 2.4 99.35 
18D06 1.3 2.4 99.35 
18D07 1.5 2.3 99.25 
18D08 1.5 2.5 99.25 
18P09 0.7 2.7 99.65 
18P10 0.8 2.6 99.6 
18P11 0.8 2.6 99.6 
18P12 0.7 2.7 99.65 
Key: CIED = cardiac implantable electronic device; cm = centimetres; FSD = field 
to source distance. 
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(a)  
(b)  
Figure 5.9: Example of the final placement of the CIED (a) pacemaker 
contained in superflab located in the centre of a 10cm x 10cm field with an 
FSD of 100cm to the middle of the pacemaker; (b) the superflab on top of 8 
cm of solid water with an appropriate build-up to ensure dmax will be 
received at the centre of the device (18MV).   
 
As the devices would have created a large amount of artefact on a computed 
tomography (CT) image, a manual calculation of MUs was used for irradiation. Due 
to the fact that the study incorporated a 10cm x 10cm field with dose calculated at 
the depth of dmax, a standard of 1Gy = 100 monitor units (MU) was used to calculate 
the appropriate monitor units given in each stage, summarised in table 5.5. 
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Table 5.5: Monitor unit calculations per fraction 
Stage Dose per 
stage (Gy) 
Number of 
fractions 
Dose per 
fraction (Gy) 
MU per 
fraction 
1 2 10 0.2 20 
2 5 10 0.5 50 
3 3 3 1 100 
4 5 1 5 500 
  Key: Gy = Gray; MU = monitor units. 
 
Irradiation was carried out using standard dose rates, up to 565MU/minute for 6MV 
beams and 630MU/minute for 18MV beams. All treatments were pre-programmed 
and treatment delivery time stamped on the Elekta patient management system 
Mosaiq to ensure accurate treatment delivery. 
 
5.3.7 Failure criteria 
 
Failures were analysed using the failure criteria outlined in section 2.10.1. Detected 
VT or VF was not used as an endpoint as this could not be switched on 
independently of shock therapy in some ICDs.  
 
5.4 Results 
 
A total of 317 fractions were given across 15 CIEDs. The frequency of device errors 
are shown in tables 5.6 for PM and 5.7 for ICDs. The radiation dose reached during 
the fraction that the first recorded fault was observed is shown in table 5.8.  
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Table 5.6: Incidence of errors observed in pacemaker group 
      
Group 1 
6MV PM  
Group 2 
18MV PM 
Hard 
Error   
Loss of Telemetry -  -  
Undetectable electrical signal  - -  
Soft 
Error 
Severe 
Power on reset  - -  
Pacing silence during whole 
radiation -  -  
Moderate 
Pulse amplitude changes 
>25% -  -  
Battery voltage changes >5% -  -  
Minor 
Missing pulse start/end 
radiation 5  8 
Missing pulse during 
radiation 2 5  
Increased pacing frequency 
during radiation -  1  
Pacing impedance changes 
>50% 
-  -  
  Total 7 14 
Key: PM = pacemaker; MV = photon. 
Table 5.7: Incidence of errors observed in ICD group 
      
Group 1 
6MV ICD 
Group 2 
18MV ICD 
Hard 
Error   
Loss of Telemetry  -  - 
Undetectable electrical signal  -  - 
Soft 
Error 
Severe 
Power on reset - 1 
Pacing silence during whole 
radiation 24 47 
Moderate 
Pulse amplitude changes 
>25% -  1 
Battery voltage changes >5%  -  - 
Minor 
Missing pulse start/end 
radiation 2 -  
Missing pulse during 
radiation 15 -  
Increased pacing frequency 
during radiation 21 -  
Pacing impedance changes 
>50%  - -  
  Total 62 49 
Key: ICD = implantable cardioverter defibrillator; MV = photon. 
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Table 5.8: Dose at first failure  
  CIED 
type 
Hard Error Soft Error 
Loss of 
Telemetry 
Undetectable 
electrical 
signal 
Severe Moderate Minor 
Power 
on 
Reset 
Pacing 
silence 
whole 
treatment 
Pulse 
Amplitude 
+/- 25% 
Battery 
Voltage 
+/- 5% 
Missed 
pulse 
start/end 
radiation  
Missed 
pulse 
during 
radiation 
Increased 
pacing 
frequency 
Pacing 
impedance 
+/- 50% 
6D05 ICD 0.2* - - - - - - - - - 
6D06 ICD - - - 7.0 - - 1.0 1.0 0.6 - 
6D07 ICD - - - 0.4 - - 0.2 0.2 - - 
6P08 PM - - - - - - - - - - 
6P09 PM - - - - - - - - - - 
6P10 PM - - - - - - 0.4 1.0 - - 
6P11 PM - - - - - - 0.4 1.5 - - 
18D05 ICD - - 0.8 - 0.8 - - - - - 
18D06 ICD - - - - - - - - - - 
18D07 ICD - - - 0.4 - - - - - - 
18D08 ICD - - - 0.2 4.5 - - - - - 
18P09 PM - - - - - - - - - - 
18P10 PM - - - - - - - -  - 
18P11 PM - - - - - - - -  - 
18P12 PM - - - - - - 2.0 6.0  15.0 
Dose received at end of fraction recorded as failure dose, if failure occurred during that fraction. Dose at previous fraction recorded if failure 
recorded before treatment administered. *Loss of telemetry recorded at 0.2Gy not deemed a radiation induced failure.
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5.4.1 Pacemakers 
 
5.4.1.1 Hard Errors 
No hard errors were recorded in any PM in either the 6MV or 18MV groups.  
 
5.4.1.2 Soft Errors – Severe and Moderate 
 No severe or moderate soft errors were observed in either group.  
 
5.4.1.3 Soft Errors – Minor  
No decreases in battery voltage greater than 5% and impedance changes greater than 
50% were observed in any PM.  No complete pacing silence, oversensing or partial 
resets were observed in either the 6MV or 18MV group.  
 
A total of 14 soft errors were observed in one PM (25%) in the 18MV group, with 
seven observed across two PMs (50%) in the 6MV group.  A summary of these 
results is shown in table 5.6. 
 
5.4.1.4 Soft errors - Minor, 6MV 
Minor failures were observed in two PMs at 6MV. A missed pacing pulse was 
observed at the end of multiple fractions in two separate devices (6P10 and 6P11), 
occurring three and two times respectively.  The first incidence occurred at 0.4Gy in 
both PMs. A single missed pacing pulse during irradiation was indicated at 1Gy and 
2.5Gy respectively. 
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5.4.1.5 Soft errors - Minor, 18MV 
Minor errors were observed in one PM (18P12) at 18MV, with a missed pacing pulse 
observed at the end of two fractions, beginning at 4Gy. This device was the only PM 
to miss a pacing pulse at the start of a fraction across both groups, occurring six 
times during the course of the study from 2Gy onwards. Single missed pacing pulses 
during irradiation were observed in two separate devices, at 1Gy and 2.5Gy 
respectively. A single missed pulse during irradiation was observed at 6Gy and 
6.5Gy. From fraction 22 (9Gy onwards), multiple missed pulses were observed 
during irradiation, with the most frequent occurrences during the final fraction of 
5Gy. An increase in pacing frequency was also observed intermittently during the 
final fraction. 
 
5.4.2 ICDs 
 
5.4.2.1 Hard Error 
No hard errors resulting from radiation exposure were observed. One ICD (6D05) 
was damaged at the beginning of the second fraction due to an accidental shock 
delivery when the pacing leads were inserted, causing the device to lose telemetry 
with the programmer. As a result this device was eliminated from the remainder of 
the study, but fault was not recorded as a hard error as it was not caused by radiation 
exposure. 
 
5.4.2.2 Soft Error – Severe 
 One severe soft error was observed in one ICD (18D05) at 0.8Gy which could not 
be reprogrammed without company assistance. As a result this device was eliminated 
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from further irradiation. A second ICD of the same make and model (18D06) was 
irradiated to 15Gy with no error. No severe soft errors occurred in the 6MV group. 
Pacing silence throughout the whole of the radiation was observed 24 times in two 
ICDs in the 6MV group and 47 times in two ICDs in the 18MV group. Complete 
pacing silence was observed once in 6D06 during fraction 19. Complete pacing 
silence was observed in 6D07 (n=23) from 0.4Gy onwards. Complete pacing silence 
was observed in 18D07 (n=23) and 18D08 (n=24), from 0.4Gy and 0.2Gy 
respectively.  
 
5.4.2.3 Soft Error - Moderate 
A moderate soft error was observed in 18D08 at 4Gy with a 40% increase in pulse 
amplitude from 2.5mV to 3.0mV. This was reprogrammed to 2.5mV and no further 
moderate errors were observed.  No moderate errors were observed in the 6MV 
group.   
 
5.4.2.4 Soft Error – Minor 
A total of 38 minor soft errors were observed in ICD group 1 (6MV), with no minor 
soft errors occurring in group 2 (18MV). No changes in battery voltage greater than 
5% and impedance changes greater than 50% were observed. Impedance was unable 
to be measured in two devices (6D05 and 18D05) before their respective failures. No 
failures were observed in either device before elimination. A summary of failures is 
shown in table 5.7. 
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5.4.2.5 Soft Error – Minor, 6MV 
Multiple missed pacing pulses during radiation occurred in 6D06 (n=14) and 6D07 
(n=1) from 1Gy and 0.2Gy respectively. A single missed pacing pulse at the end of 
treatment was observed in the former device twice at 3.5Gy and 4Gy. Increased 
pacing frequency in this device was also observed in 21 of 24 fractions from 0.6Gy.  
 
5.4.2.6 Soft Error – Minor, 18MV 
No minor soft errors were observed in the 18MV group. 
 
5.5 Discussion 
 
A larger number of errors were observed in the ICD group (n=111), shown in table 
5.7, than the PM group (n=21), shown in table 5.6, although there were a larger 
number of PMs used (eight PM and seven ICDs). The degree of error severity was 
also higher in the ICD groups. One ICD was eliminated from irradiation from the 
6MV group for mechanical damage after the second fraction, highlighting the greater 
complexity in technology within ICDs.  
 
5.5.1 Pacemakers 
 
 
A higher proportion of PMs exhibited a failure when exposed to 6MV (50%, n=2), 
compared to those exposed to 18MV (25%, n=1), in contrast to previous findings in 
literature. However, the 18MV group showed a greater number of failures overall, 
with these being 14 failures compared to seven. The types of failures observed in the 
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6MV group were transient, involving only one missed pulse in each failure, even 
when occurring during irradiation. Failures in the 18MV group were more 
consistent, with many missed pulses occurring for several seconds at a time. Even 
though failures observed for both groups were only minor, the effect on a patient 
could be more severe for the failures seen when using 18MV, and the suggestion of a 
greater risk to the patient when using 18MV cannot be discounted. 
 
The errors seen in the 18MV group (n=14) occurred in one device, whereas they 
included two devices in the 6MV group (n=7). The dose reached before the first 
failure was noticeably different across the two groups, with missed pulses at the start 
or end of radiation occurring at 0.4Gy for 6MV, but not until 2Gy for 18MV. 
Mouton et al. (2002) proposed that a missed pulse at the start or end of radiation is 
likely to be due to the sudden change in dose rate, causing disturbance to the internal 
device clock. This is less likely to be due to radiation damage, and more likely 
attributed to electromagnetic interference (EMI) (John & Kaye, 2004). Given that 
these issues are transient, there is no evidence that this type of error would cause 
adverse effects in a patient, especially if they are not CIED dependant. It is also 
unlikely that these errors would occur if the device was not in the direct beam 
(Uiterwaal et al., 2006).  
 
There was only one PM in the high energy group to record failures, outlined in table 
5.8. Whilst the missed pulses at the start and end of treatment observed between 
fractions ten and 19 would be unlikely to cause adverse effects in a patient, multiple 
missed pulses during each session were recorded between fractions 22 and 24. 
These, combined with the intermittent bouts of increased pulse rate observed during 
the final fraction, are of a greater clinical significance (Mouton et al., 2002). Early 
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failure was not predictive of later failures in the 6MV group. Failures observed in the 
18MV group were more consistent and increased in severity and longevity as 
irradiation continued, even though this only affected one of the four PMs in this 
group. Failure also began later in the 18MV group, with first failure not observed 
until 2Gy.  
 
As noted in section 3.5.1, previous studies showed great variability in the frequency 
of PM failures during irradiation. While not a consideration in the literature at the 
time of publication, the study conducted at 18MV (Mouton et al., 2002) showed a 
much higher proportion of PM failures than in the other two studies carried out at 
6MV and 8MV (Hurkmans et al., 2005a; Souliman & Christie, 1994). Although 
there is only a small difference in failure rates in this study, given the distribution of 
results it is reasonable to assume that the high failure rate in Mouton’s study is likely 
attributed to the high energy used rather than accumulated dose or dose rate.  
 
Variability in device function, due to multiple manufacturers, must be taken into 
account. Both 18P12 and 6P11 were single chamber Medtronic Sensia PMs, with 
both recording failures during the study. Three dual chamber Medtronic Adapta PMs 
were also involved in the study, with only one incurring a failure, although the 
remaining two were in the 18MV group. No dual chamber Biotronik PM incurred a 
failure during the course of this study, regardless of group. Although the pacing 
mode and functions were identical across all the devices, the greatest numbers of 
failures were observed in the least complex single chamber devices (see section 
2.4.1).   
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5.5.2 ICDs 
 
The number of errors observed across the 6MV group was higher than the 18MV 
group, with 62 and 49 errors respectively, as shown in table 5.7 It is important to 
note that many errors in the 6MV group occurred within the same fraction – for 
example an ICD in the 6MV group may have missed a pulse at the start and end of 
irradiation, as well as missing pulses sporadically throughout radiation accumulating 
into multiple recorded faults. An ICD in the 18MV group may have remained silent 
through the whole of the treatment, accounting for one fault only.   
 
From fraction two, there were two ICDs in the 6MV group and four ICDs in the 
18MV group. A second ICD was eliminated from further radiation from the 18MV 
group when a severe soft error in the form of a power on reset (POR) which was 
unable to be reprogrammed. No other errors were observed in this device prior to the 
POR. Sixty two errors occurred in two ICDs in the 6MV group and 47 errors 
occurred in two ICDs in the 18MV group. One ICD in the 18MV group incurred no 
failure throughout the study. It was also the same model and brand of ICD as the 
devices that incurred a mechanical failure and POR, highlighting the variability 
between devices themselves.  The rate of POR observed in this study (25%) was 
similar to that reported in Chapter Four (22.2%). Similar to the results from the PM 
group, the severity of errors was higher in the 18MV group than the 6MV group.  
 
 
Direct exposure of ICDs has only been researched via in vitro methods twice. In both 
instances the ICDs were irradiated using 6MV, with VT or VF detection a common 
failure. In this study VT or VF detection was not used as an end point as it could not 
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be enabled in all ICDs without enabling shock therapy, however was switched on 
where possible. Those that were observed coincided with long bursts of pacing 
silence, indicating that lack of observed pacing was more likely due to a reaction in 
response to an increased observation in heart rate by the ICD rather than a failure of 
the ICD to pace. All but two failures observed in the ICD study related to pacing 
frequency issues. It is likely that the pacing silences observed during this and other 
studies, including those concerning PMs (Mouton et al., 2002), are a result of 
oversensing and over-detection of VT or VFs due to the impact of direct irradiation. 
This may be due to the higher dose rate observed at the central axis which decreases 
with distance (Hurkmans et al., 2005b). In all cases, increased pacing frequency and 
pacing silences were limited to the time the ICD was exposed to radiation. Whether 
scatter radiation has the same effect on pacing frequency has yet to be observed. 
 
The earliest failures were observed in fraction one at 0.2Gy with one ICD missing a 
pulse at end of exposure and one incurring pacing silence during the whole of 
treatment. A third ICD began failing from fraction two. 6D06 was also the only three 
chamber device involved in this study and began exhibiting failure in fraction three, 
with increased pacing frequency. It was also the only device exhibiting failures that 
did not consistently fail to pace during the entire treatment, however did consistently 
exhibit increased pacing frequency between 90 and 100bpm as well as shorter pacing 
silences. Like the PMs, it is possible that although the ICDs were programmed with 
a simple VVI program, the ICDs with the greatest complexity (CRT-Ds) are less 
susceptible to radiation damage, however this needs to be further researched. Like 
the PM group, failure attributed to an accumulated dose level is not predictable. 
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In recent times, the effect of high energy treatments on ICDs has been documented 
through case studies and observational studies when exposed to scatter radiation (see 
sections 3.5.4 and 3.6). The limited number of ICDs, as well as the similar number 
of device failures in each group does not allow conclusive results on the difference in 
effect of high and low photon energies on ICD function during direct irradiation. 
 
ICDs are historically more sensitive to radiation when compared to PMs due to the 
RAM requirements for the additional anti-tachycardia therapy. It is possible that the 
direct exposure to any type of radiation, potentially due to the higher dose rate seen 
within the beam portal when compared to scatter radiation, outweighed the 
difference that may be seen for high and low energies when exposed to scatter 
radiation.   
 
5.6 Limitations 
 
As a result of the limited number of CIEDs involved in this study, conclusive results 
are not derived. It is also likely that the risk of CIED fault is overestimated by this 
type of research given that the CIEDs are directly exposed to the radiation beam. By 
being in the direct path of the beam, CIEDs are receiving the doses at a high dose 
rate. When removed from the direct beam, the risk of CIED failure may change or 
decrease due to the decreased rate at which the dose is delivered (Hurkmans et al., 
2005a; Hurkmans et al., 2005b; Mouton et al., 2002; Uiterwaal et al., 2006).  
 
This study was conducted after clinical hours at NCCC, and time constraints were 
imposed on the study. The project was delayed over 12 months due to the 
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replacement of both LINACs at NCCC to the LINACs used in this study, as well as 
subsequent upgrades required to both LINACs. A five week window before 
Christmas 2012 was given to the researchers, allowing 25 possible treatment 
fractions. The cardiac programmers were unavailable on the first day, reducing the 
time frame to 24 fractions. Without the time frame and CIED limitations, CIEDs 
would have been placed outside the beam to counteract any interference caused by 
direct irradiation. The CIEDs would have been placed at varying distances to 
coincide with typical treatments, including multiple beams given at typical treatment 
angles, preferably on top of an anthropomorphic phantom beneath 0.5cm of bolus to 
represent skin. The inclusion of available treatment techniques at NCCC, including 
volumetric modulated arc therapy, Intensity modulated radiation therapy and 
flattening filter free beams would have been investigated.  
 
While 15 CIEDs were donated to the study, only ten leads were donated. Of these 
only six were bipolar leads, which were required to enable visualisation of the pacing 
frequency and amplitude on the oscilloscope. As a result, leads were shared among 
the CIEDs, requiring daily insertion and removal. Any VTs or VFs that were 
detected between the after treatment CIED check of the previous day and the before 
CIED check of the current day were discounted as these were most likely attributed 
to the lead insertion and removal.  
 
Only two manufacturers (Medtronic and Biotronik) participated in this study. St Jude 
Medical also contributed eight ICDs, however the cardiac programmer for these 
devices was unavailable at the beginning of the study. Three of these ICDs were 
compatible as unipolar devices only, with no pacing frequency and amplitude 
visualisation available. As a result, five of these ICDs were formed into a shorter 
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study involving indirect irradiation when the programmer did become available, 
detailed in Chapter Six.   
 
Given the limited number of devices, and the time constraints imposed by 
conducting this study in a clinical department, it was necessary to test these devices 
within the treatment field using the described methodology. It is assumed by the 
author that this type of study allows the results to communicate the most extreme 
level of failure that might occur in a CIED under radiation therapy. As any flaw in 
the CIED function in a dependant patient could potentially be fatal, it is important to 
analyse the worst case scenario. Further study will need to analyse the effect of 6MV 
and 18MV on CIEDs when placed at an equal distance outside the beam with 
changing dose rates, following a similar treatment protocol to assess the change in 
risk.  
 
5.7 Conclusion 
 
Although exposed to direct irradiation, failure of both PMs and ICDs were not 
universal, even at doses exceeding common recommendations (Hurkmans et al., 
2012; Sundar et al., 2005; Tondato et al., 2009). Errors were observed at doses below 
2Gy in 46.7% of CIEDs (n=7), with 53.3% (n=8) at doses below 5Gy. No additional 
devices failed between 5Gy and 15Gy.  Whilst the number of errors was similar 
across both groups, the severity of errors was increased in the 18MV group. 
Accumulated dose at failure was not predictable, supporting the theory that CIED 
damage is not a dose accumulated effect.  
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Due to the fact that devices were irradiated directly due to time constraints, it is 
hypothesised that failures observed have outlined a worst case scenario for the risk 
of device failure. It is also hypothesised that while frequency of failure was similar 
between both dose groups, when exposed to scatter radiation a noticeable difference 
will be observed.   
5.8 Further Research 
 
A modified shortened study of five ICDs was developed to compare the impact of 
indirect irradiation at 6MV and 18MV, detailed in chapter six. An observational 
study was also performed, detailed in chapters seven and eight to assess failures 
during radiation therapy with a specific view to the relationship with accumulated 
dose and indirect exposure.  
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Chapter 6: A comparison of the effect of scattered 
radiation from 6MV and 18MV radiation therapy beams 
on ICDs 
 
6.1 Introduction 
 
Indirect exposure of ICDs to irradiation has been the topic of multiple recent articles. 
While Kapa et al. (2008) observed no failure in 20 ICDs treated to 4Gy (80Gy to the 
isocentre), Hashii et al. (2012) observed failures to occur more frequently at 18MV 
than 10MV, even when located 140cm from the field. In this study, large in-field 
doses were used (600Gy and 1600Gy) with the dose received by ICDs unknown. 
Multiple case studies have also reported on severe soft failures occurring at energies 
greater than 10MV (Elders et al., 2013; Gelblum & Amols, 2009; Makkar et al., 
2012). Chapter Four also detailed five patients that incurred power on resets in their 
ICD during treatments using 18MV. However there is limited data on the dose at 
which published failures have occurred, or the frequency of their occurrence, in the 
radiation therapy population. Chapter Four indicated POR may occur in as many as 
22.2% of high photon energy treatment to ICDs.  
 
Chapter Five detailed the observed effect of using 6MV and 18MV radiation on 
CIEDs under direct exposure to radiation. While not conclusive, due to limitations of 
interference observed within the direct beam (Uiterwaal et al., 2006), it was more 
common for CIEDs to incur a more serious failure when exposed to 18MV radiation. 
This chapter describes a modified shortened study of five ICDs to compare the 
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impact of high and low energy radiation therapy on ICD function when exposed to 
scatter radiation, with central axis dose consistent with palliative radiation therapy. 
No PMs were in this study due to limited CIED donations.  
 
6.2 Study Aims and Outcomes 
 
The aim of this study was to observe the effect of accumulated dose and dose rate 
from scatter radiation on ICDs.  This study was also used to compare the impact of 
direct irradiation (the aim of the study presented in chapter five) to the impact 
observed in this study. These aims were associated with the following outcomes: 
1. Obtain CIEDs for irradiation. 
2. Develop a treatment protocol that would model acceptable radiation therapy 
treatments. 
3. Develop a failure criteria based on current literature. 
4. Obtain programming and monitoring equipment for analysis of CIEDs pre 
and post exposure to radiation therapy. 
5. Modify monitoring equipment for review of CIEDs during exposure to 
radiation. 
6. Analyse failures observed in relation to 6MV and 18MV. 
7. Analyse failures observed in relation to current literature. 
8. Analyse failures observed in relation to previous study. 
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6.3 Materials and Methods 
 
This study was developed with the aid of cardiologists at Nepean Hospital Cardiac 
Services Department, and radiation therapists and medical physicists at Nepean 
Cancer Care Centre (NCCC).  
 
6.3.1 Donated ICDs 
 
Eight ICDs were originally donated to this study by the biomedical device 
manufacturer St Jude Medical (Saint Paul, MN). Five ICDs were able to be used in 
this study, shown in figures 6.1 and 6.2. These were a combination of new devices 
which had passed their sterility date and explanted devices. The conditions of 
individual devices were not disclosed by the manufacturers, thus no further analysis 
of the condition or age of the device was undertaken. The ICDs were originally split 
evenly into two treatment groups. Table 6.1 and 6.2 detail the different groups by 
model and device type. Due to the limited leads available for this and the previous 
study, leads were shared across all ICDs, with daily insertion and removal. 
 
Figure 6.1: St Jude Medical ICDs for exposure to scatter; 6MV group  
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Table 6.1: Irradiation group 1 (6MV) 
Study ID Brand Model Device Type Used in study 
6D01 St Jude Medical Current Accel VR ICD No 
6D02 St Jude Medical Current Accel DR ICD No 
6D03 St Jude Medical Atlas II + DR ICD Yes 
6D04 St Jude Medical Atlas II + DR ICD Yes 
Key: ICD = implantable cardioverter defibrillator. 
 
 
 
Figure 6.2: St Jude Medical ICDs for exposure to scatter radiation; 18MV 
group.  
Table 6.2: Irradiation group 2 (18MV) 
Study ID Brand Model Device Type Used in study 
18D01 St Jude Medical Current Accel DR ICD Yes 
18D02 St Jude Medical Current Accel DR ICD No 
18D03 St Jude Medical Atlas II + DR ICD Yes 
18D04 St Jude Medical Atlas II + DR ICD Yes 
Key: ICD = implantable cardioverter defibrillator. 
 
ICDs 6D01, 6D02 and 18D02 were single lead ICDs. Although single lead PMs 
were able to be observed in the direct irradiation study, no oscilloscope reading 
could be observed from these devices. These ICDs had to be eliminated from the 
study before the study began.    
6.3.2 ICD Programming 
 
All ICDs required programming before the start of treatment using the St Jude 
Medical Merlin™ programmer with attached wand.  All ICDs were programmed 
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using the same criteria as detailed in section 5.3.2, summarised in table 6.3. Battery 
voltage and pacing impedance were also recorded during the study.  
 
Table 6.3: ICD Programmed Parameters 
Parameter Settings 
Mode VVI or VVIR 
Pacing Frequency 60 bpm 
Pulse Amplitude 2.5V 
Pulse Duration 0.5ms 
Lead Parameters Bipolar 
VT/VF monitoring and anti-tachycardia 
pacing 
On (where possible) 
Anti-tachycardia therapy (shock) Off 
Key: bpm = beats per minute; V = volts; ms = milliseconds; VT = Ventricular 
tachycardia; VF = ventricular fibrillation. 
 
6.3.3 Fractionation  
 
Device irradiation was carried out after normal working hours at the NCCC using 
Elekta Synergy LINACs. This study was run in tandem with the final ten fractions of 
the direct irradiation study (Chapter Five). Irradiation was carried out at room 
temperature, which was approximately 23°C.   
 
A total of ten fractions were delivered over a two week period, as shown in table 6.4. 
Irradiation was performed five days a week, with breaks over one weekend to mimic 
normal radiation therapy and allow any device recovery that would normally occur.  
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Table 6.4: Fractionation Protocol 
Stage Fraction 
number  
Dose per fraction 
at central axis 
(Gy) 
Number of 
fractions (#) 
Accumulated 
Dose at central 
axis (Gy) 
  1 1-10 3 10 30 
Key: Gy = gray; # = fractions. 
 
 
The fractionation protocol was chosen due to the time limitations imposed by the 
previous study (see section 5.6). The central axis dose was determined as an accurate 
depiction of a normal to high range daily fraction dose when considering the number 
of fractions available, in line with treatments such as high dose palliative brain 
treatments.   
 
6.3.4 Thermoluminescent Dosimetry (TLDs) 
 
 
As the ICDs were placed outside the primary field, the accumulated dose received by 
the ICDs was determined by the radiation physicists at NCCC through the use of 
thermo luminescent dosimetry (TLDs). Nine chips were placed on the anterior and 3 
chips placed on the posterior side of both 6MV and 18MV ICDs, shown in figure 
6.3.  
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Figure 6.3: TLDs attached to the anterior side of a 6MV ICD  
 
Irradiation of separate TLDs were then required within the central axis of a radiation 
beam to confirm the beam properties used to irradiate the ICDs. This was performed 
directly after the first TLD readings, without exposure of further ICDs during this 
process.  The accumulated dose was recorded in table 6.5. 
 
Table 6.5: TLD results 
Energy Anterior accumulated 
dose (Gy) 
Posterior accumulated 
dose (Gy) 
6MV 0.03 0.01 
18MV 0.05 0.02 
Key: MV = Megavoltage; Gy = Gray 
 
 Full TLD results are detailed in appendix C. 
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6.3.5 Equipment  
 
The scatter radiation study used a similar setup to the direct irradiation study. 
Detailed description of equipment can be found in section 5.3.4. Equipment used in 
the treatment room included: 
• Leads  
• Cardiac Simulator  
• Oscilloscope  
• Video Camera  
• Bolus  
 
Before and after each session, the programming wand was used to record basic 
device parameters and check normal telemetry function.   
 
6.3.6 Treatment Beam  
 
A 10cm x 10cm field was used to irradiate the central axis of the beam to 3Gy. A 
field to source distance (FSD) of 100cm was set to the anterior side of a 1cm slab of 
solid water, aligning to the anterior side of the ICD with the approximate central axis 
level.  No build up was required to regulate dose as TLDs were used to measure the 
device dose.  
 
The ICDs were placed 60cm distally from the central axis, 55cm from the beam 
edge, to mimic the approximate distance between the pelvis and the expected 
location of an ICD during radiation therapy. The in-room set up is shown in figure 
6.4. 
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Figure 6.4: Scatter irradiation treatment room setup. 
 
The dose administered at the central axis of the beam was 300MU. This was derived 
from a manual calculation, as detailed in section 5.3.6.   
 
Irradiation was carried out using standard dose rates of 565MU/minute for 6MV 
beams and 630MU/minute for 18MV beams. All treatments were pre-programmed 
and treatment delivery time stamped on the Elekta patient management system 
Mosaiq to ensure accurate treatment delivery. 
 
The dose received at the anterior surface of the device at the end of each fraction was 
recorded. This was recorded as the failure dose, if the device failure occurred during 
that fraction. The dose at the end of the previous fraction was recorded, if failure was 
noted before that daily treatment was administered. 
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6.3.7 Failure Criteria 
 
Failures were analysed using the failure criteria outlined in section 2.10.1. 
 
6.4 Results 
 
A total of 50 fractions were given across five ICDs. Results of error frequency and 
dose at first fault are shown in tables 6.6 and 6.7 respectively.  
 
6.4.1 Hard Errors 
 
No hard errors were observed. 
 
6.4.2 Soft Errors – Severe 
 
 No severe soft errors were observed.  
 
6.4.3 Soft Errors - Moderate 
 
No moderate soft errors were observed.  
 
6.4.4 Soft Errors – Minor 
 
Minor failures were observed in four of the five ICDs. Minimal increased pacing 
frequency between 65-74bpm were shown twice in one 6MV ICD, and four times in 
two separate 18MV ICDs. These did not occur for the whole of treatment, ranging 
from 2% to 11% of the time of an individual treatment at 6MV and between 5% and 
12% at 18MV. More severe increased pacing rates, up to 110bpm, were observed 
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eight times in two 18MV ICDs. One of these devices also recorded sensed rates 
between 100bpm to 300bpm. None of these increased rates were sustained long 
enough to be recorded as a VT or VF. 
 
A missed pulse at the end of irradiation was recorded in one 18MV ICD in fraction 
three. No other minor soft errors were recorded. No changes in battery voltage 
greater than 5% and impedance changes greater than 50% were observed. One 
device in the 6MV energy group recorded no failures throughout treatment.  
 
 A total of two soft errors were observed in the 6MV ICD group, and 13 in 18MV 
ICD group. A summary of failures is shown in table 6.6. The dose at first failure of 
each ICD is shown in table 6.7.  
Table 6.6: errors observed in ICD group when exposed to scatter radiation 
      
Group 1 
6MV ICD 
Group 2  
18MV ICD 
Hard 
Error   
Loss of Telemetry  -  - 
Undetectable electrical signal  -  - 
Soft 
Error 
Severe 
Power on reset - - 
Pacing silence during whole 
radiation - - 
Moderate 
Pulse amplitude changes 
>25% -  - 
Battery voltage changes >5%  -  - 
Minor 
Missing pulse start/end 
radiation - 1 
Missing pulse during 
radiation - -  
Increased pacing frequency 
during radiation 2 12  
Pacing impedance changes 
>50%  - -  
  Total 2 13 
Key: MV = photon; ICD = implantable cardioverter defibrillator.
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Table 6.7: Accumulated dose (Gy) received by the ICD at first observed failure  
  Hard Error  Soft Error 
Loss of 
Telemetry 
Undetectable 
electrical 
signal 
Severe Moderate Minor 
Power 
on 
Reset 
Pacing 
silence 
whole 
treatment 
Pulse 
Amplitude 
+/- 25% 
Battery 
Voltage 
+/- 5% 
Missed 
pulse 
start/end 
radiation  
Missed 
pulse 
during 
radiation 
Increased 
pacing 
frequency 
Pacing 
impedance 
+/- 50% 
6D03 - - - - - - - - 0.12 - 
6D04 - - - - - - - - - - 
18D01 - - - - - - - - 0.05 - 
18D03 - - - - - - 0.15 - 0.1 - 
18D04 - - - - - - - - 0.2 - 
 
 -156- 
6.5 Discussion 
 
The number of errors observed across the 6MV group (n=2) was lower than the 
18MV group (n=13), as shown in table 6.6. Although the 18MV group included 
more devices, this does not offset the difference in the number of failures. The 
severity of pacing increases observed was higher in the 18MV group, with maximum 
pacing rates over 100bpm when the nominal pacing rate was set to 60bpm. Increases 
observed in the 6MV group were minimal, up to 74bpm. The duration of these 
increases were comparable across the groups, up to 12% and 11% of the treatment 
time respectively. The single missed pulse observed in one ICD at 18MV was 
transient and unlikely to cause adverse effects in a patient (Mouton et al., 2002). 
 
The earliest failure occurred at the first fraction in an 18MV ICD at an accumulated 
dose of 0.05Gy with increased pacing rate as shown in table 6.7. By the time the 
6MV ICD also indicated the same issue, all 18MV ICDs had shown at least one 
episode of increased pacing rate. Two of the 18MV ICDs showed this failure at 
accumulated doses lower than the failure observed in the 6MV ICD, at 0.05Gy, 
0.1Gy and 0.12Gy respectively. As these failures did not occur consistently during 
treatment, it is unlikely that this was a dose driven effect.  
 
One device in the 6MV group showed no alteration in pacing function during all 
treatments.  This device was the same make and model as three others which did 
show pacing changes, with one being the other device in the 6MV group. This result 
highlights the variability within devices themselves, as previously shown by 
Hurkmans et al. (2005b).  
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6.5.1 Direct vs. Scatter Irradiation 
 
When compared to the direct irradiation study in chapter five, the severity of errors 
was noticeably decreased. Unlike the direct irradiation study, there was a clear 
distinction between the greater number of errors occurring in the 18MV group and 
those occurring in the 6MV group, even when considering the difference in group 
numbers.  
 
The presence of interference in the direct irradiation of a CIED is clearly shown in 
the pacing silences at the start and end of treatment, as well as silences during 
treatment which were rarely present in this study (see section 5.4) (Uiterwaal et al., 
2006). This study confirms that direct irradiation of ICDs is potentially dangerous. It 
is expected that if this study also included PMs the same conclusion would be 
reached.  
 
No hard or severe to moderate soft errors occurred within the part of the study 
exposing the ICDs to scatter only. Due to the limited number of devices, as well as 
the limited time frame used, the risk of these failures occurring cannot be discounted. 
It is well documented in the literature, as well as in chapter four, that severe soft 
errors in the form of POR at treatment energies greater than 10MV are possible at 
both the low accumulated doses and dose rates of scatter radiation. This thesis 
suggests in chapter four that the rate of POR may be over 20% of ICDs exposed to 
scatter radiation.   
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6.6 Limitations 
 
As a result of the limited number of devices involved in this study, conclusive results 
could not be reached. PMs were not included in this study as none were donated by 
St Jude Medical. The collection of CIEDs for both chapters five and six began in 
mid-2010. CIEDs remained the property of the manufacturers after explantation, and 
are required to be returned to the country in which the manufacturer is located before 
further distribution or destruction, none of which is within Australia making device 
allocation difficult. An additional year was allowed for CIED collection after both 
studies were completed, to the end of 2013. No further devices were donated to this 
study during that time. A greater number of devices would have allowed the 
exploration of different dose regimes, as well as different dose rates by creating 
additional groups placed at varying distances from the treatment beam. A variation 
of treatment techniques, including IMRT and VMAT would also have been 
investigated.  
 
This study was conducted after clinical hours at NCCC and met the same time 
constraints as imposed on the previous study (see section 5.6). Without the time 
constraints, this study would have used a dose regime similar to high dose curative 
techniques, with central axis doses up to 80Gy. Accumulated dose to the devices 
would not have been matched to the previous study due to the high doses that would 
have been required at central axis to achieve this, outside clinically accepted 
treatment guidelines.  
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Further study is needed to assist in analysing the effect of 6MV and 18MV on CIEDs 
when exposed to general treatment regiments at a variety of sites and accumulated 
doses.  
6.7 Conclusion 
 
ICD failures at treatment energies of both 6MV and 18MV were not universal. 
Errors were observed in ICDs from the first fraction and well below current 
guidelines of 1Gy, supporting the theory that CIED failure is not a dose responsive 
relationship. The number and severity of errors was increased in the 18MV group, 
however the severity of errors was decreased when compared to direct irradiation.  
 
6.8 Further Research 
In order to assess the risk of different treatment energies further, a case controlled 
observational study was performed, detailed in Chapters Seven and Eight. Further 
analysis of accumulated dose to the CIED, treatment technique and treatment intent 
was also performed.  
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Chapter Seven: Case Control Observational Study – 
Effect of Radiation Therapy on Pacemakers 
 
7.1 Introduction 
 
The position of a cardiac implantable electrical device (CIED) within a patient, in 
relation to the cancer treatment site, will directly impact on the dose received by the 
CIED and leads during radiation therapy. Each patient who attends a Radiation 
Oncology department is treated with a uniquely optimised plan to suit their 
individual treatment requirements, considering factors such as the treatment intent, 
position and size of the tumour, dose required and fractionation schedule. The total 
accumulated dose to the CIED is often regarded as the main constraint (Croshaw et 
al., 2011), however previous studies have so far been unable to find evidence for a 
“safe” accumulated dose that CIEDs may receive before risk of failure outweighs 
benefit of treatment (Sundar et al., 2005).  Recommended accumulated dose limits 
vary from 1Gy to 5Gy, based on limited irradiation studies, case studies and more 
recently, retrospective and prospective observational studies (see sections 3.5 and 
3.6). Some manufacturers do not propose any dose limit, with a cautious approach 
recommended instead (Boston Scientific, 2012; St. Jude Medical, 2011). In a recent 
study, Hurkmans et al. (2012) echoed a call from Last (1998) to increase the safe 
radiation threshold to 10Gy, proposing that benefit to the patient from treatment 
should be the priority over accumulated dose, with a focus on limiting beam energy 
to 10MV or less due to neutron contamination (see section 3.9).  
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Chapters Five and Six detailed the impact of both direct and indirect radiation on 
CEID’s. Failures occurred more frequently than observed through examining recent 
reported case studies, described in Chapter Four. While the irradiation studies 
allowed the analysis of higher than normal CIED doses when compared to current 
practice, it is likely that these studies provided a ‘worst case scenario’ (see section 
5.5). By assessing the impact of radiation therapy on CIEDs in a larger cohort of 
patients, such as at a major Sydney hospital, realistic treatment practices with a 
variety of treatment sites and techniques could be analysed. 
 
In all published literature, only CIEDs receiving radiation therapy are considered, 
without a comparison to a control group (Wadasadawala et al., 2011). The 
incorporation of a control group would allow reported failures to be put into context, 
as well as allow the assessment of the different components of radiation therapy, 
rather than being limited solely to the dose received by the CIED and the treatment 
energy. There has been no assessment of any observed trends in CIED changes for 
patients undergoing radiation therapy, with current literature reporting hard errors or 
major soft errors only (see sections 3.5 and 3.6). In addition to this, to date no 
assessment of the impact of the maximum dose received by the heart has been 
carried out, which may impact on the functioning of a CIED.  
 
This chapter describes a retrospective observational study, detailing patients with 
PMs treated between 2005 and 2012 inclusive. This study is the first to compare a 
group of radiation therapy CIED patients to a control group of non-radiation therapy 
CIED patients to provide a comprehensive assessment of the impact of radiation 
therapy on CIEDs  to assess patient risk.  
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7.2 Study Aims and Outcomes 
 
The aim of this study was to assess the risk of PM failures during radiation therapy 
when managed by an existing departmental protocol based on current literature.  
This aim was associated with the following outcomes: 
1. Identify patients with cardiac devices undergoing radiation therapy at the 
participating hospital. 
2. Obtain radiation therapy details of patients for detailed analysis of potential 
causes of PM failure during radiation therapy. 
3. Identify control patients for comparison to the radiation therapy group. 
4. Obtain cardiac device check data for both radiation therapy and control 
patients. 
5. Analyse cardiac device checks for both radiation therapy and control patients 
to assess risk associated with radiation therapy. 
 
7.3 Materials and Methods 
 
This study was conducted at the Royal Prince Alfred Hospital (RPA) Radiation 
Oncology and Cardiology departments. This site was deemed to be the most suitable 
of the Sydney metropolitan area hospitals in which to conduct this study for a 
number of reasons. Firstly, a CIED protocol had been established for the treatment of 
CIED patients of any cancer site (see appendix D) which accurately reflected 
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recommendations from literature that was available at the time of the beginning of 
the study. Secondly, the radiation therapy department has a strong collaborative link 
to the Cardiology department, making it possible to collect the required data. Finally, 
there is a high patient load from a wide demographic allowing analysis of patients 
with a variety of tumour locations and treatment techniques, as well as age and 
health status, due to the location, size and reputation of the hospital. 
 
7.3.1 Initial study protocols 
 
Implementation of the study began in June 2011. Ethics approval was granted for 
two protocols by the RPA human research ethics committees (HREC) – a 
retrospective study of CIED patients treated between 2007 and 2010 who had been 
followed up by cardiology at six months post radiotherapy, and a prospective study 
of CIED patients between 2011 and 2014 with patients consenting to weekly CIED 
checks regardless of accumulated dose received by the CIED. Recruitment of 
patients to the latter study was limited; identification of appropriate patients to the 
researcher often occurred after treatment had begun. The former study was also 
limited in recruitment due to the stringent guidelines of length of patient follow-up, 
as many patients were lost to either death or follow up being performed outside the 
participating hospital. 
 
7.3.2 Current study protocol 
 
The updated protocol received ethics approval in 2011 from the RPAH HREC 
committee (X110351 and LNR/11/RPAH/554; LNRSSA/12/RPAH/130), which 
combined the original prospective and retrospective study protocols into a larger 
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single retrospective study. A copy of these ethics forms are found in appendix E. 
This study incorporated patients treated between 2005 and 2012, with six month 
follow up included if available from the cardiology department. Due to the revised 
research protocol, it was possible to include a greater range of patients in the study, 
including both palliative and radically treated patients. It also served to reduce 
potential selection bias by only including patients healthy enough to survive to six or 
more months, potentially decreasing their reliance on their CIED. The desire to 
collect data from a six month follow up period post treatment continued to be 
problematic due to death, or patient follow up occurring  outside the participating 
hospital. After data collection was concluded, it was deemed that there were 
insufficient results to carry out an analysis on the follow up period and this portion 
of the study was subsequently removed. Ethics approval was granted for the 
collection of de-identified data from stored records without requiring patient consent.    
 
7.3.3 Selection criteria 
 
For the purpose of this thesis, this study was split into two chapters. This chapter 
details the effect of radiation therapy on PM when compared to a control group; 
chapter eight investigates the effect on ICDs. 
 
7.3.3.1 Radiation therapy group 
 
All patients treated within the Radiation Oncology department with CIEDs in situ 
before the first stage of treatment planning, and who had at least two separate PM 
checks before the first fraction and after the final fraction of treatment were included. 
Patients with PMs implanted during the course of treatment were not included due to 
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the difficultly that would be faced in estimating the received dose to the PM and 
limited PM checks. Thermoluminescent dosimetry (TLD) is routinely used to 
estimate the dose received by the PM on the first day of each radiation therapy. This 
measurement is performed regardless of treatment site, therefore the paper catalogue 
of TLD results were used to identify patients eligible for this study.  
 
Between 2005 and 2012 inclusive, 85 PM patients were treated with radiation 
therapy at RPA through 100 treatment courses, representing 0.77% of all treatment 
courses (n=13,048; excluding superficial and brachytherapy patients). A graph 
showing the number of treatments performed on PM patients per year is shown in 
figure 7.1. The graph shows an increasing trend, highlighting that a rising number of 
patients will present for treatment in future years. As departments expand or increase 
their patient loads to keep up with the growing need for radiation therapy in 
Australia(Radiation Oncology Tripartite Committee, 2012), as well as the increasing 
number of PM implantations (Mond & Proclemer, 2011), this number is expected to 
increase further. This research is important to ensure all patients are treated with the 
appropriate protocol, limiting the exposure of these patients to potentially harmful 
risks associated with radiation therapy. 
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Figure 7.1: Number of radiation therapy courses to pacemaker patients 
per year between 2005 and 2012 
 
After collection of the radiation therapy and cardiac data checks, 59 patients over 64 
treatment courses were included in the study, resulting in a 69.4% participation rate, 
detailed in figure 7.2. Two patients received treatment for multiple sites 
concurrently; these were counted as one treatment course during analysis. The 
radiation therapy group contained 41 multiple lead PMs and 23 single lead PMs, 
resulting in 105 leads analysed in this group.  
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Figure 7.2: Flow chart showing the number of radiation therapy PM 
patients excluded due to the study criteria 
 
Treatment was given to a variety of areas, as shown in figure 7.3. Anatomical 
treatment areas indicated between the red lines are areas where the PM is likely to be 
situated within the volume covered by the planning CT scan of the area and may 
require treatment variation or PM relocation to avoid direct exposure of the PM unit.  
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C-T = Cervical-Thoracic; T = Thoracic; L-S = Lumbo-Sacral; PM = Pacemaker 
Figure 7.3: Radiation therapy treatment areas for PM patients.  
 
 
Thirty five (54.7%) radiation therapy patients were treated with a palliative intent, 
with the remaining 29 (45.3%) treated with a curative intent. There was a higher 
proportion of palliative patients in this group than remaining radiation therapy 
population at RPAH between 2005 and 2012, as shown in figure 7.4. This may be 
due to the comorbidities associated with CVD and cancer, with the possibility that 
they were not referred for curative management using radiation therapy due to their 
PM reliance.  
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Figure 7.4: A bar chart showing the percentage of pacemaker radical vs. 
palliative patients treated at RPAH compared to total treatments carried 
out at RPAH 2005 to 2012 inclusive 
 
7.3.3.2 Control group 
 
The PM control group patients were matched to the radiation therapy group as either 
a single or dual lead PM. Two control patients were identified for every radiation 
therapy patient included in the study. A randomised approach was adopted to 
identify patients within the control group. Patients were randomly selected from the 
cardiac services database and included if they had the appropriate number of leads 
required for analysis. Each control patient was required to have had two device 
checks between 2005 and 2012. A time limit was not imposed on these checks due to 
the large variation of time between checks seen in the RT group. Severe failure 
information for the control group was not available to the researcher during the 
selection phase to reduce potential bias. The exclusion criteria for this group were 
patients with known previous radiation therapy exposure and patients that had less 
than two PM checks within a six month period. Given the relatively short lifespan of 
a PM, a control patient was assumed to not have a history of radiation therapy during 
53.50% 
44% 
2.50% 
45.30% 
54.70% 
Curative Palliative Unknown
All RPA Treatments (%) RT PM Group (%)
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the time of the device checks if this was not in their records and no history of cancer 
was readily identified. One hundred and twenty eight patients were chosen for the 
control group, with 82 multiple lead PMs and 46 single lead PMs, totalling 210 
leads. 
7.3.4 Group Comparison 
The PM cardiac parameters were split into categories according to the lead assessed, 
where multiple lead PMs were used - i.e. RV or RA lead. A total of 192 patients 
incorporating 315 leads were compared during the analysis. A comparison of the 
group demographics is shown in table 7.1. A higher proportion of males than 
females were represented in both groups in this study. This is consistent with the 
1997 ICPES world survey (Mond, 2001) where Australia saw a 55:45 male to female 
ratio of all CIED implantations. Demographic data was not available for Australia in 
the 2001, 2005 or 2009 surveys (Mond et al., 2008; Mond et al., 2004; Mond & 
Proclemer, 2011). There are a higher proportion of females in the control group as 
opposed to the radiation therapy group. This is likely due to the fact that females are 
more likely than males to schedule regular follow up appointments with doctors than 
males (Cockerham, 2007). It is not believed that this difference impacted the results.  
 
The mean age in this study (74:75) is similar across both groups and comparable to 
that reported in the survey (Mond, 2001). The mean device age is higher in the 
radiation therapy group as opposed to the control group. As RPA is a major 
treatment centre it is possible that patients receive PM implantation and initial follow 
up at RPA. As the time from implant increases, patients move into the private clinics 
and hospitals which are more accessible to the patient. Time between device checks 
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is much larger in the control group than in the radiation therapy group, and due to the 
nature of the retrospective study is unavoidable. 
Table 7.1: Radiation therapy and control group demographic comparison  
 RT Group Control Group 
 n=  n= 
Gender  male 47 (73.4%) 
64 
77 (60.2%) 
128 
female 17 (26.6%) 51 (39.8%) 
Age (years) Range 20-97 
64 
21-98 
127 
Mean±SD 75.3±10.9 73.8±14.2 
Age of Device 
(months) 
Range 1-130 
58 
1-109 
125 
Mean±SD 46.4±33.4 25.5±23.2 
Time 
Between 
Checks 
(days) 
Range 4-298 
64 
67-385 
128 Mean±SD 37.4±49.9 213.6±71.6 
RT = Radiation Therapy; SD = standard deviation. 
 
 
A variety of PM brands were represented in each group and are shown in figures 7.5 
(a) and (b). The largest proportions of manufacturers represented in both groups 
were Guidant, Medtronic, Biotronik and St Jude Medical. It is assumed that the 
similarities between the groups will limit variability in results due to varying 
manufacturer device specifications.    
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(a)  
(b)  
Figures 7.5: Pacemaker brands represented for the (a) radiation therapy 
group and (b) control group. 
 
7.3.5 Radiation Therapy Planning  
 
When a PM patient presents to the Radiation Oncology Department, an 
individualised treatment plan is created based on the process described in section 
2.6.3. For the purpose of this study, variations were made by the researcher to the 
outlines drawn on the original CT plans by the planning team. The outlines that were 
altered were the organs/structures at risk outlines for the PM, heart and leads. This 
Guidant Biotronik Medtronic St Jude Medical
Vitatron Sorin Boston Scientific Unknown
Guidant Biotronik Medtronic St Jude Medical
Vitatron Sorin Boston Scientific Unknown
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was done so that a more accurate estimation of the doses received by these structures 
during radiation therapy could be made. Treatment plans were created using the 
Varian Eclipse treatment planning system (Palo Alto, CA), which calculates the dose 
to outlined volumes within the radiation therapy plan. 
 
7.3.5.1 Planning Data 
 
The Varian ARIA Oncology information system (Palto Alto, CA) was used to access 
the patient treatment information, listed in table 7.2. Radiation oncology paper 
history files were accessed when data was unavailable on ARIA.  
Table 7.2: Radiation therapy data collection 
Aria/Patient File Eclipse 
Date of Birth/Age at treatment Heart Maximum Dose 
Treatment Area PM Maximum Dose 
Fractionation/dates of treatment Lead Maximum Dose 
Dose  
Treatment energy  
Previous treatment  
PM maximum dose (TLD)  
Key: PM = pacemaker; TLD = thermoluminescent dosimetry. 
 
7.3.6 Organ at risk contouring and estimated dose 
 
Contouring of critical structures not within the treatment volume, generally referred 
to as organs at risk (OAR), is performed on a 3D treatment planning system (TPS) 
during the planning process. This gives an estimation of the volume occupied by that 
organ, and hence allows an estimation of the dose received by the total volume of the 
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OAR during treatment. According to the standard protocol of the participating 
hospital, the PM is outlined during routine planning. The heart is only outlined if it is 
within the treatment field boundaries, and the leads are never routinely outlined. The 
dose received by the OAR are displayed using a dose volume histogram (DVH) (see 
section 2.6.3), shown in figure 7.6. 
 
Figure 7.6: Dose volume histogram indicating heart (red), leads (blue) and 
pacemaker (yellow) dose. The percentage of the volume of the organ is 
indicated on the vertical axis, with the accumulated dose (cGy) indicated 
on the horizontal axis. 
 
The dose received by the PM was confirmed on the first day of treatment using 
thermoluminescent dosimetry (TLD) (see section 2.6.3).  
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7.3.6.1 Pacemaker contouring and TLD dose estimation 
 
The PM was contoured by the researcher on all CT slices in which it was visible. It 
was outlined using the outer casing as a guide, encompassing all circuitry and battery 
components. The outer casing was visualised by decreasing the contrast in the CT 
dataset, limiting the amount of artefact visualised in the scan as shown in figures 7.7 
(a) and (b).  As a result the PM outlined by the researcher was a consistently smaller 
volume than that outlined by the radiation therapists for treatment planning purposes, 
as shown in figure 7.8.  The previous outlines may overestimate the maximum 
accumulated dose received by the PM due to the larger contoured area.  
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(a )  
(b)  
Figure 7.7: Change in pacemaker visualisation by the reduction of contrast 
between (a) before window width adjustment  and (b) after window width 
adjustment 
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Figure 7.8: An image showing the comparison of pacemaker outlines. The 
green line represents the previous contour applied during the original 
planning process, with the yellow line representing the contour by the 
researcher 
 
The maximum dose estimated by the TPS via the DVH was then compared to the 
TLD result to assess the accuracy of plan estimates. The measured dose to the TLD 
was significantly higher (p=0.042) than that estimated through the DVH, as shown in 
figure 7.9. Differences may be due to the location of TLD placements or limitations 
of the TPS calculation algorithms. Additional dose may also have been measured by 
the TLD due to the common practice of additional treatment verification imaging 
during the first treatment fraction, when the TLDs were performed. TLDs have 
previously been  found to be accurate in estimating CIED dose during treatment 
(Studenski, Xiao, & Harrison, 2012). Large variations between estimated dose from 
the TPS and TLD were suggested to be attributed to the number of lateral beams 
used in treatment. The largest difference seen in this study was associated with an 18 
field IMRT treatment incorporating multiple lateral beams. Two of the remaining 
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three that showed differences between 1Gy and 1.3Gy were included treatment 
beams with MeV. Smaller differences were associated with lateral oblique fields.  
 
Figure 7.9: Comparison of the estimated plan dose to the pacemaker 
compared to the measured TLD dose. 
 
As a result, the recorded TLD dose to the PM was used rather than the estimated 
dose from the DVH when analysing the PM function, as this was a consistent 
measurement regardless of whether the PM was visualised within the planning CT 
scan.  
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7.3.6.2 Leads 
 
The leads of the PM were contoured when they were within the planning CT scan 
range. Leads were easily visualised on the scans due to their density. Figure 7.10 
shows a digitally reconstructed radiograph (DRR) of a right lung plan with leads that 
were from the PM to the RV outlined in blue. A DRR is reconstructed from the 
scanned CT slices and may be visualised from the point of view of any treatment 
beam.  The quality of the DRR is associated with the thickness of the CT slices, 
where a smaller slice thickness will give a clearer DRR. The extension of the leads to 
the right subclavicular area and comparatively central location of the PM indicates 
that the PM was relocated before radiation therapy due to the right sided treatment 
location. Relocation of a CIED via surgery before treatment may occur when it is 
likely that the CIED will be within the required treatment fields. CIED relocation 
may also occur when an infection or abnormality occurs within the existing location.  
 
Figure 7.10: Lead outlining (blue) and device relocation DRR.  
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7.3.6.3 Heart 
 
As all patients included in the study had impaired cardiac function, the dose to the 
heart was deemed to be relevant when looking into PM function. A dose of 40Gy to 
5% of the whole heart volume correlates to a risk of cardiac mortality exceeding 2% 
in breast irradiation where no prior cardiac comorbidities were present(Gagliardi, 
Lax, Ottolenghi, & Rutqvist, 1996). The effect of radiation therapy on a heart with a 
pre-existing cardiac condition has not been analysed, as only the dose to the PM is 
generally considered. It is therefore reasonable to assume that high maximum doses 
to the heart ( greater than 40Gy) may affect the function of the PM as the heart 
becomes further damaged. Accurate contouring of the heart is required to accurately 
estimate the dose received during treatment.  
 
Twenty three patients had hearts that were visualised within their planning CT scan. 
The whole heart was outlined according to the Cardiac Atlas specified by Feng et al. 
(2011), summarised in table 7.3 
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Table 7.3: Heart outlining protocol 
Heart Anatomy Heart levels proposed by 
Feng et al. (2011) 
Heart contours followed 
in study 
Superior Aspect of Heart  
 
Begins just below the left 
pulmonary artery 
Superior contour 
contoured one slice below 
the bifurcation of the left 
pulmonary artery 
Inferior aspect of heart: 
 
May blend with 
diaphragm inferiorly; 
include pericardium given 
the high number of cardiac 
vessels in the fatty tissue 
of the pericardium 
regardless of heart tissue 
visualised 
Inferior contour contoured 
to the lowest level that the 
pericardium was still 
visualised, with or without 
heart tissue being 
visualised.  
Inclusion of the superior 
vena cava (SVC) 
May or may not be 
included depending on the 
quality of the scanned data 
set.  
SVC was included in the 
whole heart outline given 
the poor quality of some 
of the scanned data sets.  
  
The pericardium was also outlined given the risk of pericarditis as a late effect of 
radiation therapy which includes the heart (Gagliardi et al., 2010). 
 
7.3.6.4 Heart Contouring Study 
 
 In order to ensure accuracy by the researcher in heart outlining following the above 
protocol, a reproducibility study was conducted by the researcher prior to the main 
study, using the Elekta Xio treatment planning system (Stockholm, Sweden) 
available at the University of Sydney Faculty of Health Sciences.  
 
A series of 16 data sets, encompassing a variety of treatment sites and CT slice 
thickness were contoured using the Cardiac Atlas described in table 7.3. The superior 
level of the heart was contoured first, as this can be the most difficult to delineate. 
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The SVC was included in the superior slices due to the poor quality of the CT scans. 
The inferior level of the heart was then contoured, followed by the interpolation of 
the remaining slices. The slice level of the superior and inferior heart contour, as 
well as the volume of the heart outlined, was recorded. 
 
Contouring of the heart was repeated four weeks after the first contouring session. 
All previous outlines were deleted prior to the second contouring to prevent any bias 
of the new contour. Results are detailed in table 7.4. The difference in volume was 
then analysed using the SPSS statistics package (version 21; Armonk, NY). A paired 
sample T-test was used to assess the difference in volume between the two contours. 
A result was deemed significant if p<0.05.  
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Table 7.4: Heart Contouring Study results 
Pt 
No 
Site of 
treatment 
CT slice 
thickness 
(mm) 
Change in no. 
of slices 
contours (2-1) 
Vol. 
Difference 
(cc) (2-1) 
Vol. 
Difference 
(%) (2-1) 
1 Abdomen 4.25 0 1.05 0.127 
2 Left Breast 3 0 23.89 3.143 
3 Left Breast 5 0 11.32 1.987 
4 Left Chest Wall 3 0 18.01 2.471 
5 Right Chest Wall 5 0 19.27 3.86 
6 Lung 3 0 8.55 1.415 
7 Lung 3 0 9.73 1.488 
8 Oesophagus 5 0 1.11 0.201 
9 Right Breast 3 0 24.57 3.78 
10 Hodgkin’s 3 0 37.69 4.872 
11 Right Lung 3 0 19.77 2.169 
12 Left Breast 5 0 16.51 2.908 
13 Right Lung 5 0 1.12 0.147 
14 Right Lung 5 0 9.64 1.655 
15 Left Lung 3 0 10.46 1.299 
16 Oesophagus 3 0 13.43 1.885 
Key: cc - cubic centimetres 
 
An average difference in heart volume of ± 2.1% was seen between session one and 
two, with a range of 0.1% to 4.8%. The difference in volume was not deemed 
statistically significant with a p value of 0.726. This study demonstrated that the 
researcher was sufficiently accurate in delineating heart volumes according to the 
heart atlas.  
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7.3.7 Cardiac Device Checks 
 
Once patients were initially identified as eligible, PM checks were collected using 
the PM database located within the theatres of the participating cardiology 
department. These checks monitor the correct functioning of a PM (see section 2.4.7) 
and had been carried out by the cardiac technicians within the department. PM 
checks are performed routinely every six to twelve months, with more regular check-
ups performed after PM implantation, battery end of life or upon patient request or 
illness requiring hospitalisation.  
 
Information that was collected from the device checks is detailed in table 7.5.  A 
definition of these parameters is located in section 2.4.7. Parameters were either 
deemed as device or lead specific – a device specific parameter will not change 
regardless of the lead assessed whereas a lead specific parameter is only relevant to 
the specific lead assessed.  
Table 7.5: Cardiac Device check parameters analysed 
Parameter  Measurement Lead or Device  
Age of device at first check Months Device 
Time between check 1 and 2 days Device 
Battery V Device 
Signal Amplitude  
(R wave – Ventricle; P wave – Atrium) 
mV  Lead 
Lead Impedance Ω Lead 
Capture Threshold Amplitude* Yes/No; V Lead 
Capture Threshold Pulse Width* ms  Lead 
Output amplitude* Yes/No; V Lead 
Output Pulse Width* ms Lead 
Event Yes/No Device 
*Threshold and Output amplitude results were analysed twice to assess both the 
frequency or number of changes occurring as well as the size of any changes.  
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The radiation therapy group and control group were compared across all parameters 
to assess the overall impact of radiation therapy on PMs. Subsequent analysis of 
treatment energy maximum dose to PM, leads and heart, previous radiation therapy, 
lead type and radiation therapy treatment intent was also performed.  A breakdown 
of the PM groups analysed in this study is shown in table 7.6. 
Table 7.6: Pacemaker groups used for comparison of results 
RT Group Control Group 
RT treatment 
1. RT Group 1. Control Group 
Treatment Energy used 
1. 6MV±MeV/MeV only 
2. 18MV ±6MV 
1. Control Group 
Accumulated pacemaker maximum dose level (TLD level) 
1. <1Gy 
2. 1Gy - <2Gy 
3. ≥2Gy 
1. Control group 
Accumulated lead maximum dose level 
1. Low dose (not on CT scan) 
2. <25Gy 
3. ≥25Gy 
1. Control group 
Accumulated heart maximum dose level 
1. Low dose (not on CT scan) 
2. <20Gy 
3. ≥20Gy 
1. Control group 
Treatment Intent 
1. Radical 
2. Palliative 
1. Control 
Treatment Technique 
             1. 3D-CRT 
             2. IMRT 
              1. Control 
Previous RT Treatment 
             1. Yes 
             2. No 
              1. Control 
Lead Type 
1. Right Ventricular Lead 
2. Right Atrial Lead 
1. Right Ventricular Lead 
2. Right Atrial Lead 
RT = Radiation Therapy; MV = photons; MeV= electrons; TLD = 
thermoluminescent dosimetry; Gy = gray; CT = computed tomography; 3D-CRT = 
Three dimensional conformal radiation therapy; IMRT = Intensity Modulated 
Radiation Therapy 
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7.3.8 Statistical Analysis 
 
PM checks were analysed by subtracting the values obtained during the first check 
from the second check to identify any changes that occurred during this time period. 
Time between device checks varied within the radiation therapy group due to the 
varying length of patient treatment courses, as well as the hospital protocol, which 
allows use of CIED checks taken within three months of the initial radiation therapy 
as the first check. Routine CIED checks were performed at six monthly intervals at 
the hospital; in addition to this, three monthly checks were performed in newly 
implanted CIEDs and CIEDs nearing battery end of life (EOL). 
  
Kolmogorov- Smirnov normality tests were performed on all parameters, with all 
returning significant results. As a result non-parametric tests were used throughout 
the study. A Mann-Whitney U test was used to compare both nominal and 
continuous variables when only the radiation therapy group and control group were 
compared. The effect size (r) was calculated by the following formula: 
r = z / square root of N (where N = total number of cases) 
The effect size is calculated as 0.1 = small effect, 0.3 = medium effect, and 0.5= 
large effect. 
 
A Kruskall-Wallis test was used instead of a Mann-Whitney U test for comparison 
when three or more groups were analysed. Significant results from a Kruskall-Wallis 
test required subsequent analysis of pairs of groups using Mann-Whitney U tests. To 
control type 1 errors, a Bonferroni adjustment was used to alter the alpha value, 
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originally 0.05, by dividing the alpha level by the number of tests that were to be 
performed. Effect size was calculated on the new tests as described above. 
 
Results are presented as median and range. A Chi-Square test for independence was 
used for group comparisons, with Yates’ Correction for Continuity applied where 
only two groups were compared to compensate for an overestimation of the chi-
square value when used in a two by two table.   
 
7.4 Results 
 
Results of the analysis conducted are detailed below. Tabulated results for radiation 
therapy subgroups, such as the analysis for treatment energy and type, are found in 
appendix F.  Due to space constraints, figures for the radiation therapy subgroup 
analysis are only presented for significant results.  
 
7.4.1 Radiation therapy group vs. Control Group 
 
A summary of the results of the analysis between the radiation therapy group and the 
control group are shown in tables 7.7 and 7.8. Figures in this section present the 
groups as radiation therapy (group 1) and Control (group 2). Figure 7.11 shows the 
distribution of results detailed from table 7.7 in the form of boxplots. The central line 
indicated the median of the distribution, with the box representing 50% of the data, 
from 25th to 75th percentile. The whiskers represent the smallest and largest values as 
determined by SPSS. Outlying results are represented by a circle, when the value lies 
more than 1.5 box lengths from the edge of the box, and extreme outliers represented 
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by an asterix (*), when the value lies more than three box lengths from the edge of 
the box. Due to the small values involved in these results, extreme outliers were not 
excluded. Figure 7.12 represents the results from table 7.8 as column graphs 
representing the percentage in which change occurred within each group. 
 
No significant results were observed across all parameters analysed. Two events 
(3.1%) were recorded across the radiation therapy PM group, shown in figure 
7.12 (c). One patient experienced an inappropriate mode change to VVIR after 24 
fractions of a prostate treatment. Reprogramming was required to restore the 
previous DDDR mode. A second patient experienced an increased heart rate during a 
single treatment fraction to the C-T spine, with heart rate returning to normal at the 
completion of the treatment beam. At the first check, this patient was paced 100% of 
the time by the PM.  
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Table 7.7: Radiation therapy group vs. control group; Mann-Whitney U tests 
Change 
(check 2 - check 1) 
Radiation Therapy (Group 1) Control (Group 2)  
n= Median (Range) n= Median (Range) U Z r p value 
Battery (V) 59 0.00 (-0.05 - 0.03) 89 0.00 (-0.03 - 0.06) 2412.5 -0.99 0.08 0.324 
Signal Amplitude (mV) 85 0.00 (-4.48 - 4.40) 184 0.00 (-11.60 - 8.00) 7520.0 -0.51 0.03 0.608 
Impedance (Ω) 102 -2.50 (-193.00 - 90.00) 210 -0.50 (-232.00 - 287.00) 10541.0 -0.23 0.01 0.821 
Capture Threshold Amplitude (V)^ 102 0.00 (-0.68 - 0.50) 207 0.00 (-0.63 - 1.50) 9372.5 -1.74 0.10 0.083 
Capture Threshold pulse width (ms) 104 0.00 (0.00) 210 0.00 (0.00 - 0.50) 10816.0 -1.00 0.06 0.319 
Output Amplitude (V)^ 100 0.00 (-1.40 - 1.38) 210 0.00 (-3.00 - 2.00) 10007.0 -0.95 0.05 0.342 
Output pulse width (ms) 99 0.00 (0.00 - 0.35) 210 0.00 (0.00 - 0.10) 10282.5 -0.78 0.04 0.433 
Key: V = Voltage; mV = millivolts; Ω = ohms; ms = milliseconds; U = Mann-Whitney U value; r = effect size 
^ Capture threshold and Output measures were analysed for both the frequency of change and size or amplitude of the change that occurred  
Table 7.8: Radiation therapy group vs. control group; Chi Square test with continuity correction 
 
 
 
 
 
 
 
Key:  χ2 = Chi Square Value 
# cell value less than five 
- test could not be performed due to small numbers 
Change 
(check 2 - check 1) 
Radiation Therapy Control  
n= n= 
χ2 (continuity 
correction) Phi coefficient 
p value 
 yes no yes no 
Capture Threshold Amplitude^ 42 60 105 102 2.13 -0.09 0.144 
Output Amplitude^ 17 83 46 164 0.73 -0.06 0.394 
Events 2# 62 0# 128 - - - 
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(a)  (b)  
(c)  (d)  
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(e) (f)  
(g) 
Figure 7.11: Radiation therapy Group (group 1, left in 
figures) vs. Control (group 2, right in figures) (a) 
Battery voltage; (b) Signal Amplitude; (c) Impedance; 
(d) Capture Threshold Voltage; (e) Capture Threshold 
pulse width; (f) Output Voltage; (g) Output pulse width. 
The study ID number is shown next to outlying results.   
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(a)  
(b)  
(c)  
Figure 7.12: Radiation Therapy group vs Control group observed changes 
for (a) Capture threshold amplitude; (b) Output amplitude; (c) Notable 
Events. 
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7.4.2 Radiation Therapy Treatment Energy 
 
 
The radiation therapy PM group was split into patients treated with 6MV, with or 
without the addition of an electron boost (6MV group) and patients treated with 
18MV energy only, or a mixture of 6MV and 18MV beams (18MV group) for 
comparison to the control group. Results on the effect of radiation therapy treatment 
energy on PMs are found in tables F1 and F2 in the appendix. Notable events 
occurred once in the 6MV group (2.2%) with increased heart rate, and once in the 
18MV group (5.6%) with an inappropriate mode change. 
 
7.4.3 Accumulated dose level to pacemaker 
 
The radiation therapy group was divided into PM TLD dose levels as described in 
table 7.6. Sixty two of the 64 radiation therapy PMs had a valid TLD dose record. 
The dose received by the PM ranged from 0.02Gy-4.7Gy with a mean dose of 
0.7Gy±0.85. The results are summarised in tables F3 and F4 in the appendix. PMs 
receiving greater than or equal to 2Gy recorded a change in capture threshold 
amplitude in 66.7% (4) of PMs, compared to 63.6% (14), 32.9% (23) and 50.7% 
(105) in the 1Gy to less than 2Gy, less than 1Gy and Control groups respectively, 
shown in figure 7.13. These results only led to a change in output amplitude in 
16.7% (1), 30% (6), 12.8% (9) and 21.9% (46) in the greater than 2Gy, 1Gy to less 
than 2Gy, less than 1Gy and control group respectively, shown in figure 7.14. 
Neither capture threshold or output amplitude were associated with a significant 
difference in size of change. 
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Figure 7.13: Representation of frequency of observed change in capture 
threshold amplitude in relation to TLD measured dose to the pacemaker. 
 
Figure 7.14: Representation of frequency of observed change in output 
amplitude in relation to TLD measured dose to the PM. 
 
The observed mode change occurred at a maximum dose less than 1Gy to the PM. 
The increased pacing rate was not observed as no TLD dose to the PM was available 
for this patient.  
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7.4.4 Accumulated maximum dose to pacemaker leads 
 
Twenty six radiation therapy PM patients had leads that could be visualised within 
the CT scan volume, which was taken of the treatment area. This allowed an 
estimated plan maximum dose to the PM leads to be recorded from the TPS DVH. In 
multiple lead devices, both leads were contoured as one, as the CT scan quality did 
not allow for separate delineation. A mean dose of 30.03Gy±19.03Gy was received 
by the leads shown in the CT scans, with a range of 1.114Gy-61.12Gy. Results are 
shown in tables F5 and F6 in the appendix. 
 
Capture threshold amplitude change occurred more frequently in the greater than or 
equal to 25Gy group (57.1%) than the control group (50.7%). This did not translate 
to a difference in the frequency of output amplitude change, with the control group 
recording the highest incidence (21.9%), shown in table F6 in the appendix. Both 
notable events occurred in the ‘low dose’ group, as shown in figure 7.15. No 
significant change was observed in any cardiac parameter.  
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Figure 7.15: Notable cardiac device events occurring in relation to 
estimated maximum dose to the pacemaker leads. 
 
7.4.5 Accumulated maximum dose to heart 
 
Twenty three radiation therapy PM patients required treatment to an area close to the 
heart volume and were within the planning CT scan, allowing an estimation of the 
maximum dose received by the heart to be acquired from the TPS DVH. Hearts that 
could be visualised within the treatment CT had a mean dose of 25.13Gy±19.31, 
with a range of 0.26Gy-59.21Gy. Results are shown in tables F7 and F9 in the 
appendix. Both notable events occurred in the out of scan/low dose group. 
 
The difference in the size of the output amplitude change was found to be significant 
between the groups (Gp 0, n= 65: out of scan; Gp1, n= 17: <20Gy; Gp2, n= 18: 
≥20Gy; Gp3, n= 210: Control), (χ2 (3, n= 310) = 9.35, p= 0.025). All groups showed 
a median score of 0. Post-Hoc tests (see appendix F.4.1) showed a significant 
difference between the greater than 20Gy group and the out of scan group (z=-2.78, 
p=0.006) with a medium effect size (r=0.30), the less than 20Gy group (z=-2.62, 
p=0.009) with a small effect size (r=0.27), and the control group (z=-2.78, p=0.005) 
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with a small effect size (r=0.18), visualised in figure 7.16 (a). Changes in output 
amplitude occurred more frequently than any other group, as shown in figure 7.16 
(b). The largest output decrease of 38% occurred in a device that was 37 months old 
and was not close to the elective replacement battery indicator (ERI). 
(a)  
(b)  
Figure 7.16: Representation of (a) size of change and (b) frequency of 
change in output amplitude (V) in relation to estimated maximum dose to 
the heart (pacemaker).  
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Capture threshold changes also occurred more frequently in the greater than or equal 
to 20Gy radiation therapy group (66.7%) when compared to hearts receiving less 
than 20Gy (52.9%), out of scan (31.3%) and control (50.7%), shown in figure 7.17. 
When considering maximum heart doses greater than 40Gy, seven leads (87.5%) 
recorded a capture threshold change, with one lead remaining stable. The final lead 
did not have enough data to analyse. 
 
Figure 7.17: Frequency of observed change in capture threshold 
amplitude (V) in relation to estimated maximum dose to the heart 
(pacemaker). 
 
Both notable events occurred in the out of scan group. 
 
7.4.6 Treatment Intent 
 
There was no significant difference between the changes observed in palliative 
patients and radical patients across all parameters, shown in tables F10 and F11 in 
the appendix. One notable event occurred in both the curative and palliative groups. 
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7.4.7 Treatment Technique 
 
Three radiation therapy PM patients received treatment using IMRT, with the 
remaining radiation therapy patients receiving treatment using 3D-CRT. No included 
patient was treated using VMAT or SBRT. No significant difference in cardiac 
device parameters was observed between 3D-CRT and IMRT when compared to the 
control group, as shown in tables F12 and F13 in the appendix. Both notable events 
occurred during exposure to 3D-CRT. 
 
7.4.8 Previous radiation therapy to current pacemaker 
 
Fifty six radiation therapy PM patients had no previous radiation therapy to the 
current PM. Eight patients were on at least their second course of treatment. There 
was no significant result observed in any cardiac device parameter when considering 
previous treatment, shown in tables F14 and F15 in the appendix. Both notable 
events occurred in patients who had no previous exposure to radiation therapy.  
 
7.4.9 Lead Type 
 
Both the radiation therapy and control group were split into RV and RA leads, with 
only lead parameters analysed (see table 7.5). There was no significant difference 
between the changes observed in RV leads when compared to RA leads across all 
parameters. A summary of these results are shown in tables F16 and F17 in the 
appendix.   
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7.5 Discussion 
 
This study was the first case control observational study to compare a group of 
patients who received radiation therapy with a PM in situ with a control group who 
did not receive radiation therapy.  
 
There were no differences found when comparing changes in the PM parameters of 
the whole radiation therapy group to the control group, as shown in tables 7.7 and 
7.8.  Changes in permanent PM function that were observed over the course of 
radiation therapy were similar to that of the control group. Radiation therapy did not 
appear to contribute to harmful changes in battery longevity, pulse amplitude, 
capture threshold and output amplitude, or pulse width. No change in lead integrity 
was observed, with similar impedance results across both groups. By conducting this 
study, any changes that were observed were put into context by the introduction of a 
control group.  
 
Only two notable events in two separate PMs occurred over the duration of the study 
– an inappropriate mode change and heart rate increase during a radiation therapy 
session, as described in section 7.4.1. No notable events occurred in the control 
group. The small amount of failures observed is consistent with other PM 
observational studies (Makkar et al., 2012; Soejima et al., 2011; Wadasadawala et 
al., 2011). The mode change that was observed is likely a direct result of exposure to 
the radiation due to the timing of the change during the 24th treatment. Mode changes 
are known to occur in ICDs as a part of a POR; only one PM reset has been reported 
in the literature and was also attributed to the high photon energy used (Soejima et 
 -201- 
al., 2011). The observed increased heart rate may have been a physiological response 
to the stress of treatment (Wood & Ellenbogen, 2002), however is more likely to 
have been due to the radiation therapy, due to the heart rate increase beginning at the 
start of treatment and suddenly ceasing as the treatment beam concluded. This 
patient was also paced at 100% of the time at the first check. Increases in pacing 
pulse were observed (see section 5.4.1) when PMs were exposed to direct irradiation; 
these were thought to be a result of temporary interference caused by the beam. 
Increasing pacing pulse was also observed in section 6.4.4, however only ICDs were 
involved.  
 
When considering treatment energy, the mode change occurred at 18MV, with the 
increased pacing occurring during a 6MV treatment (see section 7.4.2). A mode 
change would be seen as a more severe response to radiation therapy, as it required 
reprogramming to correct the error. The high number of severe failures in Mouton et 
al. (2002) when compared to other in vitro studies (Hurkmans et al., 2005a; 
Souliman & Christie, 1994) is thought by this author to be attributed to the high 
energy (18MV) used in this study. This is consistent with more severe errors 
occurring at 18MV (see section 5.4.1) than at 6MV. While suggestions have been 
made for limiting the treatment energy used for ICDs (Elders et al., 2013; Lau et al., 
2008), none has been proffered for limiting exposure to PMs. While rare, occurring 
only once in this study, alteration of PM function requiring reprogramming is 
concerning, especially when taking into account the risk of these malfunctions not 
being discovered until weeks or months after they have occurred. This highlights the 
importance of regular routine cardiac device checks during radiation therapy, 
especially when exposed to energies greater than 10MV. The observed increased 
 -202- 
pacing pulse was transient in nature and was unlikely to cause harm to the patient 
due to the short treatment times involved in radiation therapy. This issue may be 
easily observed through the use of an ECG during treatment and action taken 
immediately on symptomatic effects that may occur as a result. 
 
The maximum dose received by the PM, measured using TLDs placed on the skin of 
the patient at the site of the PM, was not shown to significantly impact PM function, 
as described in section 7.4.3. The number of changes observed involving capture 
threshold changes did not translate to the PM’s requiring output amplitude 
reprogramming by the cardiac technician, therefore, the size of these changes were 
not deemed significant (see table F3). The observed mode change occurred at a low 
maximum dose - less than 1Gy - suggesting dose received by the PM is not the cause 
of failure. This thesis has previously suggested that damage to a PM is not a dose 
driven effect (section 5.5), in line with recent published literature (Kapa et al., 
2008).The dose to the pacing leads was also not shown to impact the appropriate 
functioning of the PM, as shown in section 7.4.4. Both notable events occurred in the 
‘out of scan’ group. Again, the frequency of changes observed in the capture 
threshold group did not lead to large changes in the frequency of output amplitude 
changes, shown in figures 7.13 and 7.14. This study appears to support the findings 
of Kirova et al. (2012), who found no damage to PM leads, even when they are 
within the radiation therapy fields.  
 
No study to date has assessed the impact of the dose received by the heart volume on 
the normal functioning of a PM. In this study, while both notable events occurred at 
low doses (see section 7.4.5), a significant difference was found in the size of output 
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amplitude changes between the greater than 20Gy group and all other groups (see 
table F8). These changes, as well as changes in capture threshold, occurred more 
frequently in the greater than 20Gy group than any other group. The size of the 
change in capture threshold amplitude was almost significant (p=0.054), as shown in 
table F7 in the appendix. Wilm et al. (1994) associated decrease in output amplitude 
as an early warning for severe irreversible damage of the PM in the days or weeks 
following radiation therapy. The patient with the largest output amplitude decrease 
(38%) would have met the failure criteria described in section 2.10.1. The PM was 
also not a new implant, being just over three years since implantation. While later 
failure was not observed in this study, it is possible that the increased need for 
changes are early indications of failure. Further follow up of these patients is 
required.  
 
The capture threshold indicates the minimum energy that is required to pace the 
heart, and is not a static measure, with small changes expected during the life of the 
device, due to inflammation, patient position and patient activity (Lau & Siu, 2010). 
Output is directly programmed in response to the capture threshold with added safety 
margins. Failure to appropriately program the output safety margin as a result of 
changing capture threshold may result in the loss of pacing capture (Ellenbogen & 
Wood, 2005). At maximum heart doses greater than 40Gy, 87.5% of the leads 
recorded a capture threshold change, with one lead remaining stable.  
 
Limiting the maximum dose received by the heart may also limit the need for 
changes to pacing output, decreasing the amount the patient would need to be 
observed by the cardiac technician during treatment. As previously discussed (see 
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section 7.3.5), 40 Gy doses to 5% of the whole heart correlates to a risk of cardiac 
mortality exceeding 2% in patients with no prior CVD (Gagliardi et al., 1996). In 
view of these results, it is feasible to propose limiting the maximum dose to the heart 
to 40Gy, with further reductions encouraged.  
 
No significant difference was seen in treatment intent, technique or previous 
exposure to radiation therapy (see sections 7.4.6 to 7.4.8). Notable events were not 
deemed to be a result of previous exposure or the use of IMRT which may introduce 
an increase in EMI to treatments as they include more treatment beams than 3D-CRT 
with multiple beam segments (see section 2.7.2). The type of lead and its 
implantation site in the heart (RV or RA) was not shown to impact the function of 
the PM (see section 7.4.9).  
 
No PM received a dose higher than the department protocol of 5Gy, and no PM was 
in the direct radiation beam. Whilst this did not allow for the analysis of traditionally 
high risk patients (Hurkmans et al., 2012), it has led to confirmation of the efficacy 
of a department protocol with device dose and beam placement limitations.  
 
7.6 Limitations 
 
This study is affected by the general limitations inherent in retrospective 
observational studies, with the foremost being a high attrition rate (Carlson & 
Morrison, 2009). One hundred and two radiation therapy patients were identified for 
the study, with a further 36 courses eliminated due to missing data, as shown in 
figure 7.2. Only two patients were eliminated for reasons that would have remained 
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the same in a retrospective study - death as a result of cancer before treatment 
conclusion and PM implantation between CT scan and treatment. Given the time 
limit imposed on this study, as well as the difficulty involved in initial patient 
recruitment and the limited number of patients who qualify for the radiation therapy 
group (0.77% of all patients treated with radiation therapy at the hospital between 
2005 and 2012), the benefits of the retrospective study ultimately outweighed its 
limitations.  
 
Ethics approval was granted for the inclusion of 200 radiation therapy patients across 
both PM and ICDs (see chapter 8). An increased number of patients may have led to 
greater validity of some statistical analysis, such as the cause of mode change or 
notable events. It is also possible that due to the rare nature of these malfunctions 
during radiation therapy in current literature, major failures such as mode changes, 
disruption of function or large parameter changes are unlikely to be represented in 
large values. The limited return on malfunctions limited the strength and use of 
statistical analysis on some parameters. Any results that do not return a significant 
result cannot be completely discounted due to the limited number of results, 
requiring trends and single events to be closely examined.   
 
Initially patients were to be matched to the control patients on the manufacturer and 
PM model, as well as gender, age (± 5 years) and implantation date (± 2 years). After 
complications with control data collection within the ICD department, detailed in 
section 8.3.2, a randomised approach to control matching was undertaken as this was 
the only viable option within the time constraints. 
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The time between cardiac device checks within the control group and the radiation 
therapy group was large, as shown in table 7.1.  Time between cardiac device checks 
within the radiation therapy group also varied greatly, with a range of four days to 
298 days. While this was a compromise of the retrospective style of the study, 
ideally a routine schedule of cardiac device checks would have been undertaken, in 
both the radiation therapy group and the control group. This would also have 
eliminated the issue of missing data for some parameters, as well as including a 
wider range of patients, as their files would not be missing. Effect of the patients PM 
dependency could also not be assessed as a result of the retrospective study. 
  
Further research should include patient participation, with the physiological effects 
felt by the patients also assessed. The effect of minor changes observed in cardiac 
device check parameters during radiation therapy have been thought to not cause 
noticeable patient issues (Mouton et al., 2002). It is important to associate these 
assumptions with clinical results.  
 
7.7 Conclusion 
 
The effect of radiation therapy on PMs has proven to be minimal in a controlled 
environment where a protocol has been diligently used. Rare incidents may still 
occur as a result of either radiation or EMI, however with continued monitoring, are 
unlikely to develop into dangerous conditions for a patient. It is suggested that a 
maximum heart dose limit of 40Gy be incorporated into current protocols to prevent 
further damage to cardiac compromised patients, and limit changes required in 
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increasingly adaptive PMs. An observational study on the effect of radiation therapy 
on ICDs has been presented in chapter eight.  
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Chapter Eight: Case Control Observational Study – Effect 
of Radiation Therapy on ICDs 
 
8.1 Introduction 
 
Implantable cardioverter defibrillators have historically shown an increased 
susceptibility to malfunction when exposed to radiation therapy (Hurkmans et al., 
2005b). While seemingly a rare event, between 2008 and 2011, five power on resets 
(PORs) were recorded in ICDs in three Sydney hospitals (see section 4.4).  Recent 
protocols  recommend limiting the treatment energy in which ICDs are exposed 
during radiation therapy to less than 10MV (Hurkmans et al., 2012). 
 
While an ICD POR and other severe changes in device programming have been 
reported in the literature, trends towards device failure and minor changes in device 
function have rarely been analysed. No study has compared the prevalence of device 
changes to those in a control population, who have not had radiation therapy 
exposure.  
 
This chapter details a retrospective observational study detailing patients with ICDs 
treated between 2005 and 2012 inclusive. These patients are compared to a control 
group of non-radiation therapy patients to provide a comprehensive assessment of 
the impact of radiation therapy on CIEDs to assess patient risk.  
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8.2 Study Aims and Outcomes 
 
The aim of this study was to assess the risk of ICD damage during radiation therapy, 
when managed by an existing department protocol based on current literature, in 
comparison to a control population. This aim was associated with the following 
outcomes: 
1. Identify patients with ICDs undergoing radiation therapy at the participating 
hospital. 
2. Obtain radiation therapy details of patients for detailed analysis of potential 
causes of ICD failure during radiation therapy. 
3. Identify control patients for comparison to the radiation therapy group. 
4. Obtain cardiac device checks for both radiation therapy and control patients 
to assess potential device damage associated with radiation therapy. 
5. Analyse cardiac device checks for both radiation therapy and control patients 
to assess risk associated with radiation therapy. 
6. Analyse results in this chapter and compare to previous study (Chapter Six) 
 
8.3 Materials and Method 
 
This study was conducted at the Royal Prince Alfred Hospital (RPA) Radiation 
Oncology and Cardiology Departments. The methodology followed by this study is 
based on the methodology detailed in section 7.3.  Significant change in 
methodology occurred during control group participant identification and the 
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recording of cardiac device checks. Only these changes, as well as patient 
demographics, are discussed in this section. 
 
8.3.1 Radiation Therapy group identification 
 
All patients within the Radiation Oncology department with ICDs in situ before the 
first stage of treatment planning and who had at least two separate ICD checks, one 
before and one after the radiation therapy course, were included. Exclusion criteria 
and identification method are found in section 7.3.3. 
 
Between 2005 and 2012 inclusive, 27 ICD patients were treated with radiation 
therapy at RPA through 34 treatment courses, representing 0.26% of all treatment 
courses (n=13,048; excluding orthovoltage (DXR) and superficial radiation therapy 
(SXR), and brachytherapy patients. A breakdown of ICD patient radiation therapy 
treatments per year is shown in figure 8.1. The combined incidence of PM and ICDs 
treatments is also shown. The graph shows an increasing trend, highlighting that a 
likely rising number of ICD patients will present for treatment in future years.  
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Figure 8.1: Radiation treatments to ICDs per year 2005-2012 
 
After collection of the radiation therapy and cardiac data checks, 14 patients over 15 
treatment courses were included in the study, resulting in a 44% participation rate, 
detailed in figure 8.2. Two patients received treatment for multiple sites 
concurrently; these were counted as one treatment course during analysis. The cause 
of the high attrition rate is discussed below in section 8.3.2. Due to difficulties in 
data collection, a larger range in time between device checks was accepted. The 
radiation therapy group contained nine single lead ICDs, five dual lead ICDs and one 
cardiac resynchronisation device (CRT-D) containing three leads, resulting in 26 
leads for analysis. 
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Figure 8.2: Flow chart showing the number of radiation therapy ICD 
patient exclusions due to the study criteria. 
 
Treatment was given to a variety of areas, as shown in figure 8.3. Treatments given 
to anatomical areas between the red lines are those likely to include the ICD in a 
planning CT scan of the patient volume of interest and may require treatment 
variation or ICD relocation to avoid direct exposure of the device.  
 
Key: T-L = Thoracolumbar 
Figure 8.3: Radiation therapy treatment area for included ICD patients 
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An example of an ICD close to the treatment area is shown in figure 8.4. 
 
Figure 8.4: A digitally reconstructed radiograph of an example of an 
excluded patient with an implanted ICD close to the treatment area; leads 
are within the whole field 
 
Nine (60%) radiation therapy courses were treated with a curative intent, with the 
remaining six (40%) treated with a palliative intent. There are a higher proportion of 
curative patients in this group than total radiation therapy population at RPAH 
between 2005 and 2012; however the overall CIED group indicates a higher 
proportion of palliative patients, as shown in figure 8.5. 
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Figure 8.5: A comparison of the percentage of ICD and pacemaker curative 
and palliative treatments at RPAH to the total treatments carried out 
between 2005 to 2012 
 
8.3.2 ICD cardiac device check records and control group 
identification 
 
Once patients were initially identified as eligible through the radiation therapy 
treatment files (see section 7.3.3), cardiac device check results were gathered from 
the participating hospitals’ cardiology department. Initially device check information 
was recorded through the ICD database located in the cardiology department. At the 
beginning of 2012, a ‘catastrophic failure’ of the database occurred at the hospital, 
with loss of all data recorded within this system.  Paper copies of all cardiac device 
checks were then required to obtain further data and to select the control patients. 
These paper files were stored in boxes at an off-site storage facility, sorted by clinic 
dates rather than patient names. As a result, all boxes pertaining to ICD checks from 
2005 to 2012 inclusive were requested. Figure 8.6 indicates date ranges of ICD 
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checks that were available from back storage. No checks were available from 2005 
and 2006, with large amounts of missing data in 2008, 2009 and 2010.  
 
Figure 8.6: Paper ICD data checks available from back storage, sorted by 
clinic dates 
 
Two control patients were identified for every radiation therapy patient included in 
the study. Inclusion/exclusion remained the same as the previous study. Control 
patients could only be identified from paper files within the date ranges available and 
were matched on the number of leads in use by the ICD. Thirty patients were 
identified for the control group, including 18 single lead, ten dual lead and two 
CRT-Ds, totalling 52 leads for comparison. 
 
8.3.3 Group comparisons 
 
ICD courses were split into lead parameters where multiple lead PMs were used (see 
table 7.5). A total of 45 patients were compared across 78 leads. 
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A comparison of the group demographics is shown in table 8.1. Section 7.3.4 
describes the likely causes of the difference in the male to female ratio. The mean 
age is lower in the control group than the radiation therapy group. This is most likely 
attributed to the small sample size and the minimum age range of the control group 
as opposed to the radiation therapy group. As cancer is more likely to occur with age 
(see section 2.5), this difference is expected, and is not thought to impact the study. 
The age of the ICD was comparable across both groups. There is an increased time 
between checks in the control group compared to the radiation therapy group; due to 
the nature of this study this difference is unavoidable and not expected to impact the 
results of this study. 
 
Table 8.1: ICD radiation therapy and control group demographic 
comparison 
 Radiation Therapy 
Group 
Control Group 
 n=  n= 
Gender  male 12 (80%) 15 21 (70%) 30 
female 3 (20%) 9 (30%) 
Age (years) Range 57-84 15 26-82 29 
Mean±SD 72.53±8.20 60.34±14.25 
Age of 
Device 
(months) 
Range 2-73 15 1-65 30 
Mean±SD 25.8±22.88 25.77±18.89 
Time 
Between 
Checks 
(days) 
Range 1-623 15 84-609 30 
Mean±SD 120.13±178.15 186.57±90.65 
Key: SD = Standard Deviation. 
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A variety of device brands were represented in each group and are shown in figures 
8.7 (a) and (b). A smaller proportion of brands are represented in this study than in 
the PM study (see section 7.3.4). This was unavoidable due to the method required to 
collect control patients for comparison.  
(a)  
(b)  
Figures 8.7: ICD brands represented for the (a) radiation therapy group 
and (b) Control group 
 
  
Guidant Biotronik Medtronic St Jude Medical
Guidant Medtronic St Jude Medical
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8.3.4 Radiation therapy planning and data collection 
 
 
The radiation therapy planning and contouring was carried out as detailed in sections 
7.3.5 and 7.3.6. 
 
Only five radiation therapy patients had ICDs that could be visualised within the 
treatment scan volume. One patient had an estimated dose to the ICD of 9 Gy, but no 
TLD dose was recorded.  This patient required a magnet placed over the ICD during 
treatment to disable the adaptive functions of the ICD (see section 2.4.2) due to the 
high dose received by the device. A second patient had an estimated dose of 2.01Gy 
to the ICD, but a TLD dose recorded between 1.8Gy to 9Gy as the TLD was placed 
distally to the ICD, again due to the location of the magnet during treatment. This 
patient was replanned after the second fraction due to the original plan irradiating the 
ICD to 11.7Gy, confirmed by TLD measurements. Due to this large discrepancy and 
small number of cases, statistical analysis could not be performed. The four 
remaining patients appeared to have fairly consistent dose estimates between the 
treatment planning system (TPS) and TLD, as shown in figure 8.8. 
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Figure 8.8: Comparison of the estimated plan dose to the ICD compared to 
the measured TLD dose.  
 
Both treatments resulting in high ICD doses were treated using bilateral IMRT head 
and neck techniques. The ICD of the first patient, who received an estimated 9Gy 
with no TLD information, was located within the exit beam of two of three right post 
oblique fields, and within 1.1cm of the left anterior oblique field. A total of 13 beams 
were used. The second patient, who required replanning after the second fraction, 
was irradiated using twelve fields at six gantry treatment angles, replanned from 14 
fields at seven gantry angles. At no point was the ICD within the visualised 
treatment field, as shown in figure 8.9.  
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(a)  (b)  
Figures 8.9: Planning DRRs showing the proximity of ICD to treatment 
fields (a) 2.6cm to the nearest field edge of the right anterior oblique 
treatment field angle and (b) 3.2cm from the nearest field edge of the 
anterior field.  
 
8.3.5: Statistical Analysis 
 
The radiation therapy and control groups were analysed across all parameters 
described in table 7.5. Subsequent analysis of treatment energy, maximum dose to 
PM, leads and heart, previous radiation therapy, treatment intent, lead type and 
magnet use was also performed, shown in table 8.2. 
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Table 8.2 ICD analysis groups 
Radiation Therapy Group Control Group 
RT treatment 
1. RT Group 1. Control Group 
Treatment Energy 
1. 6MV only/6MV+electron 
boost/Electrons only 
2. 18MV only/18MV+6MV 
1. Control Group 
Accumulated ICD maximum dose level (TLD level) 
1. <1Gy 
2. ≥1Gy 
3. Expected high dose 
1. Control group 
Accumulated lead maximum dose level 
1. Low dose (not on CT scan) 
2. <25Gy 
3. ≥25Gy 
1. Control group 
Accumulated heart maximum dose level 
1. Low dose (not on CT scan) 
2. <20Gy 
3. ≥20Gy 
1. Control group 
Treatment Intent 
1. Radical 
2. Palliative 
1. Control 
Treatment Technique 
             1. 3D-CRT 
             2. IMRT 
              1. Control 
Previous RT Treatment 
             1. Yes 
             2. No 
              1. Control 
Lead Type 
1. Right Ventricular Lead 
2. Right Atrial Lead 
3. Left Ventricular Lead 
1. Right Ventricular Lead 
2. Right Atrial Lead 
3. Left Ventricular Lead 
Use of magnet to limit adaptive ICD functions during RT 
1. Yes 
2. No 
1. Control 
Key: RT = Radiation Therapy; MV = photons; MeV = electrons; TLD = 
Thermoluminescent dosimetry; Gy = gray; CT = computerised tomography; 3D-
CRT = three dimensional conformal radiation therapy; IMRT = intensity modulated 
radiation therapy.  
 
 
Statistical analysis was performed in the same manner as described in section 7.3.8, 
with non-parametric tests again used due to the distribution of results. Post hoc 
 -222- 
analysis was performed where assumptions of the statistical tests were not broken. In 
these cases the p value was used as a guide only.  
 
8.4 Results 
 
Results of the analysis conducted are detailed below. Tabulated results for radiation 
therapy subgroups, such as the analysis for treatment energy and type, are found in 
Appendix G. Due to space constraints, figures for the radiation therapy subgroup 
analysis are only displayed for significant results. 
 
8.4.1 Radiation therapy group vs. Control Group 
 
A summary of the analysis between the radiation therapy group and the control 
group are shown in tables 8.3 and 8.4. Figures in this section (figures 8.10 and 8.11) 
visualise groups as radiation therapy (group 1) and control (group 2). No significant 
result was observed for any of the parameters analysed. Three events occurred in the 
radiation therapy group, including three power on resets (POR) in two ICDs and an 
incident of undersensing, corrected by programming. 
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Table 8.3: ICD radiation therapy Group vs. Control Group; Mann-Whitney U tests 
Change 
(check 2 - check 1) 
Radiation Therapy Control U Z r p value n= Median (Range) n= Median (Range) 
Battery (V) 14 -0.01 (-0.18 -0.02)  30 -0.03 (-0.24 - 0.00) 137.0 -1.871 0.28 0.061 
Signal Amplitude (mV) 21 0.00 (-3.80 - 5.90) 42 0.00 (-2.70 - 7.80) 409.0 -0.468 0.06 0.640 
Impedance (Ω) 22 -6.50 (-80 - 264) 44 0.00 (-272.00 - 72.00) 398.0 -1.172 0.14 0.241 
Capture Threshold Amplitude (V)^ 17 0.00 (-0.25 - 0.5) 42 0.00 (-1.00 - 0.50) 344.5 -0.241 0.03 0.809 
Capture Threshold pulse width (ms) 17 0.00 (-0.10 - 0.00) 42 0.00 (-0.30 - 0.60) 330.0 -0.862 0.11 0.389 
Output Amplitude (V)^ 21 0.00 (-1.00 - 0.00) 44 0.00 (-1.00 - 0.00) 433.5 -0.637 0.08 0.524 
Output pulse width (ms) 21 0.00 (-0.60 - 0.1) 44 0.00 (0.00 - 0.60) 420.0 -1.275 0.16 0.202 
Key: V = Voltage; mV = millivolts; Ω = ohms; ms = milliseconds; U = Mann-Whitney U value; r = effect size. 
Table 8.4 ICD radiation therapy Group vs. Control Group; Chi Square test with continuity correction 
Change 
(check 2 - check 1) 
Radiation 
Therapy Control χ2 
(continuity 
correction) 
Phi coefficient p value n= n= 
yes no yes no 
Capture Threshold Amplitude^ 7 10 15 27 0.009 0.051 0.924 
Output Amplitude^ 3# 18 7 37 - - - 
Events 3# 19 0# 44 - - - 
Key: χ2 = Chi-Square Value 
^ Capture threshold and Output measures were analysed for both the frequency of change (Chi Square test) and size or amplitude of the change 
that occurred (Mann-Whitney U test). 
# cells with values less than five 
- test could not be performed due to small numbers
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(a) (b)   
(c) (d)  
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(e) (f)  
(g)
Figure 8.10: ICD radiation therapy group (group 1, left 
in figures) vs. control (group 2, right in figures) (a) 
Battery voltage; (b) Signal Amplitude; (c) Impedance; 
(d) Capture Threshold Voltage; (e) Capture Threshold 
pulse width; (f) Output Voltage; (g) Output pulse width. 
The study ID number is shown next to outlying results.   
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(a)  
(b)  
(c)  
Figure 8.11: ICD Radiation Therapy group vs Control group observed 
change (a) Capture threshold amplitude; (b) Output amplitude; (c) 
notable events.
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8.4.2 Radiation therapy treatment energy 
 
Results showing the effect of radiation therapy treatment energy are displayed in tables 
G1 and G2 in the appendix. The radiation therapy group was split into a 6MV group and 
an 18MV group. The 6MV group contained all patients treated with 6MV photons,  
electrons (MeV), or a combination of both modalities. The 18 MV group contained all 
patients treated with 18MV photons, or a mixture of 18MV and 6MV photons. The size 
of output amplitude change was found to be significant (Gp1, n=16: 6MV group; Gp2, 
n=5: 18MV group; Gp3, n=44: Control), (χ2(2, n=65)=9.47, p=0.009), shown in figure 
8.12. Due to the small amount of data a post hoc analysis was not performed. For groups 
where n<5 reliable statistical results cannot be obtained. The 18MV group showed a 
decrease in median value (Md = - 0.10) when compared to the 6MV group (Md = 0.00) 
and Control group (Md = 0.00). The frequency of output amplitude change was higher 
in the 18MV group than both the 6MV and Control groups, as shown in figure 8.13. 
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Figure 8.12: ICD - observed size of change in output amplitude (V) during 
treatment in relation to radiation therapy treatment energy (group 1 - 
6MV±MeV/MeV only; group 2 - 18MV±6MV; group 3 - control) 
 
Figure 8.13: ICD - observed frequency of change in output amplitude (V) 
during treatment in relation to radiation therapy treatment energy 
 
Failures occurred in a higher percentage of the 18MV group than the 6MV group at 
33.3% (2) and 6.3% (1) respectively, shown in figure 8.14. Failures were in the form of 
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an episode of oversensing (6MV group) and three power on resets (POR) between two 
devices (18MV group).  
 
Figure 8.14: ICD - observed notable events occurring during treatment in 
relation to radiation therapy treatment energy 
 
8.4.3 Maximum dose level to ICD 
 
Fourteen of the 15 radiation therapy ICDs had a valid TLD dose recorded to the ICD. 
Eleven of these patients were split into two groups receiving less than 1Gy and greater 
than or equal to 1Gy. Due to the difficulty in estimating the dose to the ICD in two 
patients (see section 8.3.4), including one without a valid TLD dose, these patients were 
separated into their own group of “expected high dose”. Dose received by the ICDs 
ranged between 0.02Gy and up to 9Gy, with a mean not calculated due to the uncertain 
high values. Results are displayed in tables G3 and G4 in the appendix. 
 
The frequency of capture threshold amplitude change was found to be more common in 
the expected high dose group, with all leads experiencing a change (3). Two leads in 
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both the greater than or equal to 1Gy group (66.7%) and the less than 1Gy group 
(18.2%), compared to the control group (35.7%) experienced a change in capture 
threshold amplitude. These results are shown in figure 8.15. 
 
 
Figure 8.15: ICD - observed frequency of change in capture threshold 
amplitude (V) during treatment in relation to the maximum dose to the ICD. 
 
All three notable events occurred in the less than 1Gy radiation therapy group. No 
notable event occurred in any other group, as shown in figure 8.16.  
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Figure 8.16: ICD - observed notable events occurring during treatment in 
relation to the maximum dose to the ICD. 
 
8.4.4 Estimated maximum to ICD leads 
 
Six radiation therapy ICD patients had leads that could be visualised within the CT scan 
of the treatment area, allowing an estimated plan maximum to be recorded. In multiple 
lead devices, all visualised leads were contoured as one as the CT scan quality did not 
allow for separate delineation. A mean dose of 50.12Gy±12.78Gy was received by the 
leads shown in CT scans, with a range of 25.74Gy to 60.84Gy. Results are shown in 
tables G5 and G6 in the appendix. As all visualised leads received doses above 25Gy, 
the radiation therapy group was split into low dose (out of scan) and greater than or 
equal to 25Gy only. 
 
 The size of the capture threshold amplitude change was found to be significant (Gp0, 
n=10: low dose; Gp2, n=7: ≥25Gy; Gp3, n=42: control), (χ2 (2, n=59) = 7.75, p=0.021), 
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shown in figure 8.17. The greater than 25Gy group had a higher median score 
(Md=0.10) than both the low dose (Md=0.00) and control groups (Md=0.00). A post-hoc 
analysis, shown in appendix G.3.1, identified a large significant effect between the size 
of the capture threshold amplitude change of the low dose (Md = 0.00, n=10) and greater 
than or equal to 25Gy group (Md = 0.10, n=7), U = 10.5, z=-2.68, p=0.014, r=0.65.  
 
Figure 8.17: ICD - observed size of change in capture threshold amplitude (V) 
during treatment in relation to the estimated maximum dose to the ICD leads 
(group 0 = out of scan; group 2 = ≥25Gy; group 3 = control). 
 
All three notable events occurred in the low dose (out of scan) radiation therapy group. 
 
8.4.5 Estimated maximum dose to the heart 
 
Three radiation therapy ICD patients required treatment to an area close to the heart 
volume, allowing an estimated heart maximum dose to be acquired from the planning 
CT. Hearts that could be visualised within the treatment CT had a mean dose of 
45.8Gy±13.7Gy, with a range of 30.25Gy-56.25Gy. Results are shown in tables G8 and 
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G9 in the appendix. As no heart that was visualised in a CT scan had an estimated dose 
of less than 20Gy, the heart dose of less than 20Gy group had no results in all tests. 
Again, all three events occurred in the low dose (out of scan) radiation therapy group. 
No notable event occurred in any other group.  
 
8.4.6 Treatment intent 
 
Results for the effect of radiation therapy treatment intent are found in tables G10 and 
G11 in the appendix. Notable events occurred in 16.7% (n=2, POR and oversensing) 
and 10% (n=1, POR) of curative and palliative patients respectively.  
 
8.4.7 Treatment technique 
 
Two radiation therapy patients received IMRT to three ICD leads, with the remaining 
radiation therapy patients receiving treatment using 3D-CRT. No included patient was 
treated using VMAT or SBRT. No significant difference was seen between groups, as 
shown in tables G12 and G13 in the appendix. All three notable events occurred in the 
3D-CRT group.  
 
8.4.8 Previous radiation therapy to the current ICD 
 
Twelve radiation therapy patients had no previous radiation therapy to the current ICD. 
Three patients were on at least their second course of treatment. There was no 
significant result observed in any cardiac device parameter when considering previous 
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treatment, shown in tables G14 and G15 in the appendix. Both PORs occurred in 
patients who had not previously received radiation therapy, with the other notable event 
occurring in a patient on their second course of treatment. 
 
 8.4.9 Lead type 
 
Both the radiation therapy and control groups were split into RV, RA and LV leads, 
with only lead parameters analysed, shown in tables G16 and G17 in the appendix. The 
size of output pulse width change was found to be significant (Gp1, n=14: radiation 
therapy RV Lead; Gp 2, n=6: radiation therapy RA leads; Gp3, n=1: radiation therapy 
LV lead; Gp4, n=30: Control RV lead; Gp5, n=12: Control RA lead; Gp6, n=2: Control 
LV lead), (χ2(5, n=65)=16.8,  p=0.005), shown in figure 8.18. Due to the small amount 
of data, a post hoc analysis was not performed.  
 
Figure 8.18: ICD - observed size of change in output pulse width (ms) during 
treatment in relation to the lead type (group 1 = radiation therapy RV lead; 
group 2 = radiation therapy RA lead; group 3 = radiation therapy LV lead; 
group 4 = control RV lead; group 5 = control RA lead; group 6 = control LV 
lead). 
 -235- 
 
8.4.10 Use of magnet during radiation therapy 
 
The use of a magnet during radiation therapy to limit adaptive ICD functions was 
analysed. Three patients received a magnet placed over their ICD for the duration of 
each radiation therapy session, with the remaining eleven treated without magnet 
placement. No significant difference was observed between the groups, as shown in 
tables G18 and G19 in the appendix. All three notable events occurred in the non-
magnet group, shown in figure 8.19. 
 
Figure 8.19: ICD - observed notable events occurring during treatment in 
relation to the use of a magnet to deactivate adaptive ICD functions. 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
Yes No
%
 w
ith
in
 g
ro
up
 
ICD - Notable events 
1 - Magnet used
2 - Magnet not used
3 - Control
 -236- 
8.5 Discussion 
 
This study was the first case control observational study to compare a radiation therapy 
group of patients who received radiation therapy with an ICD in situ with a control 
group who did not receive radiation therapy. This section will also compare results from 
this study to those observed in Chapter Seven (see section 7.5). 
There was no difference found when comparing changes in the ICD parameters of the 
whole radiation therapy group to the control group as shown in tables 8.3 and 8.4. 
Changes in permanent ICD function were similar across both groups.  There was a small 
drop in the remaining battery voltage observed in the control group; this is likely 
attributed to the greater time between checks for the control group (186.6±90.7 days) 
when compared to the radiation therapy group (120.1±178.2 days). No significant 
change in pulse amplitude, capture threshold and output amplitude or pulse width, was 
observed. No change in lead integrity was observed, with similar impedance results 
across both groups. By conducting this study, any changes that were observed were put 
into context by the introduction of a control group.  
 
Three notable events occurred in three separate ICDs during radiation therapy, with one 
ICD incurring two POR within three days; this was counted as one failure during the 
study. Another device also suffered a single POR, with another patient observing an 
episode of undersensing. These results are similar to those reported by Makkar et al. 
(2012) and Gelblum and Amols (2009), but less than half as those reported by Elders et 
al. (2013). All failures in the latter study occurred at 10 or 18MV.  
 -237- 
 
When considering the treatment energy, all PORs occurred in the 18MV group. Only 
one study has reported a POR occurring at a treatment energy less than 10MV (Makkar 
et al., 2012), with a number of studies reporting failures at energies greater than 10MV 
(see section 3.5.4 and 3.6). This thesis also notes three additional PORs observed in 
Sydney hospitals (see Chapter Four), as well as an additional POR during the direct 
irradiation study as presented in Chapter Five. All of these errors occurred at 18MV. 
While this study has presented a failure rate of approximately 33% when exposed to 
18MV±6MV, this is dropped to 22.2% when considering patients that were eliminated 
from this study for other reasons (see section 4.5). The risk of ICD failure at high photon 
energies is proposed to be due to neutron contamination of the sensitive ICD circuitry, 
as discussed in section 2.10. New protocols have suggested limiting ICDs to treatment 
energies less than 10MV, which has been supported by these studies. Given the 
prevalence of new treatment techniques, such as VMAT and IMRT which do not require 
high photon energies to deliver treatments to areas such as the prostate, it is feasible that 
this recommendation may be easily introduced into Australian hospitals. Hospitals with 
limited access to newer techniques, which are therefore unable to limit the use of high 
photon energies, should monitor ICD patients vigilantly with regular cardiac device 
checks. The undersensing was observed at 6MV, similar to that observed by Dasgupta et 
al. (2011). It is important to note that limitation of treatment energy will not be 
successful in preventing all malfunctions, and so all patients are required to undergo 
continued monitoring during treatment.  
 
 -238- 
As noted in section 7.5, a decrease in output amplitude was noted as an early sign of PM 
failure by Wilm et al. (1994). While the decrease observed in the 18MV group was 
small (Md=0.10V), it was deemed significant between the groups (p=0.009). The 
frequency of output amplitude change in the 18MV group was also notably different to 
the 6MV and control group. It is possible that the need for decrease is due to early signs 
of malfunction, however this study was hampered by the limited number of ICD patients 
which could be included after data collection issues. Further analysis of these patients, 
preferably to six or twelve months post treatment would be required for confirmation.  
 
Capture threshold changes occurred in all leads when the ICD was exposed to “high” 
doses of up to 9Gy, than those receiving greater than 1Gy and the control (see figure 
8.15). These changes may be due to the proximity of the ICD to the treatment area or 
due to the use of a magnet during treatment; due to the low number of devices receiving 
high doses this cannot be further analysed. All three notable events occurred in ICDs 
receiving less than 1Gy, supporting recent literature proposing that CIED damage is not 
a dose driven effect (Hurkmans et al., 2012; Kapa et al., 2008). In this study, both ICDs 
which were to receive a “high” dose had a magnet placed over the ICD during treatment 
to limit the adaptive functions of the device; this process may have prevented errors 
occurring at high accumulated doses to the ICD, but cannot be confirmed. 
 
 Increased maximum dose to the leads was also not associated with increased rate of 
failure, as shown in tables G5 and G6 in the appendix.  High dose, greater than 25Gy, 
received by the leads was associated with a significant increase in capture threshold 
amplitude with a large effect size when compared to the low dose/out of scan group 
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(p=0.014). This increase was at odds to previous results, where the significance was 
associated with decreases in capture threshold or output amplitude. Again, the change is 
only minimal (0.10V) and may be due to the small amount of data available within this 
study. Further analysis of a greater number of ICDs is required to confirm these 
changes.   
 
The effect of the estimated maximum heart dose was not found to be statistically 
significant when compared to a control group. Only three patients received doses to the 
heart greater than 25Gy, with no patients with hearts in the CT scan lower than 25Gy. 
This small number of results may have limited effects being shown. All notable events 
occurred in the low dose group.   
 
No significant difference was seen in radiation therapy treatment intent, technique or 
previous exposure to radiation therapy (see sections 8.4.6 to 8.4.8). Notable events were 
not associated with previous exposure of the ICD to radiation therapy or to the use of 
IMRT. The lead type was associated with a significant decrease in output pulse for the 
radiation therapy LV lead, however as this group only contained one ICD it is likely that 
this would not be significant in a larger cohort of patients.  
 
For patients with treatment sites close to the location of the ICD, a magnet was used to 
limit the adaptive functions of the device. All notable events occurred in patients that 
did not use a magnet during treatment. Boston Scientific (2012), Medtronic (2008) and 
St. Jude Medical (2011) all suggest considering the use of a magnet during treatment if 
oversensing, inappropriate shock or inhibition of pacing occur. Sepe et al. (2007) report 
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the only in vivo case study of the treatment of an ICD without failure, noting that the 
active functions of the ICD were deactivated daily. Elders et al. (2013) reported POR 
occurring when only the shock function of the ICD was switched off; this is similar to 
the POR observed during the direct irradiation study in section 5.4.2. While small on 
numbers, this research suggests that the use of a magnet during treatment, if it is not 
harmful to the patient, may limit the number of failures observed during treatment; 
removing only the ability of the ICD to deliver a shock will not prevent these failures. A 
larger treatment cohort would be required to confirm this hypothesis.    
 
8.5.1 Comparison to the Pacemaker Case Control Study 
 
Similar results were observed across both the PM and ICDs in these studies. Radiation 
therapy was not associated with increased battery loss, signal amplitude changes or lead 
integrity changes noted in the form of changes to impedance. Larger changes that were 
observed were able to be viewed in context due to the use of a control group for 
comparison.  
 
In both the PM and ICD studies, more severe failures were observed at treatment 
energies of18MV±6MV than 6MV±MeV/MeV only. These results agree with current 
literature to limit the treatment energies to ICDs to 10MV or less. Higher failures of 
PMs under 18MV is not unheard of, with the largest in vitro study reporting an 
unmatched failure rate of 16.7% at 5Gy (Mouton et al., 2002). Until now,  the high 
failure rate presented by Mouton et al. (2002) has not been associated with the high 
energy used. Soejima et al. (2011) also noted a failure of a PM at 15MV, presumably 
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due to neutron contamination. The author would suggest that the recommendation to 
limit exposure of ICDs to 10MV include PMs as well where possible. 
 
No previous study has assessed the impact of the maximum dose received by the heart 
to the function of a CIED. While no significant result was observed in the ICD study, 
this may be due to the limited number of ICDs located close to the treatment location. In 
the PM study, significant decreases in capture threshold occurred in the greater than 
20Gy group. While changes observed were only small, suggestions that these may be an 
indication of early failure cannot be discounted without follow up studies (Wilm et al., 
1994). In conjunction with known cardiac mortality associated with doses of greater 
than 40Gy in patients without previous CVD (Gagliardi et al., 1996), it is again 
reasonable for radiation oncology centres to limit the dose received by the heart to a 
maximum of 40Gy.  
 
The use of low photon energy IMRT in patients with CIED has been associated with no 
malfunctions in either study. There have been only two previous studies to report on the 
use of IMRT for treatment of a CIED patient, with both reporting failures. The 
malfunction observed during 15MV IMRT (Soejima et al., 2011), is presumed to be 
associated with the energy used, rather than the technique. The issue of undersensing 
observed during 6MV IMRT by Dasgupta et al. (2011) was also observed in this study 
during 3D-CRT, again suggesting this was not due to the treatment technique. 
 
Both of these studies have suggested that failure is not a dose driven effect. While this 
theory was originally postulated by Last (1998), it has only recently been included in 
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new treatment recommendations (Hurkmans et al., 2012). The most current protocols 
have suggested lifting the maximum accumulated doses to 10Gy; treatments to ICDs in 
this study were carried out to at least 9Gy with no negative effect. In both cases 
however, a magnet was used to limit adaptive functions. In cases where it is safe to do 
so, it is suggested that a magnet be used during treatment as a precaution. Consultation 
with a cardiologist would be required for each patient prior to treatment to assess their 
suitability.  
Previous treatment or treatment intent was not associated with an increased risk of 
device failure in either study. While a record of previous radiation exposure should be 
kept, this should not limit the patients access to further radiation therapy where required. 
 
8.6 Limitations 
 
Like the study presented in Chapter Seven, this study was affected by the general 
limitations inherent in retrospective observational studies, with the foremost being a 
high attrition rate (Carlson & Morrison, 2009). This was enhanced by a catastrophic 
failure of the cardiac services database in early 2012. This failure also required a change 
in the study design from a matched control group to a randomly selected control group. 
This prevented the impact of device age from being assessed in this study. Given the 
time limit imposed on this study, as well as the difficulty involved in initial patient 
recruitment and the limited number of patients who qualify for the radiation therapy 
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group (0.26% of all patients treated with radiation therapy at the hospital between 2005 
and 2012), the benefits of the retrospective study ultimately outweighed its limitations.  
 
Ethics approval was granted for the inclusion of 200 radiation therapy patients across 
both PM and ICDs. An increased number of patients may have led to greater validity of 
some statistical analysis, however ICDs were represented in such low quantities that 
additional patients would ultimately have to be identified from other hospitals. This 
study originally sought ethics approval at a second site in Sydney; after a protracted 
period in which the submission was misplaced multiple times and due to time 
constraints on this study, the ethics was withdrawn.    
 
The time between cardiac device checks within the control group and the radiation 
therapy group was large, as shown in table 8.1.  Time between cardiac device checks 
within the radiation therapy group also varied greatly, with a range of one day to 623 
days. While this was a compromise of the retrospective style of the study, ideally a 
routine schedule of cardiac device checks would have been undertaken, in both the 
radiation therapy group and the control group. This would also have eliminated the issue 
of missing data for some parameters, as well as including a wider range of patients, as 
their files would not be missing. The effect of the patients ICD dependency could also 
not be assessed as a result of the retrospective study.  
 
This study had approval to assess patients post treatment; due to the loss of data there 
were not enough results to compare during this time frame and therefore could not be 
included. Future research should follow patients post treatment to assess any late effects 
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observed by these patients. Further research should include patient participation, with 
the physiological effects felt by the patients assessed with changes that occur within the 
CIED. 
8.7 Conclusion 
 
The effect of radiation therapy on ICDs has proven to be minimal in a controlled 
environment. Dose to the ICD should not be a limiting factor in access to treatment, 
with a variety of techniques available to decrease risk of device damage. Rare incidents 
may still occur as a result of radiation, however with continued monitoring, are unlikely 
to develop into dangerous conditions. Where safe to use, a magnet should be placed over 
the ICD to limit active device functions, potentially decreasing the risk of ICD damage 
during radiation therapy. High photon treatment energies should be avoided in favour of 
new treatment techniques, such as IMRT, where possible. 
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Chapter Nine: Discussion and Clinical Recommendations 
 
9.1. Synthesis of findings 
 
Until recently, the effect of radiation therapy on CIEDs was associated only with the 
maximum accumulated dose received by the device and its proximity to the treatment 
field. Recent literature has also proposed that neutron contamination caused by high 
energy photon irradiation is associated with severe soft errors in ICDs. The studies 
undertaken in the current research have entailed a more detailed analysis of the risks 
posed by radiation therapy, and assessed the implementation of an evidenced based 
protocol for the treatment of CIED patients. 
 
9.1.1 What is the risk of severe soft errors during high energy radiation 
therapy (18MV) for patients with ICDs? 
In ICDs, severe soft errors in the form of power on resets (PORs) during radiation 
therapy have been noted in the literature since 2004, but it wasn’t until 2008 that this 
was strongly associated with neutron contamination caused by high energy photon 
treatments (Kapa et al., 2008). PORs have not been associated with severe patient 
symptoms, making these hard to detect without the use of a programmer. The current 
research identified five cases of POR during high energy photon treatments at three 
Sydney hospitals between 2008 and 2011. No PORs were identified at energies lower 
than 10MV. The risk of POR during high energy photon irradiation is not absolute, with 
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a further nine patients identified as having been treated with whole or partial high 
energy radiation therapy without incident at a single hospital, resulting in a 22.2% risk 
of failure. In 2008, this rate of failure could have been associated with up to 13 ICD 
PORs in Australian patients (Radiation Oncology Tripartite Committee, 2012). With 
increasing incidence of cancer and implantation rates, this number will continue to 
increase without further action being taken. It is apparent that high photon energy 
treatments should be avoided; if not, the potential rate of failure should be 
communicated to the patient prior to treatment consent.  
9.1.2 Is an increased rate of failure observed in CIEDs during radiation 
therapy at high photon energy (18MV) when compared to a lower photon 
energy (6MV)? 
 
In an attempt to verify these results, both a direct and indirect study of high and low 
photon energies was developed and run at the Nepean Cancer Care Centre (NCCC). It 
was found that the irradiation using 18MV energy photons was associated with a greater 
number and severity of failures in PMs, but only adversely affected one of the irradiated 
devices when compared to 6MV, which produced deleterious effects in two devices. It is 
likely that all the effects seen in the 6MV group were associated with electromagnetic 
interference (EMI), as they only occurred as the beam was turned on and off. Only a 
single incidence of change in pacing frequency was seen at doses between 10Gy and 
15Gy in a PM treated with a photon energy of 18MV. A greater number of errors 
occurred in the 6MV ICD group than in the 18MV group, however this was due to the 
failure criteria, which allowed multiple failures within each treatment to be recorded as 
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separate incidents. During exposure to 18MV, complete pacing silence was observed in 
two devices. A POR was also observed in one device. It was assumed that the severity 
and types of errors would be greatly reduced if the CIEDs were placed outside the direct 
beam  
In the case controlled studies presented in chapters 7 and 8, the use of 18MV was again 
found to be associated with more severe errors, or notable events, in both PM and ICDs.. 
Where possible, the use of 18MV should be limited for both PM and ICD patients, with 
dependent ICD patients deemed the most at risk. 
9.1.3 Does removing the CIED from the direct treatment beam eliminate 
the risk associated with radiation therapy at both high and low photon 
energies? 
A controlled irradiation  of explanted ICDs, placed within the direct path of the 
treatment beam, and located 60cm distally to the treatment beam was carried out using 
high (18MV) and low (6MV) photon treatment energies. The rates of these changes 
were less severe than those seen during direct irradiation. The frequency of pacing rate 
increases was again more common at 18MV than 6MV.  The time limitations posed on 
the study meant that placement of CIEDs within the direct beam to assess increased 
accumulated dose was required. These same time restrictions did not allow for a similar 
accumulated dose to be assessed in the indirect scatter study. Due to the limited number 
of devices made available by the manufacturers, a relatively small number of CIEDs 
(n=20) were included across both studies. This study was valuable in order to assess a 
‘worst case scenario’ of CIED failures; however, in order to assess the risk posed by 
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radiation therapy on CIED patients in a true clinical situation, a case controlled 
observational study over an extended time period was required. 
 
9.1.4 Does the accumulated dose to the CIED affect the risk of failure? 
This research has confirmed that CIED failure is not a dose driven effect, however 
exposure to the direct radiation beam is contra-indicated due to risk of interference. In 
both the direct and scatter radiation studies presented in chapters five and six, first 
failures occurred at doses well below accepted dose guidelines for CIEDs, starting at 
0.05Gy. During the case controlled studies presented in chapters seven and eight, no 
significant difference was observed in both PMs and ICDs when the accumulated dose 
to the device was compared. In the latter study, an ICD received up to 9Gy without 
incident. In two cases where an ICD was to receive a higher than accepted dose, the 
magnet was used to deactivate the pacing and shock functions of the ICD without 
incident. Therefore, a maximum of 10Gy to a CIED should be set as an indication of 
proximity to a beam, rather than a dose limit. 
9.1.5 Do other radiation therapy considerations affect the risk of CIED 
failure? 
The case control observational studies undertaken for the current study were the first to 
assess the complex relationship between radiation therapy regimes and CIED failures. 
By conducting this study, in addition to treatment energy and accumulated dose to the 
CIED, a wider range of radiation therapy considerations could be taken into account; 
these included treatment technique and intent, previous exposure to radiation therapy, 
and the accumulated maximum dose to the heart and pacing leads. Assessment was also 
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carried out of individual pacing leads. The use of a control group allowed for 
perspective in CIED function, as measured rates will vary from patient to patient. As the 
dose to the heart was deemed to be an important consideration for CIED patients, this 
was also examined, and it was found that accumulated heart maximum doses greater 
than 25Gy were linked to a significant difference in capture threshold amplitude 
changes, when compared to both the control group and lower maximum heart doses. 
The frequency of both output amplitude and capture threshold changes were increased in 
the greater than 25Gy group. Changes in capture threshold occurred more frequently in 
PMs receiving greater than or equal to 2 Gy; this was not associated with an increased 
number of changes in output amplitude. Radiation therapy treatment protocols should 
include a maximum heart dose of 40Gy to limit further damage to cardiac compromised 
patients, which may in turn affect the appropriate function of their CIED. 
While no PM received over the departmental protocol of 5Gy, two ICDs received up to 
9Gy with no negative effects observed in the patient. In these, as well as in an additional 
patient, a magnet was placed over the device to limit the adaptive device function during 
treatment. Three events occurred in the ICD group, all in patients who did not have a 
magnet used during their treatment.  
 
The use of IMRT, previous exposure to radiation therapy and treatment intent was not 
associated with a significant change in CIED operating parameters. However, it is noted 
that few cases were presented in this research. The use of VMAT and SBRT could not 
be assessed due to the limited access to cardiac checks and high attrition rate of these 
patients. Radiation therapy was not associated with increased battery loss, signal 
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amplitude changes or lead integrity changes, noted in the form of changes to impedance. 
Larger changes that were observed were able to be viewed in context due to the use of a 
control group for comparison.  
9.1.6 Is the risk of failure of CIEDs effectively managed when using a 
current departmental protocol? 
Chapters seven and eight detail a comprehensive study of CIED patients who have been 
treated using an evidence based protocol implemented at the department. This study 
showed a minimal failure rate, much lower than in vitro studies found in the literature, 
Failures that did occur were identified and managed in a timely fashion, reducing the 
risk of severe complications, including death. In future protocols, a maximum of 10Gy 
to a CIED should be set as an indication of proximity to a beam, rather than a dose limit. 
A limitation of the use of high energy photon beams in both PM and ICD treatments 
should be included in further protocols. A maximum dose limit of 40Gy to the heart 
should be included in new protocols to both limit the risk of device failure as well as 
reducing the risk of further cardiac complications in the future.   
Although precautions may be taken to reduce the risk of damage to CIEDs caused by 
radiation therapy, they cannot eliminate the risks entirely. All patients should be 
monitored carefully during treatment through the use of ECG, with regular cardiac 
device checks in high risk patients. In many hospitals, these are already performed, but 
limited co-operation still exists between radiation therapy and cardiology departments. It 
is hoped that through this research and detailed recommendations, a better 
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understanding of the risk of failure can be communicated through both departments so 
that these patients may be treated without incident.  
As a result of this research, a list of treatment recommendations has been provided in 
section 9.3. These recommendations are intended as a guide for centres for the treatment 
of CIED patients undergoing radiation therapy. These recommendations should be 
updated as knowledge and technology advances in radiation therapy.  
 
9.2 Future Directions 
 
The largest hurdle in this research has been access to resources and limited patient 
numbers. While VMAT and SBRT were used on CIED patients at RPAH, these patients 
were eliminated from the study due to either missing radiation therapy or cardiology 
data.  Continued research should be undertaken to confirm the results proposed in this 
study. Assessment of new treatment technologies, such as IMRT, VMAT and SBRT 
should be carried out, either with increased patient numbers in the form of an 
observational study, or as an in vitro study with treatment techniques to a variety of 
anatomical sites.  
 
It was not possible to assess the effect of dose rate on CIED function, as low dose rates 
(scatter) and high dose rates (in beam) were affected by the impact of interference 
caused by direct irradiation. It is proposed that in vitro analysis be performed on 
flattening filter free (FFF) technology, which may result in dose rates 2.4 times higher 
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than traditional radiation therapy.  While not currently in use in Australia, FFF 
technology is in trial stages in multiple Sydney hospitals, including NCCC, with the aim 
to decrease treatment time for patients undergoing any form of beam modulated 
treatment. As beam modulated treatments, including IMRT, VMAT and SBRT are 
increasingly incorporated into normal radiation therapy practice, FFF technology may 
have serious implications for CIED patients in the near future.  
 
It is important for all professionals in the process of treating CIED patients  to be 
qualified in cardiopulmonary resuscitation (CPR). It would be ideal for all radiation 
therapists to have a basic understanding of expected ECG readouts of CIED patients, 
and what to expect when a malfunction occurs. A training program should be developed 
that may be implemented into departments, with the assistance of the Cardiology 
department.  
 
As new treatment recommendations are implemented, monitoring of patients with 
CIEDs undergoing radiation therapy should continue in a wider range of hospitals. The 
development of a centralised database for reporting of radiation therapy to CIED 
patients is required.  Due to limited communication between Cardiology and Radiation 
Oncology (RO) departments, it is highly possible that incidents as a result of radiation 
therapy are occurring but not being reported back to the RO department. Instead, these 
failures would be known by the cardiology departments and manufacturers only. This 
failure to report incidents prevents RO departments from adjusting protocols in a timely 
manner to reduce future patient risk. The protocol published by the Cancer Institute 
NSW through the EviQ portal (Cancer Institute of NSW, 2014), with regular updates, 
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would be ideal for coordinating and reporting these treatments. A national survey on 
radiation oncology departments management of CIED patients could allow the 
introduction of these recommendations to a wider range of treatment centres and 
standardise the treatment of CIED patients nationally.   
 
9.3 Recommendations for the treatment of CIED patients using 
radiation therapy 
 
A list of radiation therapy recommendations, spanning pre-treatment to post-treatment 
follow up, has been derived as a combination of findings presented in this thesis and 
current literature. Many of these recommendations have already been employed by 
radiation therapy departments in NSW due to the development of NSW Cancer Institute 
EviQ protocol since 2010, of which this author has been a primary contributor. 
Limitations of treatment energies to 10MV have been incorporated in some departments 
for the treatment of ICD patients. The recommendations from this research go further to 
suggest additional treatment energy limitations to PM patients, or increased monitoring 
protocols. This is also the first proposed protocol to suggest limitation to the dose 
received by the heart to limit further damage to patients with pre-existing CVD.   
 
Increased accumulated dose limits of 10Gy to the CIED have only recently been 
incorporated into the EviQ protocol. While CIED damage is not associated with a dose 
driven effect, the incorporation of dose limits within protocols is linked with the 
distance of a CIED to the treatment field and effective dose rate received. It would 
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therefore be unwise to eliminate the use of dose limits to CIEDs from treatment 
recommendations.  
 
Current monitoring protocols contain a range of measures, such as observation through 
CCTV, blood pulse oximetry and daily electrocardiograms (ECGs). Regular cardiac 
device checks are always recommended, however access to these may be restricted for 
regional RO departments. As a result, regular cardiac device checks during treatment are 
not always performed. In some cases, the limited knowledge of Radiation Oncologists 
and their registrars to the potential for CIED damage during radiation therapy means 
these patients go unidentified throughout treatment. While this thesis could not assess 
the difference observed in dependent and non-dependent CIED patients, a cautious 
approach should be taken due to the potential for harm for patients reliant on their 
device.  
 
 
The list of recommendations within the current work also aims to increase the 
knowledge of cardiologists, radiation oncologists and radiation therapists. By providing 
treatment recommendations, as well as the reasons behind them, it is hoped that 
Radiation Oncology and Cardiology departments will be able to incorporate these 
protocols with ease.  
 
Electromagnetic interference (EMI) has been reduced in newer treatment machines. The 
risk of EMI for modern CIEDs is minimal, but may cause transient interference with 
CIED function. Transient effects are unlikely to cause harm to a patient, however 
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continuous monitoring is recommended. Repetitive transient malfunctions, such as those 
which may appear in respiratory gating due to the beam being switched on and off 
multiple times, may cause greater effect.  
 
9.3.1 Risk Assessment 
 
Patients should be assessed on a case by case basis to determine the level of 
management that they require during all stages of the radiation therapy treatment 
process. Considerations of risk include: 
• Type of CIED (PM or ICD) 
• Accumulated dose to the CIED 
• CIED dependency 
• Dose energy 
 
Based on the above considerations, a quick reference guide to monitoring levels has 
been developed in table 9.1. The monitoring levels are outlined in table 9.2. 
 
Table 9.1: Monitoring Levels 
 
Pacemaker ICDs 
Non-Dependent Dependent Non-Dependent Dependent 
≤10MV >10MV ≤10MV >10MV ≤10MV >10MV ≤10MV >10MV 
<2Gy 1  2# 2  2# 2 3# 3 NA 
2Gy - 
<10Gy 
1* 2*# 2* 2*# 2* 3*# 3* NA 
≥10Gy 2* 2*# 2* 3*# 3* 3*# NA NA 
     - Level One Monitoring;      - Level Two Monitoring,      - Level Three Monitoring,                                   
-   - Treatment contraindicated (see table 9.2). 
Key: MV = photon; ICD = implantable cardioverter; NA - treatment not advised  
* consider CIED relocation prior to treatment to reduce treatment dose 
# consider implementation of treatment techniques that do not require high treatment 
energies to reduce patient risk, i.e. IMRT and VMAT.  
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Where the CIED is likely to be within, or close to, the treatment field, surgical 
relocation of the CIED is recommended. Consideration of CIED relocation may also 
occur when the dose to the device is within 2Gy to 10Gy to limit the proximity of the 
CIED to the treatment field. Discussion with a cardiologist should be conducted to 
assess treatment options. 
 
Current research suggests limiting the use of high energy photon treatments in the case 
of ICD patients. The results from the study undertaken in the current work, and reported 
in section 5.4.1, suggest the negative impact of high energy treatment may also extend 
to PMs. Therefore recommendations are also made for limiting exposure of PM patients 
to high energy.  
 
A suggested monitoring protocol for each category is shown in table 9.2. It is 
understood that not all departments will have access to all types of monitoring 
equipment. It is suggested that these monitoring protocols be tailored to each department 
in consultation with cardiologists, cardiac technicians and CIED manufacturers. 
 
9.3.2 Pre-simulation consult 
 
The radiation oncologist or registrar should identify all patients with CIEDs during the 
pre-simulation consultation, ensuring that the following information is recorded. All 
patients should have a CIED identification card with them that may be photocopied 
containing relevant information (an example is shown in figure 9.1): 
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1. Type of CIED - ICD or PM 
2. Brand of CIED and model number (if known) 
3. Implantation date of the CIED 
4. Patients cardiologist 
5. CIED location and approximate distance to expected treatment fields (patient 
examination) 
6. Patients level of CIED dependency (contact cardiologist to determine) 
 
 
Figure 9.1: Example of a St. Jude Medical CIED patient identification card (St. 
Jude Medical Health, 2014) 
 
Contact with the patient’s cardiologist/electrophysiologist should be made, to inform 
them of the proposed radiation therapy procedure and risk to the CIED. If not feasible, 
contact with local Cardiology department or CIED manufacturer cardiac technicians 
should be contacted. An assessment, in consultation with the cardiologist, should be 
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made at this stage as to whether the CIED requires relocation. If required, relocation 
should be performed before simulation for radiation therapy.  
 
Contact with the local cardiology department or CIED manufacturer should be made to 
create a management plan for the patient, including frequency of CIED monitoring 
during radiation and if a magnet may be used during treatment of an ICD to prevent 
errors and potential interference. The effect of a magnet on the limitation of PM 
function has not been investigated, but may be effective.  
A full assessment of the CIED should be performed prior to simulation. If a previous 
CIED check has been performed in the month prior to consultation, a record of this may 
be obtained in place of a new CIED check prior to simulation. 
 
9.3.3 Simulation 
 
9.3.3.1 Computed Tomography (CT) 
 
Use of a CT scanner for simulation of CIED patients, it is believed to have a limited 
impact on the device if passing momentarily though the x-ray beam, approximately less 
than three seconds (McCollough et al., 2007). The U.S. Food and Drug Administration 
(2008) recommends: 
1. Cardiologist consultation prior to simulation 
2. Deactivate CIED anti-tachycardia pacing and shock therapy (if practical, non-
dependent patients only). 
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3. Use of CT scout view to locate CIED on scan and limit exposure to CIED by: 
a. Excluding CIED from scan range 
b. Using the lowest possible x-ray tube current to obtain the image 
c. Ensure the x-ray beam does not dwell over the CIED for more than a few 
seconds.  
4. If CT procedures required scanning over the CIED continuously for more than a 
few seconds, staff should be ready with a crash cart to treat adverse reactions if 
required.  
It is suggested by the author that treatment techniques such as respiratory gating 
requiring 4D-CT scans not be used to treat these patients where possible. This is due to 
the risk of malfunction due to the increased exposure during the CT scan, as well as the 
increased risk of EMI during treatment. 
  
If the CIED has the potential to interfere with the dose distribution of the treatment plan, 
an extended HU is recommended during scanning (Gossman et al., 2011). 
 
9.3.3.2 Magnetic Resonance Imaging (MRI) 
 
MRIs are contraindicated with most CIEDs due to concerns of excessive heating of 
leads, CIED or lead movement and changes in CIED function. In recent years, some 
new model CIEDs and leads have been manufactured to be MRI compatible (Shinbane, 
Colletti, & Shellock, 2011). A discussion with the patient’s cardiologist, as well as 
CIED manufacturer to determine the CIED MRI compatibility is required before any 
MRI scan is performed.  
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9.3.3.3 Positron Emission Tomography (PET) 
 
PET scans may be conducted on CIED patients without known risk (Medtronic Inc., 
2006).  
 
9.3.4 Treatment Planning 
 
The CIED should be outlined accurately during the planning stage if visualised within 
the scan. The contrast of the CT scan will need to be decreased to prevent the outlining 
of any artifact caused by the CIED, as shown in section 7.3.6.1. 
 
The maximum dose received by the CIED may be calculated through the use of a DVH 
in the TPS. If the heart is within the treatment area, it is suggested that the heart dose be 
limited to a maximum of 40Gy, Outlining protocols for the heart are found in Feng et al. 
(2011). The pericardium should also be included in outlining due to the risk of 
pericarditis as a late effect of treatment (Gagliardi et al., 2010) (see section 7.3.6.3).   
 
Direct irradiation of the CIED is contraindicated.  Techniques such as non-coplanar 
beams and MLC shielding should be used to limit CIED exposure to direct irradiation. 
 
Treatment should be planned without the use of high energy beams, where energies of 
less than 10MV should be used if possible for both PMs and ICDs. The use of IMRT, 
VMAT or SBRT may assist in limiting treatment energy.   
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The use of treatments where high dose rates (such as with FFF beams) should be used 
with caution as there is limited information on the impact of high dose rates on CIEDs. 
 
9.3.5 Treatment 
 
Notation of the patient’s CIED status should be prominent in both paper and electronic 
files to ensure treatment protocols are followed. CIED checks should be carried out on 
day one prior to the first treatment for all monitoring levels. A post treatment CIED 
check should also be performed for comparison before the patient leaves the centre.  
 
Treatments using electrons or orthovoltage/superficial treatments are not expected to 
cause CIED malfunction if not within the treatment field. Monitoring is not required for 
these patients unless the patient is symptomatic. Monitoring suggestions based on the 
levels determined in table 9.1 are shown in table 9.2.  
 
Disabling of anti-tachycardia therapy in ICDs with the use of a magnet has been 
suggested in current literature and in current manufacturer protocols to prevent device 
malfunction when anti-tachycardia therapy has already occurred (see section 3.8). 
Current research suggests that the use of a magnet should be used prophylactically, and 
this is supported by the findings of the current study. Discussion with the cardiologist or 
cardiac technicians is advised before this is performed to disable anti-tachycardia pacing 
and shock therapy. 
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In vivo monitoring, such as the use of TLDs, is suggested for levels two and three, when 
dose is expected above 2Gy to the variations shown between estimated and planned 
doses in section 7.3.6.1 and 8.3.4., however may be carried out on all patients at the 
discretion of the radiation oncologist and physicists. 
 
ECG, BP and pulse oximetry monitoring should be carried out by qualified personnel 
within the department - for example nurse, registrar or radiation oncologist. It is 
suggested that all qualified personnel be familiar with possible changes that may occur 
during treatment and visualised on an ECG.  
 
A crash cart containing resuscitation equipment should be available outside the 
treatment room during all treatments, regardless of monitoring level. A nurse or doctor 
should be alerted by the treating radiation therapist before each patient treatment to 
ensure timely action for resuscitation if required.  
 
As with all patients on treatment, CIED patients should be monitored during treatment 
with audiovisual monitoring, such as CCTV. Patients should be encouraged to alert 
treatment personnel if they suddenly begin to feel unwell and treatment stopped 
immediately to assess the patients situation.  
 
9.3.6 Post treatment 
 
All patients should receive a CIED check within a week of treatment concluding to 
assess any possible CIED damage, preferably on the final day of treatment. Results of 
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final CIED check performed after the final treatment fraction should be incorporated 
into the radiation therapy treatment file. 
 
All outcomes of patient treatment should be recorded within a hospital database, 
whether adverse effect has occurred or not. By recording this information, follow up 
with the patient to ensure adequate cardiac monitoring may also allow for a more timely 
identification of CIED issues as a result of radiation therapy.   
 
A flow chart of the radiation therapy process has been created in figure 9.2, based on the 
Dutch protocols (Hurkmans et al., 2012). These have been changed to include caution to 
the used of high photon energies for PMs as well as ICDs. This should be used by 
radiation oncologists, therapists and physicists to determine appropriate monitoring 
levels for the patients based on the treatment plan. 
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Table 9.2: Monitoring recommendations  
Level CIED relocation 
CIED 
check 
prior to 
simulation 
Use of 
magnet 
(ICD only) 
Day 1 
In-Vivo 
dosimetry 
Day 1 BP 
and pulse 
oximetry 
monitoring* 
Daily BP 
and pulse 
oximetry 
monitoring* 
Daily ECG 
Audiovisual 
monitoring 
during tmt 
Day 1 
CIED 
check 
Weekly 
CIED 
check 
CIED 
check 
at 
end 
of 
tmt 
Crash 
cart 
available 
1 
Consider if 
>2Gy; 
Relocation 
should be 
carried out 
if CIED is 
within the 
field 
Yes na As requested No No No# Yes Yes No Yes Yes 
2 Yes 
As advised, 
where 
appropriate 
As 
requested, 
when 
greater 
than 2Gy 
Yes Yes  
In 
treatments 
>10MV 
Yes Yes Yes Yes Yes 
3 Yes Yes Yes Yes As required Yes Yes Yes 
Yes, 
potential 
daily 
checks 
Yes Yes 
Table adapted from Cancer Institute of NSW (2014) 
Key: BP = Blood Pressure; CIED = Cardiac implantable electronic device; tmt =  treatment; na - not applicable; Gy = gray 
* If ECG monitoring is occurring during treatment, BP and pulse oximetry monitoring is not required unless the patient complains of 
feeling unwell.  
# While an ECG is not required daily, if available within the treating department it is suggested that daily or weekly ECG monitoring 
be continued on all patients regardless on monitoring level.  
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Figure 9.2: Flowchart of treatment recommendations, based on Hurkmans et al. (2012) 
When the tumour is 
within this area, the 
likely dose to the CIED is: 
 < 2Gy 
 2Gy - 10Gy 
 >10Gy 
 
 
 
 
 
 
 
 
 
  
Patient with CIED indicated for radiation therapy 
• Inform cardiologist and patient 
• Determine patients CIED dependency 
• If ICD, determine if anti-tachycardia therapy may be switched off by 
magnet 
• If CIED check > 3 months, organise check-up prior to simulation 
<10Gy 
 
10Gy+ 
Reconsider radiation therapy, 
treatment technique or CIED 
relocation 
>10MV 
• Avoid simulation with MRI or 4DCT (unless otherwise advised) 
• Estimate plan dose to CIED 
• Minimise dose to CIED with treatment planning optimisation 
Level 1: 
- Day 1 in vivo (TLDs) as 
requested 
- Audio-visual monitoring of 
patent during tmt 
- CIED checked at end of 
treatment  
- Crash cart available 
Level 2 = Level 1 plus: 
- Use of magnet (where 
advised by cardiology, ICD) 
- Day 1 in vivo dosimetry 
where >2Gy 
- Daily BP and pulse oximetry 
as required 
- Daily ECG >10MV 
- Day 1 CIED check 
- Weekly CIED check 
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checks (consult with 
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9.4 Conclusion 
 
While all risks of CIED malfunction under treatment are unknown, this research has 
allowed further quantification of the risk of failures, as well as eliminating various 
radiation therapy considerations as a cause of failure. Large changes observed in patient 
CIED checks have been put into context with the comparison of these patients to a 
control group. An expected 1.03% of radiation therapy patients may present with CIEDs 
every year; in 2008 this would have equated to 817 patients nationally. With CIED 
implantations on the rise and the increasing human lifespan, this number will continue to 
increase. While damage to CIEDs during radiation therapy can be minimalised through 
the use of a comprehensive treatment protocol, these protocols need to be updated as 
radiation therapy treatment techniques evolve. 
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Summary
The increasing human lifespan and development of technology over the last
number of decades has seen an increase in the number of pacemaker and
implantable cardioverter deﬁbrillator (ICD) implantations worldwide. Given
the number of risk factors common to both heart disease and cancer, it is not
uncommon for several of these patients to present for radiation therapy
treatment each year. A systematic review was conducted using online data-
bases Medline and Scopus. Results were grouped into in vitro and in vivo
studies. In 1994, the American Association of Physicists in Medicine (AAPM)
deﬁned guidelines for the management of these patients, which have since
been adopted by many radiation oncology departments internationally. More
recently, a number of studies have reported an increase in radiation sensi-
tivity of these devices (encompassing the coiled metal leads and generator
unit) due to the incorporation of complementary metal oxide semiconductor
circuitry. Further avenues of device failure, such as the effect of dose rate and
scatter radiation, have only more recently been investigated. There are also
the unexplored avenues of electromagnetic interference on devices when
incorporating newer treatment technologies such as respiratory gating and
intensity modulated radiation therapy. It is suggested that each radiation
oncology department employ a policy for the management of patients with
ICDs and pacemakers, potentially based upon an updated national or inter-
national standard similar to that released by the AAPM in 1994.
Key words: complementary metal oxide semiconductor; implantable cardio-
verter deﬁbrillator; pacemaker; radiation therapy.
Introduction
Over the last few decades, there has been an increase in
the number of pacemaker and implantable cardioverter
deﬁbrillator (ICDs) implantations worldwide, with over
21 000 implanted in Australia alone between 2006 and
20071 (see Fig. 1). This can be attributed to the increas-
ing human lifespan, as well as increasing indications for
device (encompassing the coiled metal leads and gen-
erator unit) implantation.2 Due to the overlap in risk
factors for heart disease and malignancies, such as
increasing age, smoking, poor diet and sedentary
lifestyle,3,4 it is no surprise that on occasion, some of
these patients will present for radiotherapy, and it can be
expected that any busy radiation oncology department
might see these patients several times a year. While this
number may be small, irradiation of a pacemaker or ICD
may result in potentially lethal problems for the patient.
Failure to identify a patient with a cardiac device is
perhaps the most important risk factor.2
Pacemakers are electrical devices that may stimulate
either the atria, ventricles or both (single-chamber and
dual-chamber models, respectively) in order to regulate
the hearts natural rhythm.5 ICDs are generally larger
than pacemakers, and also incorporate an internal
device that can actively shock the heart back into normal
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rhythm in the event of a dangerous arrhythmia.5 Modern
pacemakers and ICDs incorporate complementary metal
oxide semiconductor (CMOS) circuitry into their genera-
tor units (encompassing a sealed lithium battery pack
and circuitry only). A MOS transistor is a (relatively)
simple device capable of ampliﬁcation. It has a ‘gate’
(electronic circuit that passes a pulse only when a signal
is present at a second input), ‘source’ and ‘drain’ (ter-
minals connected by a channel that provide electron or
hole carriers that ﬂow to the other terminal to be drained
if a current is present; the direction of ﬂow depends on
the impurities added to various regions of the silicon to
create either a p-type material where a large number of
‘holes’ predominate, or n-type material where a larger
number of electrons move freely6). The terminals are
composed of silicon (Si), and silicon dioxide (SiO2)
serves as an insulator between the various parts of
circuitry.3,7 The introduction of CMOS circuitry has
increased device reliability and improved energy con-
sumption.8 However, a number of authors have reported
an increase in the radiation sensitivity of each device2.
Exposure to ionising radiation leads to the formation of
excess electron hole pairs in the SiO2, resulting in ‘holes’
being created in the valence band and excess electron
energy being dispersed from the device. The ‘holes’
created in the valence band are slow to move and are
generally attracted to any structural device defects.3 This
results in the formation of aberrant electrical pathways in
the insulator, which may be short lived or more perma-
nent, resulting in a variety of minor or signiﬁcant mal-
functions.3,9 These malfunctions may include altered
sensitivity, amplitude changes of electrical signal, telem-
etry and programming defects preventing reprogram-
ming, or adjustment of function or complete loss of
functioning.2,7,10 In some cases, devices may return to
normal functioning within seconds to days after irradia-
tion (device recovery), but often these changes become
permanent if continually exposed to radiation.3 ICDs
have also proven to be more sensitive to radiation than
pacemakers due to the effect of scatter radiation on the
random access memory (RAM).11,12
The American Association of Physicists in Medicine
(AAPM) published guidelines in 1994 on the manage-
ment of patients with implanted pacemakers undergoing
radiation therapy.13 This study only incorporated pace-
maker technology, and is based on the ﬁrst generation of
CMOS circuitry. Since then, no formal revision to these
guidelines has been published, despite changing tech-
nology,2 and there remain no ofﬁcial guidelines on the
management of ICD patients. Therefore, a review has
been conducted to assess the most recent ﬁndings and
create a comprehensive list of recommendations in the
management of these patients.
Methods
The online databases Medline and Scopus were searched
using the following keywords: pacemaker (pacemaker,
artiﬁcial; cardiac pacing, artiﬁcial) or implantable cardio-
verter deﬁbrillator (deﬁbrillators, implantable) and radio-
therapy. Results were included if they were published in
English between 1994 and 2008. Articles were excluded
if their primary focus was not on photon irradiation of
devices (such as neutron therapy) or devices that were
implanted after radiation therapy. The reference lists of
selected articles were searched for relevant articles that
did not appear in the database search.
Results
One hundred twenty-seven articles were returned in the
initial search. Of them, 23 articles met the relevant
inclusion criteria. In the last 14 years since the release
of the AAPM guidelines, pacemaker technology has
changed signiﬁcantly, altering device sensitivity to radia-
tion and types of malfunctions observed. These guide-
lines fail to address the growing issue of ICD irradiation,
as well as the changing technology of linear accelerators.
Since then, only ﬁve in vitro studies have been per-
formed (two ICD studies14,15 and three pacemaker stud-
ies8,10,14). Ten of the remaining articles are based on in
vivo case studies.16–25 The rest of the literature is pre-
sented in the form of review articles.
In vitro studies
From the selected literature the earliest pacemaker in
vitro study was performed by Souliman et al. in 1994.8 It
incorporated eighteen explanted single and dual
chamber pacemakers irradiated with 8MV X-rays in frac-
tions of 2.8 Gy per fraction. A total dose of 70 Gy was
given to each pacemaker unless the pacemaker failed at
a lower dose. Electromagnetic interference (EMI) was
concluded to have no impact on pacemaker malfunction.
No pacemakers failed at doses less than 16.8 Gy. Eleven
of the 18 pacemakers failed between doses of 16.8 and
70 Gy, with no device recovery observed. Loss of the
ability to inhibit output shown by ﬁxed rate pacing in
interference mode preceded complete failure. Other mal-
functions observed included loss of atrial pacing in con-
Fig. 1. Implantation rates in Australia 2000–2007.1
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junction with a decrease in pulse rate (three
pacemakers), and increased pulse interval and corre-
sponding pulse rate reduction (ﬁve pacemakers), both
indicative of battery depletion. Two pacemakers showed
no failure before reaching 70 Gy. Researchers concluded
that patients with pacemakers should be closely moni-
tored due to the potential of a fatal pacemaker failure.
In 2002, Mouton et al. conducted the largest study to
date on the impact of radiation on pacemaker operation,
incorporating 96 explanted pacemakers, and was the
ﬁrst study to consider the importance of the effect of
dose rates on pacemaker function.10 Doses of up to
200 Gy were delivered at varying dose rates (ranging
from scatter radiation to four times the normal dose rate
for direct irradiation). The failures observed were cat-
egorised into eight sections, with three classed as im-
portant (potentially lethal for pacemaker dependent
patients) – amplitude changes of electrical signal >10%
(A10), silences in electrical signal >10 s (S10) and per-
manent silence (undetectable electrical signal) (PS).
Sixty-six per cent of pacemakers incurred an A10 failure,
50% PS failure and 41% S10 failure. The minimum at
which these occurred was 2, 0.5 and 0.15 Gy, respec-
tively. Two important failures were observed at doses
equivalent to scatter radiation. At doses 5 Gy or less,
16.7% of pacemakers showed an important failure. This
dropped to 11.5% for doses of 2 Gy or less. Researchers
proposed that there is no safe radiation dose due to
important failures appearing at doses equivalent to
scatter radiation, and that manufacturers should rede-
sign devices with radiation ‘hardened’ circuitry, or at the
very least specify safe doses for each individual device.
They also suggest that cardiac monitoring (ECG) should
be carried out on pacemaker-dependant patients so that
treatment may be stopped if anomalies appear. The last
of these studies was by Hurkmans et al. in 2005.14 Nine-
teen new pacemakers were irradiated to doses of 20 Gy
in seven fractions of increasing dose, with 2–5 days
between each fraction, resulting in an irradiation period
of 5 weeks. The pacemakers were analysed, then irradi-
ated to 120 Gy or point of failure, whichever occurred
ﬁrst. Failures were classiﬁed into changes in pacing pulse
(amplitude or pulse deviation changes > 25% and com-
plete loss of signal, which may prevent the heart from
being stimulated), pacing frequency (all frequency
changes of more than 10% before or after irradiation or
device inhibition), sensing threshold changes > 25%,
telemetry (temporary or permanent loss of telemetry
capability, preventing inspection or adjustment of pace-
maker settings) and miscellaneous (battery problems
and lead impedance changes). Complete loss of signal
was observed in seven pacemakers, with all but one
recovering 1 week after the ﬁnal fraction. Amplitude
deviation >25% was only seen in three pacemakers after
the ﬁnal fraction. Pacing frequency inhibition during irra-
diation was observed in eight pacemakers, but stopped
immediately as the radiation was switched off. Tempo-
rary or permanent loss of telemetry capability was seen
in three pacemakers, one occurring at 20 Gy. This device
had the earliest malfunction (poor telemetry) at 10 Gy.
Five devices showed no errors. The researchers pro-
posed that the AAPM 1994 guidelines were still valid;
however, more studies were needed to assert ‘when and
how new protocols’ should be changed.
Hurkmans et al. also conducted the ﬁrst study on ICD
irradiation in 2005,12 incorporating 11 new ICDs with
similar parameters to their pacemaker study. In addition
to the failures observed in the pacemakers, shock deliv-
ery was also assessed. First malfunctions were observed
at 0.5 Gy, with shock energy deviations >25%. First
permanent failure was also shown at 0.5 Gy. Four ICDs
from the same manufacturer reached their point of
failure 2.5 Gy. A ﬁfth ICD of the same model and type
withstood irradiation to 120 Gy, displaying great vari-
ability within the models themselves. No other ICD failed
at doses less than 10 Gy. Sensing threshold changes
were often seen as the ﬁrst malfunction. In four cases,
ventricular tachycardia (VT) or ventricular ﬁbrillation
(VF) detection occurred, which would have resulted in
the inappropriate delivery of a shock. No signiﬁcant
changes in pulse amplitude or frequency, as well as no
telemetry problems, were noted. Rigorous protocols
were proposed for the management of ICD patients on
treatment due to the inability to predict or detect ICD
failure and the potential for the ICD to inappropriately
deliver a shock to the patient.
Uiterwaal et al. released a study on ICD irradiation in
2006.15 Eleven new ICDs were irradiated to 20 Gy with
fractionation in order to assess interference detection
(which if occurred during irradiation may result in inhi-
bition or triggering of pacing pulses and in the incorrect
delivery of a shock). Three setups were used – ICD
placed inside the irradiation ﬁeld, ICD and leads were
placed outside the irradiation ﬁeld, and leads only placed
inside the irradiation ﬁeld. All ICDs showed interference
detection from the ﬁrst fraction when placed inside the
ﬁeld. Four ICDs showed VT/VF detection, which would
have resulted in the inappropriate delivery of a shock.
When placed outside the ﬁeld, no interference was
detected. Researchers proposed a conservative recom-
mendation list, including the need to reprogram the ICD
to ‘monitor only’ to avoid inappropriate delivery of a
shock, and necessity of emergency resuscitation equip-
ment, including an external deﬁbrillator. These results
are summarised in Tables 1 and 2.
In vivo studies
The majority of the literature pertaining to pacemaker
and ICD irradiation is found in clinical case reports. Less
than a third (30%) of these reports describe device
malfunction. Tsekos et al. in 2000 irradiated a Medtronic
pacemaker that was located in the lower lateral quadrant
of the treatment portal to treat a neuroendocrine carci-
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noma to 50.4 Gy in 28 fractions.16 During treatment, the
magnetic frequency of the pacer began to decrease
(indicative of battery load), but no malfunction was
recorded. In 2001, Nibhanupudy et al. reported on the
treatment of a pacemaker patient with left breast carci-
noma (50.4 Gy breast/50 Gy supraclavicular).17 The
pacemaker was relocated to the contra lateral pectoral
pocket, and the pacemaker received a total dose of
1.8 Gy during treatment. Again, no malfunction was
recorded.
Santhanam et al. (2002) reported on six patients with
implanted pacemakers who had been treated within a
4-month period at their centre.18 In ﬁve cases, the dose
received by the pacemaker ranged from 0.5 to 1.3 Gy,
with no malfunctions recorded. In a sixth patient, the
pacemaker received a dose of 26.7 Gy in 10#, as the
pacemaker was situated within the irradiated ﬁeld, again
with no malfunction recorded.
Suggestions for the planning of patients with pace-
makers or ICDs have also been recorded. Riley et al.
(2004) reported on the advantages of using three-
dimensional (3D) computer-assisted planning in lung
cancer radiotherapy.19 In this case, the pacemaker lay
directly inferior and partially overlapped the lung
tumour. Relocation of the pacemaker was avoided due to
the ﬁnancial status of the patient. Non-coplanar beams
were used to shield the pacemaker and critical organs
while dosing the gross tumour volume to 63 Gy. The
pacemaker was limited to 5 Gy. Mitra et al. (2006)
reported a similar case where pacemaker relocation was
contra indicated due to patient instability.20 The pace-
maker was situated just inside the edge of the radiation
portal, overlying the tumour in the lung. Chemotherapy
was used to shrink the tumour, and a parallel-opposed
anterior/posterior beam arrangement was used, with
lead shielding over the pacemaker from the AP beam.
40 gray was given to the tumour volume, while the
pacemaker dose was limited to <2 Gy. In 2008, Munshi
et al. employed partial breast irradiation to treat a left
breast tumour and avoid the pacemaker, which was
situated in the left pectoral pocket.21 The pacemaker was
restricted to 4.3 Gy, while the rest of the volume
received 50.4 Gy in 28 fractions. In all cases, no device
malfunctions were reported.
In contrast, Thomas et al. (2004) reported on the
electrical reset of an ICD located close to the treatment
ﬁeld during treatment of a bronchial carcinoma.22 The
tumour was treated to 56 Gy in 28 fractions using 18 MV
X-rays. During a routine follow-up, it was discovered that
electrical reset of the ICD had occurred 9 days earlier,
during treatment. As the patient was not ICD dependant,
and with the lack of any physical symptoms, this had
gone undetected. The total dose received by the ICD was
unable to be accurately determined. In 2004, John et al.
also reported an ICD malfunction after treatment for left
breast cancer.23 While the generator had been shielded
with lead, due to the employment of tangent beams, the
leads received a full dose with partial exposure of the
Table 1. Summary of results for in vitro pacemaker studies
Author Year Pacemakers Outcome
Souliman8 1994 18 (dual- and single-chamber models,
various companies)
11 pacemakers failed with no recovery, ﬁrst complete failure at accumulated
dose of 16.8 Gy
Mouton10 2002 96 (various companies and models) 66% amplitude change >10%, 50% permanent silence, 48% slowed down rate,
41% silence longer then 10 s, 30% accelerated rate, 27% missing impulses
at start of irradiation, 23% signal compatible modiﬁcation, 17% shape
deformation.
NB. Five per cent of all pacemakers were concerned with multiple short
silences, which are considered harmful
Hurkmans14 2005 19 (4 manufacturers) All pacemakers showed a point of failure at or above 90 Gy except one at
20 Gy; 5 of 19 pacemakers showed a battery replacement warning. Loss of
output was the most commonly observed point of failure. Pacemakers
showed a large variation in their sensitivity to radiation.
Table 2. Summary of results for in vitro ICD studies
Author Year ICD Outcome
Hurkmans12 2005 11 (4 manufacturers) First malfunction was observed at 0.5 Gy. Sensing threshold changes were often seen as the
ﬁrst malfunction. Four ICDs failed 2.5 Gy, four ICDs showed ventricular tachycardia or
ﬁbrillation, which would have resulted in delivery of a shock. No signiﬁcant changes in
pulse amplitude or pulse frequency were observed. No telemetry problems were recorded.
Uiterwaal15 2006 11 Interference detection observed for all ICD’s irradiated in the treatment ﬁeld, this interference
was noted from the ﬁrst radiation fraction. Four ICDs showed VF or VT detection.
ICD, implantable cardioverter deﬁbrillator; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
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generator. When the ICD was changed due to battery
depletion, it was discovered that shock impedance was
more than 125 W, suggestive of shock coil failure, pos-
sibly due to structural damage to the leads.
Sepe et al. (2007) reported on the irradiation of an
ICD to 2.5 Gy (0.5 Gy above their recommended
maximum generator dose) when treating a laryngeal
carcinoma to 60 Gy.24 Thermo luminescent dosimetry
was used to verify the dose on treatment. The ICD was
externally deactivated during each treatment, with the
generator checked periodically. No malfunction was
recorded at any stage during treatment.
The only case study found to demonstrate a potentially
lethal effect on the patient due to device failure was in
2007 when Nemec et al. reported the collapse of a
patient being treated for lung cancer during the third
fraction.25 Originally, the ICD was not moved, as it would
not be in the treatment ﬁelds. During the third fraction,
the patient collapsed and eventually needed cardiopul-
monary resuscitation. The ICD was removed, and the
patient continued radiotherapy. Upon investigation, no
fault was found in the ICD. It was suggested that RAM
damage may have occurred. A reliable ICD dose esti-
mate could not be obtained, however, as the incident
occurred during the third fraction, this dose would have
accumulated to <5 Gy. These results are summarised in
Tables 3 and 4.
Discussion
Current pacemakers and ICDs are more sensitive to
radiation than previous models due to the incorporation
of CMOS circuitry2; however, only limited data is avail-
able on the effect and management of such devices
undergoing radiation therapy, and no data exists to
demonstrate that proposed management guidelines by
previous researchers are adequate to prevent or limit
device malfunction.2 Data that is available is limited in
device numbers and scope, and demonstrates a large
variability in results, with most presented as case
studies. Reliability of this data is also in question due to
the age and background of device models used in some
studies.
Table 3. Summary of results for in vivo pacemaker studies
Author Year Tumour Total dose Dose to pacemaker Outcome
Tsekos16 2000 Neuroen docrine carcinoma
of right arm
50.4 Gy/28# >50 Gy (not speciﬁed)
as within ﬁeld
Magnetic frequency of the pacer
began to decrease,
no failures observed
Nibhanupudy17 2001 Left breast 50.4 Gy breast, 50 Gy SCF 1.8 Gy No malfunction
Santhanam18 2002 Parotid tumour 64 Gy/32# 1.3 Gy No malfunction
Lymphoma 15 Gy/5# 0.8 Gy No malfunction
Myeloﬁbrosis/spleen 4.5 Gy/9# <0.5 Gy No malfunction
Breast – axilla 26.7 Gy/10# 26.7 Gy No malfunction
Lung 15 Gy/10# 0.8 Gy No malfunction
Lung 30 Gy/10# 0.6 Gy No malfunction
Riley19 2004 NSCLC 63 Gy GTV, 59.85 Gy PTV <5 Gy No malfunction
Mitra20 2006 NSCLC 40 Gy 0.7325 Gy estimate
from TPS
No malfunction
Munshi21 2008 Left breast 50.4 Gy 4.3 Gy No malfunction
GTV, gross tumour volume; NSCLC, non-small cell lung carcinoma; PTV, planning target volume; SCF, supraclavicular ﬁeld; TPS, treatment planning system.
Table 4. Summary of results for in vivo ICD studies
Author Year Tumour Total dose Dose to ICD Outcome
Thomas22 2004 Bronchial carcinoma 56 Gy/28# Unable to ascertain Electrical reset of ICD detected 9 days
after event
John23 2004 Left breast 50 Gy/20# Partial exposure to generator, full
exposure to leads
Battery depletion, shock impedance
>125 W indicating shock coil failure,
possibly due to leads.
Sepe24 2007 Laryngeal carcinoma 60 Gy tumour/50 Gy
lymph nodes
2.5 Gy No malfunctions
Nemec25 2007 Lung mass 59.4 Gy/33# Unable to ascertain Patient collapsed #3 and required CPR.
ICD suggestive of RAM damage but
no evidence
ICD, implantable cardioverter deﬁbrillator; RAM, random access memory.
Radiation effect on pacemakers and ICDS
© 2010 The Authors
Journal compilation © 2010 The Royal Australian and New Zealand College of Radiologists 57
Since 1994, apart from case studies, there have been
only three studies on the radiation effects on pacemak-
ers, and only two pertaining to ICDs. The largest pace-
maker study was Mouton et al. in 2002, incorporating 96
pacemakers, with 16.7% of pacemakers failing at doses
of 5 Gy or less.10 Since 1994, there has been no study
that has matched the magnitude of this study. The
remaining two pacemaker studies incorporated 18 and
19 pacemakers, respectively,8,14 with neither demon-
strating pacemaker failure at doses equal to 10 Gy or
less. Both ICD studies tested only 11 ICDs each,12,15 both
demonstrating VT/VF detection in 36.3% of devices. It
has been suggested that in vitro studies like these over-
estimate the risk of generator damage, as large doses
per fraction are often used, and whole dose is occasion-
ally delivered in one day, preventing device recovery
between fractions.3,9 Results from these studies have
prompted researchers to assume that dose rate would
also affect point of failure10,14; however, no study has
independently tested dose rate and accumulated dose
separately in order to establish this fact.
The remaining literature is presented through ten case
studies, each incorporating only one type of device. Of
these studies, none of the pacemakers failed whilst
receiving doses ranging from 0.7 to >50 Gy. Three ICDs
in these case studies failed at some point; however, the
doses at which these occurred could not be esti-
mated.22,23,25 It could be assumed that in these studies,
since the ICD doses could not be estimated, there were
no protocols in place to deal with such situations, and no
evaluation of received dose during the planning of such
treatment. ICDs are thought to be more sensitive to
radiation than pacemakers, yet minimal strategies exist
for the management of these patients.12
The pacemakers and ICDs used in the various in vitro
studies were obtained from a range of sources and
origins. These include the use of explanted models,
which were previously implanted and removed for a
variety of reasons. Although these devices were tested
and deemed reliable, it is not possible to ensure that
they were not more susceptible to measured faults
without exposure to radiation.14,15
Manufacturers will sometimes provide guidelines for
safe therapeutic radiation doses to their products;
however, each guideline differs signiﬁcantly7,26–28 (see
Table 5). While this may be partially attributed to dif-
ferences in design and products, the reliability of these
recommendations is under question, as Guidant states
that there is no ‘safe’ radiation dose that may be
received by their devices due to the random nature of
scatter particles and the effect they may have on RAM,
a common element in all devices.28 Previous research
has shown EMI to have an insigniﬁcant effect on the
pacemakers and ICDs, as it is only present momen-
tarily when the beam is turned on or off.3,13,29 While
this is true for conventional radiation therapy, the
introduction of newer technologies such as intensity
modulated radiation therapy (IMRT) and respiratory
gating may have a more signiﬁcant effect on devices
and EMI presence. This is due to the radiation being
‘held’ multiple times during treatment to allow for
shielding and motion changes. Often, these treatments
Table 5. Manufacturer guidelines for the management of patients with pacemakers or ICDs during radiotherapy
Guideline St Jude Medical27 Medtronic26 Guidant28
Treat with generator inside
ﬁeld
Pacemaker No No No
ICD No No No
Maximum dose to be
received by generator
Pacemaker 20–30 Gy 5 Gy No ‘safe’ dose
ICD Not stated 1–5 Gy depending
on model
No ‘safe’ dose
Cardiologist to examine
device before treatment
course begins
Yes – including interrogation, evaluation of pacing,
sensing, stimulation thresholds and diagnostic
measurements (e.g. battery and lead impedance)
Not stated Direct consultation with the patient’s cardiologist or
electrophysiologist to determine necessity
Cardiologist to examine
device during the
treatment course
Yes if pacemaker dependant, or if change is noted
during treatment monitoring, as well as after
every treatment once maximum dose is reached
Not stated Direct consultation with the patient’s cardiologist or
electrophysiologist to determine necessity
Cardiologist to examine
device after treatment
course completion
Yes – similar to that performed before irradiation Not stated Direct consultation with the patient’s cardiologist or
electrophysiologist to determine necessity
Monitor patient during
irradiation
ECG ﬁrst fraction only on pacemaker dependant
patients, Vital signs obtained before and after
each treatment.
After 5 Gy limit has
been reached
Determined by oncologist
ICD, implantable cardioverter deﬁbrillator.
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are of a longer duration and contain additional ﬁelds to
allow a better dose distribution.
With limited studies, there is much information that
is still lacking in understanding pacemaker and ICD
irradiation. Recently, there has been no further studies
into the effect of EMI, which is potentially an increasing
problem when introducing newer technologies to
departments such as gating and IMRT. There is also
speculation that dose rate is a factor when dealing with
pacemaker or ICD irradiation, but no deﬁnitive studies
exist. Often studies are performed in short spaces of
time with large doses per fraction, generators are
placed within the central axis of the radiation portal
and results are not reproducible. There is also no in
vitro data indicating that the guidelines proposed by
each paper prevent pacemaker or ICD failure during
irradiation. In order to adequately assess the impact of
radiation therapy on pacemakers and ICDs, a new
study should be conducted encompassing not only the
accumulated dose received by the devices, but frac-
tionation, dose rate and potential EMI interference
created using new technologies. A two-armed study
focusing on the difference between high dose rate and
low dose rate on pacemakers and ICDs would provide
an independent focus on the effect of dose rate on
pacemaker and ICD malfunction after exposure to
radiation. The incorporation of standard radiation
therapy fractionations and beam arrangements would
allow for a more accurate assessment of the potential
damage to pacemakers and ICDs during treatment.
The development of a national online database in which
pacemaker and ICD interaction can be assessed
through the availability of multiple case studies follow-
ing similar irradiation guidelines would allow for a com-
prehensive follow up to all protocols proposed.
Conclusion
From the articles reviewed, it is clear that radiation-
induced device malfunction is rare, and death associated
with that malfunction even more uncommon. However,
any such event would be a preventable death, and so
must be avoided if there is any ability to do so. While
guidelines have been proposed in many articles, data
does not yet exist to show that these are adequate
precautions. More in-depth studies need to be conducted
on the effect of radiation on pacemakers and ICDs. When
considering potential damage that may be incurred, it is
important to consider all aspects of radiation therapy
treatment, not just accumulated dose. These include the
effect of backscatter, dose rate, fractionation and poten-
tial EMI interference with new technologies such as IMRT
and respiratory gating. Recommended maximum doses
obtained from manufacturers have not proved to be
reliable and vary greatly among manufacturers. Until
such data exists, a more conservative approach is nec-
essary to minimise risk of harm to the patient. Each
radiation oncology department should employ their own
policy for the management of patients with pacemakers
and ICDs, potentially based upon an updated standard
national or international guideline similar to that
released by the AAPM in 1994. A list of patient manage-
ment recommendations has been compiled as an
example by the authors (see Appendix I).
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Appendix I
The following is a list of recommendations that has been
compiled by the authors as an example of a procedure
that may be adopted by a department.
Clinic/pre-planning
1 Patients should be identiﬁed at initial consult and
device details recorded.
2 Pacemaker dependence to be assessed. Referral to a
local cardiologist with pacemaker expertise is required.
Planning
1 3D computer-assisted planning should be utilised
(including CT data) to more accurately assess dose
received by the pacemaker and aid in beam arrange-
ment and shielding placement.
2 The device should be shielded and kept at least 5 cm
from the collimated radiation ﬁeld wherever possible
(including open port ﬁlms and electronic portal
imaging [EPI]). All shielding should originate from the
treatment head, such as multi-leaf collimators or pre-
mounted lead shielding trays.
3 Total dose received by the pacemaker/ICD should be
kept as low as possible.
 Max pacemaker dose should be kept to <2 Gy, or
device relocation should be considered. At no point
should the cumulative dose exceed 5 Gy
 Max ICD dose <1 Gy, or device relocation should be
considered.
Treatment
Equipment to be maintained by the department
1 Cardiac monitoring device (ECG);
2 ‘crash cart’ – including CPR devices; and
3 hospital deﬁbrillator with external pacemaker capacity.
Pacemaker and deﬁbrillator patients
Non-pacemaker dependant patients
1 Treatment may be undertaken as per dept protocol.
2 Regular device checks are advised after every session
ideally, at least weekly.
3 TLDs performed day 1 to check dose received by the
pacemaker.
F Hudson et al.
© 2010 The Authors
Journal compilation © 2010 The Royal Australian and New Zealand College of Radiologists60
Pacemaker dependant patients
1 Cardiac monitoring (ECG) is essential during every
treatment session by appropriately trained personnel
(with ability to respond to any arrhythmic event).
2 Device checks are advised after every session.
3 If an extreme bradycardia occurs, staff should be
prepared to resuscitate the patient using external
pacing as required (as a bridge to transvenous pacing
and device replacement).
4 TLDs performed day 1 to check dose received by the
pacemaker.
ICD patients
1 Use the deﬁbrillator programmer to disable anti-
tachycardia therapy during treatment.
2 Cardiac monitoring (ECG) is essential during every
treatment session by appropriately trained personnel
(with ability to respond to any arrhythmic event).
Monitoring must start as soon as the anti-tachycardia
therapy is switched off and continue until the anti-
tachycardia therapy is switched back on after the
treatment session.
3 Device checks are advised after every session.
4 If an extreme bradycardia occurs, staff should be
prepared to resuscitate the patient using external
pacing as required.
5 TLDs performed day 1 to check dose received by the
ICD.
Radiation effect on pacemakers and ICDS
© 2010 The Authors
Journal compilation © 2010 The Royal Australian and New Zealand College of Radiologists 61
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Appendix B: Ethics approval forms for ICD PORs (Chapter Four) 
HREC:   
Royal Prince Alfred Hospital (RPAH) - X11-0346 and LNR/11/RPAH/548. 
Site Specific Assessment: 
 RPA - LNRSSA/12/RPAH/129 
St George Hospital - LNRSSA/12/STG/63 
Westmead Hospital - LNRSSA/12/WMEAD/118 
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Appendix C: Full TLD measurements for ICD exposed to scatter 
radiation therapy (Chapter Six) 
Table C1: Full TLD measurement for ICD exposed to 6MV scatter radiation 
therapy 
Key: ICD = implantable cardioverter defibrillator; LiF = lithium fluoride; MV = 
photons; TLD = thermoluminescent dosimeter; Gy = gray; cGy = centigray; # = 
fraction; MUCF = monitor unit correction factor. 
Patient In vivo-Dosimetry 
LiF 100, TLD: Set 1 - 6MV 
Patient: ICD Study 
Measurement Date: 14/12/2012 
TLD 
Chip Position 
Sensitivity 
Factor 
Raw 
Reading 
Corrected 
Reading MUCF 
Output 
Corrected 
Reading 
Dose 
(cGy) 
1 Central Posterior Side 1.01013 4.0 4.0 0.995 4.0 0.1 
2 Central Posterior Side 0.96275 3.9 4.1 0.995 4.1 0.1 
3 Central Posterior Side 1.00781 4.4 4.4 0.995 4.4 0.1 
4 Medial Anterior Side 0.98575 11.8 12.0 0.995 12.0 0.4 
5 Medial Anterior Side 0.98987 11.6 11.7 0.995 11.8 0.3 
6 Medial Anterior Side 0.99692 12.3 12.3 0.995 12.4 0.4 
7 Central Anterior Side 1.00593 14.0 13.9 0.995 14.0 0.4 
8 Central Anterior Side 1.03648 13.0 12.5 0.995 12.6 0.4 
9 Central Anterior Side 1.00389 11.2 11.2 0.995 11.2 0.3 
10 Lateral Anterior Side 1.03211 8.9 8.6 0.995 8.7 0.3 
11 Lateral Anterior Side 1.01556 9.7 9.0 0.995 9.0 0.3 
12 Lateral Anterior Side 1.01858 8.7 8.5 0.995 8.6 0.2 
13 Control 1.01935 696.8 683.6 0.995 687.0 20.0 
14 Control 1.02763 703.5 684.6 0.995 688.0 20.0 
15 Control 1.02604 698.9 681.2 0.995 684.6 19.9 
16 Control 1.02865 700.6 681.1 0.995 684.5 19.9 
17 Control 1.03077 703.4 682.4 0.995 685.8 20.0 
18 Control 1.01095 698.8 691.2 0.995 694.7 20.2 
19 Control 1.02131 703.4 688.7 0.995 692.2 20.2 
20 Control 1.01813 686.2 674.0 0.995 677.4 19.7 
Calibration Dose:  20 cGy 
Average RAW Calibration Value: 686.8 
1cGy =  34.3 
Treatment Site # Prescribed Dose (Gy) Dose/# (cGy) Total Dose (cGy) 
ICD Anterior 10 30 0.3 3 
ICD Posterior 10 30 0.1 1 
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Table C2: Full TLD measurements for ICD exposed to 18MV scatter 
radiation therapy  
Patient In vivo-Dosimetry 
LiF 100, TLD: Set 2 - 18MV 
Patient: ICD Study 
Measurement Date: 20/12/2012 
TLD 
Chip Position 
Sensitivity 
Factor 
Raw 
Reading 
Corrected 
Reading MUCF 
Output 
Corrected 
Reading 
Dose 
(cGy) 
1 
Central Posterior 
Side 0.96827 5.7 5.9 0.995 5.9 0.2 
2 
Central Posterior 
Side 0.97334 5.1 5.2 0.995 5.3 0.2 
3 
Central Posterior 
Side 0.97192 4.7 4.7 0.995 4.9 0.2 
4 Medial Anterior Side 0.98668 13.1 13.3 0.995 13.3 0.5 
5 Medial Anterior Side 0.99098 13.6 13.7 0.995 13.8 0.5 
6 Medial Anterior Side 0.98412 13.4 13.6 0.995 13.7 0.5 
7 
Central Anterior 
Side 1.00003 12.4 12.4 0.995 12.5 0.5 
8 
Central Anterior 
Side 1.00030 13.0 13.0 0.995 13.1 0.5 
9 
Central Anterior 
Side 1.01068 14.1 14.0 0.995 14.0 0.5 
10 Lateral Anterior Side 0.99075 12.3 12.4 0.995 12.5 0.5 
11 Lateral Anterior Side 1.03892 12.6 12.1 0.995 12.2 0.5 
12 Lateral Anterior Side 1.01401 13.9 13.7 0.995 13.8 0.5 
13 Control 1.01287 553.1 546.1 0.995 548.8 20.4 
14 Control 1.00994 528.4 523.2 0.995 525.8 19.5 
15 Control 0.97256 521.7 536.4 0.995 539.1 20.0 
16 Control 1.02397 543.4 530.7 0.995 533.3 19.8 
17 Control 1.02905 556.7 541.0 0.995 543.7 20.2 
18 Control 1.02160 552.9 541.2 0.995 543.9 20.2 
Calibration Dose:  20 cGy 
Average RAW Calibration Value: 539.1 
1cGy =  27.0 
Treatment Site # Prescribed Dose (Gy) Dose/# (cGy) Total Dose (cGy) 
ICD Anterior 10 30 0.5 5 
ICD Posterior 10 30 0.2 2 
Key: ICD = implantable cardioverter defibrillator; LiF = lithium fluoride; MV = 
photons; TLD = thermoluminescent dosimeter; Gy = gray; cGy = centigray; # = 
fraction; MUCF = monitor unit correction factor. 
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Appendix D: RPAH Radiation Oncology Cardiac Devices 
Protocol (2010) 
RPAH department protocol for treatment of CIED patients included within studies 
detailed in Chapters Seven and Eight. 
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BACKGROUND 
 
 
The normal heart rate at rest is in the range 50-100 beats/minute.  The normal 
heart rhythm is sinus rhythm, in which the heart-beat starts in a special node 
of cells (the sinus node) within the right atrium and is conducted through the 
atria and atrioventricular conducting system to the ventricles.  Another 
common heart rhythm is atrial fibrillation (AF), in which the atria are 
continuously, chaotically, activated.  In AF, the ventricular rhythm is usually 
irregular but the atrioventricular node helps protect the ventricles from beating 
too fast, often assisted by node-slowing medications such as beta-blockers, 
calcium channel blockers and digoxin. 
 
Implantable pacemakers are used to treat patients who suffer, either 
intermittently or continually, from bradycardias - heart rates that are too slow.  
If the heart is going too slowly, the pacemaker stimulates it with its own 
electrical impulse.   
 
Implantable cardioverter / defibrillators (ICDs) are used to treat patients who 
have had, or are at risk of, ventricular tachycardia (VT) or ventricular 
fibrillation (VF).  If the ICD detects VT or VF, it tries to terminate the 
arrhythmia either by giving a cardioversion shock or with a brief rapid burst of 
pacing.  ICDs are also able to act as ordinary pacemakers if the patient’s 
heart ever goes too slow. 
 
Both these cardiac devices, being electronic, can show possible effects of 
interference, which can be listed as: 
 
• No change 
• The pulse period can alter 
• The pulse duration can alter 
• The pulse amplitude can alter 
• The decision circuitry can interpret the signal as valid and inhibit 
pulses. 
• The decision circuitry can interpret the signal as invalid, whilst 
stimulated, and pulse asynchronously 
• There can be permanent damage to the components. 
 
The main sources of interference which can affect cardiac devices include: 
 
• electrical 
• magnetic fields 
• radiation 
 
As radiation based interference is our area of interest, the discussion will 
centre on the effect of radiation on cardiac devices. 
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The effect of exposure to ionizing radiation on cardiac device performance 
is well documented.  The possible effects of interference are listed above, but 
the failures reported include: 
 
• increased power consumption 
• telemetry function ceasing to operate 
• spontaneous reprogramming 
• output failure 
 
International standards, such as AAPM Task Group 34, have established 
guidelines for the management of  patients with implanted cardiac devices 
who are receiving radiotherapy. Different brands, models, and modes of 
operation all contribute to determining the response of the pacemaker to 
radiation.  Some models respond by failing at doses as low as 2.00 Gy, others 
show no response to doses exceeding 100.00 Gy. 
 
PRELIMINARY PROCEDURES 
 
When a patient with a pacemaker or defibrillator presents for radiotherapy the 
first task is for the Radiation Oncologist or the Radiation Oncologist Registrar 
to note this fact on the green booking sheet and obtain details of the device 
such as brand name, model, mode, date of implant, site of implant and 
cardiologist. The pacemaker or defibrillator information should be contained 
within the patient’s medical records and on the pacemaker / defibrillator 
specifications card which patients should carry at all times. A photocopy of 
this card should be attached to the booking form. 
 
The appointments RT will make sure that all the required 
pacemaker/defibrillator details are recorded onto the Pacemaker Information 
Form or the Defibrillator Information Form.  
 
The planning Radiation Therapist will make sure the radiotherapy prescription 
details are available before planning the course of treatment. During the 
planning phase it is necessary for the planning Radiation Therapist to notify 
the staff who will play a role in the planning and treatment of the patient. This 
information should also be recorded onto the Pacemaker Information Form or 
the Defibrillator Information Form. These staff are:- 
 
• Medical Physics   
• Radiotherapy Nursing  
• The Senior Radiation Therapist for the treatment machine which will 
deliver the patient’s treatment. 
• CTSU Staff (for pacemaker clinic):   ph 58870, page 80486, 80487, 1122 
• It may be necessary to negotiate a suitable time for treatment for each 
fraction so CTSU/Cardiology  staff can attend if required.  
 
NOTE: PATIENTS WITH CARDIAC DEVICES ARE RECOMMENDED NOT 
TO HAVE TOTAL BODY IRRADIATION. 
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3.  PACEMAKER PATIENTS 
 
3.1  BEFORE TREATMENT  
 
3.1.1  Dose estimation 
 
The dose received by the pacemaker must be estimated before the patient 
starts treatment.  in most instances, the Radiation Oncologist will assign 
treatment portals which keep the dose to the pacemaker as low as possible.  
 
Estimates of dose to the pacemaker should be made using the same standard 
planning methods as for calculating a critical structure. The total calculated 
pacemaker dose must be clearly indicated on the appropriate dosimetry plot 
and the Radiation Oncologist must authorize it with his or her initials and the 
date. The dose point should be chosen to indicate the maximum dose to the 
pacemaker. For more information see the In Vivo Dosimetry Protocol. 
 
If the estimate of dose to the pacemaker is > 5 Gy then radiation therapy is 
contraindicated and the plan should be changed unless the Radiation 
Oncologist explicitly accepts the estimated dose in writing. 
 
3.1.2  Pre-treatment testing 
 
The pacemaker must be tested by CTSU staff. This should be carried out in 
Cardiology if possible. A record of the results must be stored in the patient’s 
radiotherapy department file. 
 
3.2  DURING TREATMENT  
 
NOTE 1. Do not deliver treatment to a cardiac device patient if the linear 
accelerator is or recently has been arcing. Arcing can produce intense bursts 
of interference at radio frequencies and can therefore increase the possibility 
of pacemaker malfunction. 
 
NOTE 2.  A medical officer must be present within the radiation oncology 
department building on every occasion of treatment delivery in case of an 
emergency. Please notify a medical when the treatment procedure begins and 
ends. 
 
NOTE 3. If a cardiac arrest or anomaly occurs phone 222 immediately and 
summon the nearest available medical officer. The medical and nursing staff 
will now follow the procedures in the RPAH cardiac arrest plan. 
 
 
NOTE 4. If the treatment plan is modified after the first fraction then the 
impact of this on the dose to the cardiac device needs to be assessed. 
Monitoring as for the first fraction may need to be repeated.. 
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3.2.1  First fraction 
 
A staff member from the CTSU will check the patient’s cardiac rhythm with an 
ECG before and after the first fraction.  
 
A medical physicist will measure the dose over the cardiac device. On the 
basis of this the patient’s treatment is classified as Level 1 (dose to cardiac 
device estimated to be < 1 Gy for entire treatment course), Level 2 (1 – 5 Gy) 
or Level 3 (> 5 Gy). This dose level should be reported to the Treatment 
Senior before the second fraction to allow time for him or her to arrange 
further monitoring as required. 
 
3.2.2 Subsequent fractions 
 
• Level 1 (<1.00 Gy). No daily monitoring is required, the patient is to attend 
pacemaker clinic on the last day of treatment. 
 
• Level 2 (1.00 Gy to 5.00 Gy). The pacemaker is to be tested by CTSU staff 
once a week.  If significant changes to pacemaker performance are 
detected, suspend treatment and consult with CTSU staff. 
 
• Level 3 (>5.00 Gy).  Radiotherapy is contraindicated and altered treatment 
methods must be considered, eg. extra shielding, alternative beam 
arrangements, alternative therapy. Surgically moving the pacemaker 
should be considered only as a last resort. If radiotherapy proceeds a 
registered nurse is to monitor with ECG every fraction, and to have a 
resuscitation trolley present in case of emergencies. Pacemaker to be 
tested by CTSU staff after every fraction.  If significant changes to 
pacemaker performance occur, suspend treatment and consult with CTSU 
staff.  
 
3.3  AFTER TREATMENT 
 
At the conclusion of a course of treatment CTSU will monitor pacemaker 
function. This should be carried out in Cardiology by CSTU staff where 
possible. All records of all CTSU monitoring activities, recommendations and 
pacemaker dose estimates will be then stored in the patient’s radiotherapy 
department file. 
 
NB: Magnet should never be put on a pacemaker as this will 
disable all pacemaker function and resulted in patient having 
a cardiac arrest.
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4.  DEFIBRILLATOR PATIENTS 
 
4.1  BEFORE TREATMENT  
 
4.1.1  Dose estimation 
 
The dose received by the defibrillator must be estimated before the patient 
starts treatment.  in most instances, the Radiation Oncologist will assign 
treatment portals which keep the dose to the defibrillator as low as possible.  
 
Estimates of dose to the defibrillator should be made using the same standard 
planning methods as for calculating a critical structure. The total calculated 
defibrillator dose must be clearly indicated on the appropriate dosimetry plot 
and the Radiation Oncologist must authorize it with his or her initials and the 
date. The dose point should be chosen to indicate the maximum dose to the 
defibrillator. For more information see the In Vivo Dosimetry Protocol. 
 
If the estimate of dose to the defibrillator is > 2 Gy then radiation therapy is 
contraindicated and the plan should be changed unless the Radiation 
Oncologist explicitly accepts the estimated dose in writing. 
 
4.1.2  Pre-treatment testing 
 
The defibrillator must be tested by the company who supplied the device prior 
to the first fraction in Radiation Oncology Department. 
 
4.2  DURING TREATMENT  
 
NOTE 1. Do not deliver treatment to a cardiac device patient if the linear 
accelerator is or recently has been arcing. Arcing can produce intense bursts 
of interference at radio frequencies and can therefore increase the possibility 
of pacemaker malfunction. 
 
NOTE 2.  A medical officer must be present within the radiation oncology 
department building on every occasion of treatment delivery in case of an 
emergency. Please notify a medical when the treatment procedure begins and 
ends. 
 
NOTE 3. If a cardiac arrest or anomaly occurs phone 222 immediately and 
summon the nearest available medical officer. The medical and nursing staff 
will now follow the procedures in the RPAH cardiac arrest plan. 
 
NOTE 4. If the treatment plan is modified after the first fraction then the 
impact of this on the dose to the cardiac device needs to be assessed. 
Monitoring as for the first fraction may need to be repeated.. 
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4.2.1  First fraction 
 
• A technician from the company supplied the device need to check and 
record the performance of the device prior to the first fraction of the 
treatment is delivered. 
 
• The technician needs to demonstrate the correct placement of the magnet 
over the defibrillator to both nursing staff and radiation therapists 
 
• Nursing staff will attach pulse oximeter to patient and record a daily 
baseline reading and ensure emergency trolley is available 
 
• Nursing staff will disable the defibrillator during treatment by placing a 
magnet over the defibrillator device to prevent the possibility of the patient 
receiving shocks during treatment delivery.  
 
•  Notify Medical staff immediately prior to treatment each day.  
 
• Adjust in-room camera on pulse oximeter and monitor during treatment.  
 
• If the pulse deviated by +/- 20 beats per minutes from the daily 
baseline reading recorded or the oxygen saturation level drops below 
85, stop treatment immediately and check patient status  
 
• A nursing staff and medical staff must be present at the treatment machine 
with the emergency trolley for each fraction of treatment in case of an 
emergency. 
 
• A medical physicist will measure the dose over the patient’s defibrillator for 
the first fraction. On the basis of this the patient’s treatment is classified as 
Level 1 (dose to defibrillator estimated to be < 2.00 Gy for entire treatment 
course), or Level 2 (> 2.00 Gy)  
 
4.2.2 Subsequent fractions 
 
• Level 1 (< 2.00 Gy). The company technician will perform a device check 
on the first fraction, half-way through the treatment and the last fraction of 
the treatment. Daily treatment procedure should be followed as per 
section 4.2.1  
 
• Level 2 (> 5.00 Gy).  Radiotherapy is contraindicated and altered 
treatment methods must be considered, eg. extra shielding, alternative 
beam arrangements, alternative therapy. Surgically moving the defibrillator 
should be considered only as a last resort. If radiotherapy proceeds, a 
nursing and medical staff member must monitor the patient’s cardiac 
rhythm with an ECG during the treatment. Defibrillator to be tested by 
company technician weekly. If significant changes to defibrillator 
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performance occur, suspend treatment and consult with company 
supplying the device for further infoamtion.  
 
 
 
4.3  AFTER TREATMENT 
 
At the conclusion of a course of treatment the company technician will 
evaluate defibrillator function. All records of all monitoring activities, 
recommendations and defibrillator dose estimates will be then stored in the 
patient’s radiotherapy department file. 
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CARDIAC DEVICE CHECKLIST  
Bookings 
1. Manufacturer, model number, type (eg on demand or pacing)  
2. Date device implanted  
3. Location of device in relation to treatment area - estimate of dose expected to be 
received.  
CT 
1. Magnet and emergency trolley available  
2. Nursing staff notified before simulation.  
3. Evaluate need for use of Pulse Oximeter in Sim  
4. Contact manufacturer/ technician and/or cardiologist if additional information is 
required  
 
Planning 
1. Clearly indicate on treatment sheet and in time planner that patient has a pacemaker.  
2. Verbally notify treatment senior that the patient has a pacemaker before day 1 of 
treatment  
3 Arranging the pre and post day 1 treatment pacemaker checks.  
(Appointment booked for Date ___________ Time __________ by__________) 
4. Organise and review DIODES measurements  
 
Treatment 
1. Notifying the Medical, and Nursing staff, the time for Day 1 treatment.  
2. Pre and Post treatment pacemaker checks on Day 1 (printouts of checks to be stored 
in CCC notes).  
3. Magnet in treatment suite, attach pulse oximeter to patient , ensure emergency trolley 
is available  
4. Notify Medical and Nursing of treatment time on Day 1** Notified by __________  
5. Notify Medical, Nursing staff immediately prior to treatment each day**.  
6. Last fraction - ECG and device check performed after last fraction and stored in 
Department notes  
(Appointment booked for Date ___________ Time __________ by__________) 
7. To assist in identifying patient on the daily schedule please add “PACEMAKER” into 
the activity note in time planner for each of the patients appointments. 
 
Pulse oximeter saturation should not drop below 85 and pulse 
should not drop below 60. 
 
** Treatment should not be commenced unless a member of the medical team is in 
the Cancer Centre and has provided a contact phone number. 
 
Please ensure that you contact the appropriate company related to the brand of 
pacemaker not the company that manufacture the leads. 
 
Contacts Numbers 
 
Medtronics 9879-5999  
Intermedics / Guidance Phone 1-800-245-559 
St Judes 9427-6400  
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PACEMAKER INFORMATION FORM 
 
THIS FORM MUST BE COMPLETED FOR ALL PATIENTS WITH  
PACEMAKERS RECEIVING RADIOTHERAPY. 
 
 
Patient details 
 
Patient's Name:     MRN:   DRN: 
 
Address: 
 
Date of Birth: 
 
 
Pacemaker details: 
 
Device brand name: 
 
Model:     Mode: Demand / Dependant 
 
Date of  implant:   Site of implant:         (see diagram on 
reverse page) 
 
Cardiologist: 
 
Radiation Oncologist:     Planner: 
 
Technique:      Energy: 
 
Simulator Date:      Plan ready date: 
 
Planning Radiation Therapist to notify the following: 
   
 [   ] -Physics 
 [   ] -Nursing 
 [   ] -Treatment machine senior 
 [   ] -CTSU/Cardiology  
 
CTSU comments: 
 
 
 
 
 
 
 
 
 
CTSU PAGE NUMBER: 80487
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DEFRIBILATOR INFORMATION FORM 
 
THIS FORM MUST BE COMPLETED FOR ALL PATIENTS WITH  
DEFRIBILATOR RECEIVING RADIOTHERAPY. 
 
 
Patient details 
 
Patient's Name:     MRN:   DRN: 
 
Address: 
 
Date of Birth: 
 
 
Pacemaker details: 
 
Device brand name: 
 
Model:     Mode: Demand / Dependant 
 
Date of  implant:   Site of implant:         (see diagram on 
reverse page) 
 
Cardiologist: 
 
Radiation Oncologist:     Planner: 
 
Technique:      Energy: 
 
Simulator Date:      Plan ready date: 
 
Planning Radiation Therapist to notify the following: 
   
 [   ] -Physics 
 [   ] -Nursing 
 [   ] -Treatment machine senior 
 [   ] -Device manufacture company  
 
Company technician comments: 
 
 
 
 
 
 
 
 
Contacts Numbers: 
Medtronics 9879-5999     Intermedics / Guidance Phone 1-800-245-559 
St Judes 9427-6400  
RADIATION ONCOLOGY 
 
Protocol 
 
R O Y A L  
P R I N C E  
A L F R E D  
H O S P I T A L  CARDIAC DEVICES PROTOCOL 
 
File Name Revision date: Revised by: Version: Page: 
Cardiac Devices Protocol 10/02/2010 Robert Lin 1.2 Page 12 of 13 
 
7.   PACEMAKER PROCEDURE FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PACEMAKER PATIENT PRESENTS FOR RADIOTHERAPY. 
R/O INDICATES DEFIBRILLATOR ON GREEN BOOKING 
FORM AND RECORDS DEVICE DETAILS 
APPOINTMENT SENIOR RT CHECKS THAT DEVICE DETAILS ARE 
COMPLETE 
PLANNING PERFORMED. DOSE ESTIMATE FOR 
PACEMAKER MADE. DOSE SHOULD BE  <5.0 GY 
SENIOR RT PLANNER CHECKS THAT PRESCRIPTION IS COMPLETE, AND 
NOTIFIES PHYSICS, NURSING TREATMENT SENIOR R/T AND CTSU 
LEVEL 2 
TOTAL DOSE 1.00GY – 5.00GY
LEVEL 1 
TOTAL DOSE < 1.00GY 
USE ALTERNATIVE 
TREATMENT PLAN 0R 
SURGICALLY MOVE 
PACEMAKER
PACEMAKER TO BE TESTED BY CTSU BEFORE 
FIRST FRACTION
 
TOTAL DOSE  
< 5.0 GY? 
 
HIGH DOSE 
APPROVED BY 
R/O? 
YES 
YES 
REGISTERED NURSE TO 
MONITOR ECG DAILY .  
PACEMAKER TESTED BY 
CTSU DAILY. 
PACEMAKER TESTED BY 
CTSU  AFTER FINAL 
FRACTION 
CTSU TO TEST 
PACEMAKER WEEKLY. 
PACEMAKER TESTED BY 
CTSU AFTER FINAL 
FRACTION 
LEVEL 3 
RO TO NOTE HIGH DOSE ON 
TREATMENT SHEET 
NO 
TREATMENT COMMENCES. 1ST FRACTION PHYSICIST MEASURES DOSE AND 
INFORMS TREATMENT SENIOR R/T ASAP. 
RADIATION ONCOLOGY 
 
Protocol 
 
R O Y A L  
P R I N C E  
A L F R E D  
H O S P I T A L  CARDIAC DEVICES PROTOCOL 
 
File Name Revision date: Revised by: Version: Page: 
Cardiac Devices Protocol 10/02/2010 Robert Lin 1.2 Page 13 of 13 
 
8.   DEFIBRILLATOR PROCEDURE FLOW CHART 
 
 
 DEFIBRILLATOR PATIENT PRESENTS FOR 
RADIOTHERAPY. R/O INDICATES DEFIBRILLATOR ON 
GREEN BOOKING FORM AND RECORDS DEVICE DETAILS 
APPOINTMENT SENIOR RT CHECKS THAT DEVICE DETAILS ARE 
COMPLETE
PLANNING PERFORMED. DOSE ESTIMATE FOR 
DEFIBRILLATOR MADE. DOSE SHOULD BE  <2.0 GY 
SENIOR PLANNER CHECKS THAT PRESCRIPTION IS COMPLETE, AND 
NOTIFIES PHYSICS, NURSING, TREATMENT SENIOR R/T AND 
REPRESENTATIVE FROM THE DEVICE MANUFACTUTRE 
TREATMENT COMMENCES. 1ST FRACTION PHYSICIST MEASURES DOSE  
AND INFORMS TREATMENT SENIOR RT BEFORE THE NEXT FRACTION. 
NURSING STAFF  MONITORS OXIMETER AND DISABLES 
DEFIBRILLATOR.   
LEVEL 1 
TOTAL DOSE < 2.00GY 
NURSING TO MONITOR 
OXIMETER AND DISABLE 
DEFIBRILLATOR DAILY.  
NURSING AND MEDICAL STAFF 
TO BE WITHIN CLOSE 
PROXIMITY OF THE TREATMENT 
MACHINEDAILY WITH 
EMERGENCY TROLLEY 
USE ALTERNATIVE 
TREATMENT PLAN 0R 
SURGICALLY MOVE 
DEFIBRILLATOR
DEFIBRILLATOR TO BE TESTED BY COMPANY 
TECHNICIAN BEFORE THE FIRST FRACTION 
 
TOTAL DOSE  
< 2.0 GY? 
 
HIGH DOSE 
APPROVED BY 
R/O? 
YES NO 
YES 
NO 
NURSING AND MEDICAL STAFF 
TO MONITOR ECG AND DISABLE 
DEFIBRILLATOR DAILY.  
REGISTERED NURSE  
TO BE PRESENT WITH A 
RESCUCITATION TROLLEY 
DAILY. 
LEVEL 2 
RO TO NOTE HIGH DOSE ON 
TREATMENT SHEET 
COMPANY TECHNICIAN TO 
TEST DEFIBRILLATOR  HALF 
WAY THROUGH TREATMENT 
AND AFTER FINAL 
FRACTION 
COMPANY TECHNICIAN TO TEST 
DEFIBRILLATOR WEEKLY 
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Appendix E: Ethics approval forms Case Control Studies 
(Chapters Seven and Eight) 
HREC:   
Royal Prince Alfred Hospital (RPAH) - X11-0351 and LNR/11/RPAH/554. 
Site Specific Assessment: 
 RPA - LNRSSA/12/RPAH/130 
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Appendix F: Statistical Analysis of Case Control Pacemaker Observational Study 
F.1 - Treatment Energy (Pacemaker) 
Table F1: Change in pacemaker parameters in relation to radiation therapy treatment energy - Kruskall Wallis 
analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
RT - 6MV±MeV/MeV 
only RT - 18MV±6MV Control df χ2 p value n= Median   
(Range) 
n= Median  
(Range) 
n= Median  
(Range) 
Battery (V) 42 0.00  
(-0.05 - 0.02) 
17 0.00  
(-0.02 - 0.03) 
89 0.00  
(-0.03 - 0.06) 
2 1.025 0.599 
Signal Amplitude (mV) 59 0.00  
(-4.48 - 4.2) 
26 0.00  
(-3.20 - 4.40) 
184 0.00  
(-11.6 - 8.0) 
2 0.421 0.810 
Impedance (Ω) 72 -2.50 
(-193.0 - 90.0) 
30 -2.50  
(-80.00 - 80.00) 
210 -0.50  
(-232.0 - 287.0) 
2 0.182 0.913 
Capture Threshold 
Amplitude (V) 
74 0.00  
(-0.68 - 0.50) 
28 0.00  
(-0.50 - 0.25) 
207 0.00  
(-0.63 - 1.50) 
2 3.078 0.215 
Capture Threshold pulse 
width (ms) 
74 0.00  
(0.00) 
30 0.00  
(0.00) 
210 0.00  
(0.00 - 0.50) 
2 0.994 0.608 
Output Amplitude (V) 72 0.00  
(-1.40 - 1.38) 
28 0.00  
(-0.32 - 0.00) 
210 0.00  
(-3.00 - 2.00) 
2 1.722 0.423 
Output pulse width (ms) 71 0.00  
(0.00-0.35) 
28 0.00  
(0.00 - 0.10) 
210 0.00  
(0.00 - 0.10) 
2 1.338 0.512 
Key: RT = radiation therapy; MV = photons; MeV = electrons; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree 
of freedom; χ2 = chi-square value
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Table F2: Change in pacemaker parameters in relation radiation therapy treatment energy – Chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
RT - 6MV±MeV/MeV 
only 
RT - 
18MV±6MV 
Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes no yes   no 
Capture Threshold Amplitude 
(V) 
31 43 11 17 105 102 2.553 0.091 0.279 
Output Amplitude (V) 15 57 2# 26 46 164 - - - 
Events 1# 45 1# 17 0# 128 - - - 
Key = RT = radiation therapy; MV = photons; MeV = electrons; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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F.2 Measured maximum TLD dose to pacemakers 
Table F3: Change in pacemaker parameters in relation to measured maximum TLD dose to pacemaker - Kruskall 
Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
<1Gy 1Gy - <2Gy ≥2Gy Control 
df χ2 p value n= Median (Range) 
n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range 
Battery (V) 41 0.00  
(-0.03 - 0.03) 
13 0.00 
(-0.02 - 0.00) 
3 0.00 
(-0.05 - 0.02) 
89 0.00  
(-0.03 - 0.06) 
3 0.775 0.855 
Signal Amplitude 
(mV) 
62 0.00  
(-3.80 - 4.40) 
16 0.00 
(-2.00 - 4.20) 
5 0.00 
(-4.48 - 0.35) 
184 0.00 
(-11.6 - 8.0) 
3 0.896 0.826 
Impedance (Ω) 72 0.00   
(-100.00 - 
90.00) 
20 -5.50  
(-80.00 - 
50.00) 
6 -25.00  
(-193.00 - 
48.00) 
210 -0.50  
(-232.0 - 
287.0) 
3 3.246 0.355 
Capture Threshold 
Amplitude (V) 
70 0.00  
(-0.68 - 0.38) 
22 0.00 
(-0.50 - 0.50) 
6 0.00 
(-0.25 - 0.25) 
207 0.00 
(-0.63 - 1.50) 
3 4.097 0.251 
Capture Threshold 
pulse width (ms) 
72 0.00  
(0.00) 
22 0.00 
(0.00) 
6 0.00 
(0.00) 
210 0.00 
(0.00 - 0.50) 
3 0.955 0.812 
Output Amplitude 
(V) 
70 0.00  
(-1.20 - 0.40) 
20 0.00 
(-1.40 - 1.38) 
6 0.00 
(-0.25 - 0.00) 
210 0.00 
(-3.00 - 2.00) 
3 1.446 0.695 
Output pulse 
width (ms) 
70 0.00  
(0.00-0.35) 
19 0.00 
(0.00) 
6 0.00 
(0.00) 
210 0.00 
(0.00 - 0.10) 
3 1.856 0.603 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table F4: Change in pacemaker parameters in relation to measured TLD accumulated dose to pacemaker – chi square 
analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control 
Group 
 
<1Gy 1Gy - <2Gy ≥2Gy Control 
χ2 Cramer’s V 
p value n= n= n= n= 
Yes No Yes No Yes No Yes No 
Capture Threshold Amplitude 
(V) 
23 47 14 8 4# 2# 105 102 - - - 
Output Amplitude (V) 9 61 6 14 1# 5 46 164 - - - 
Events 1# 45 0# 13 0# 3# 0# 128 - - - 
Key: Gy = Gray; χ2 = chi-square value 
# cells containing less than 5 
- test could not be performed due to small numbers 
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F.3 Estimated maximum dose to pacemaker leads 
Table F5: Change in pacemaker parameters in relation to estimated maximum dose to pacemaker leads - Kruskall 
Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
Low dose (out of 
scan) 
<25Gy ≥25Gy Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
Battery (V) 33 0.00 
(-0.02 - 0.03) 
12 0.00  
(-0.03 - 0.02) 
14 0.00  
(-0.05 - 0.00) 
89 0.00  
(-0.03 - 0.06) 
3 2.042 0.564 
Signal Amplitude 
(mV) 
52 0.00 
(-3.80 - 4.40) 
18 0.00 
(-2.00 - 4.20) 
15 0.00 
(-4.48 - 3.20) 
184 0.00 
(-11.6 - 8.0) 
3 0.285 0.963 
Impedance (Ω) 62 -1.50 
(-100.0 - 86.0) 
19 0.00 
(-193.0 - 90.0) 
21 -4.00 
(-80.0 - 48.0) 
210 -0.50 
(-232.0 - 287.0) 
3 0.193 0.979 
Capture Threshold 
Amplitude (V) 
62 0.00 
(-0.68 - 0.50) 
19 0.00 
(-0.25 - 0.25) 
21 0.00 
(-0.50 - 0.25) 
207 0.00 
(-0.63 - 1.50) 
3 3.683 0.298 
Capture Threshold 
pulse width (ms) 
64 0.00 
(0.00) 
19 0.00 
(0.00) 
21 0.00 
(0.00) 
210 0.00 
(0.00 - 0.50) 
3 0.994 0.803 
Output Amplitude 
(V) 
60 0.00 
(-1.20 - 0.40) 
19 0.00 
(-1.00 - 0.25) 
21 0.00 
(-1.40 - 1.38) 
210 0.00 
(-3.00 - 2.00) 
3 1.156 0.764 
Output pulse width 
(ms) 
60 0.00 
(0.00 - 0.35) 
18 0.00 
(0.00) 
21 0.00 
(0.00) 
210 0.00 
(0.00 - 0.10) 
3 2.683 0.443 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table F6: Change in pacemaker parameters in relation to estimated maximum dose to pacemaker leads – Chi square 
analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control 
Group 
 
Low dose 
(out of scan) 
<25Gy ≥25Gy Control 
χ2 Cramer’s V 
p value n= n= n= n= 
Yes No Yes No Yes No Yes No 
Capture Threshold Amplitude 
(V) 
21 41 9 10 12 9 105 102 6.263 0.142 0.099 
Output Amplitude (V) 10 50 3# 16 4# 17 46 164 - - - 
Events 2# 36 0# 12 0# 14 0# 128 - - - 
Key: Gy = Gray; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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F.4 Estimated maximum dose to heart (pacemaker) 
Table F7: Change in pacemaker parameters in relation to estimated maximum dose to heart (Pacemaker) - Kruskall 
Wallis analysis 
 Radiation Therapy Group Control Group  
Change 
(check 2 - check 1) 
Low dose  
(out of scan) 
<20Gy ≥20Gy Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
Battery (V) 36 0.00 
(-0.02 - 0.03) 
11 0.00 
(-0.01 - 0.02) 
12 0.00 
(-0.05 - 0.00) 
89 0.00  
(-0.03 - 0.06) 
3 1.680 0.641 
Signal Amplitude 
(mV) 
54 0.00 
(-3.80 - 4.40) 
16 0.00 
(-2.00 - 4.20) 
15 0.00 
(-4.48 - 3.60) 
184 0.00 
(-11.6 - 8.0) 
3 0.487 0.922 
Impedance (Ω) 67 -1.00 
(-100.0 - 86.0) 
17 -4.00 
(-193.0 - 46.0) 
18 -4.50 
(-80.0 - 90.0) 
210 -0.50 
(-232.0 - 287.0) 
3 0.479 0.924 
Capture Threshold 
Amplitude (V) 
67 0.00 
(-0.68 - 0.50) 
17 0.00 
(-0.25 - 0.25) 
18 -0.05 
(-0.50 - 0.25) 
207 0.00 
(-0.63 - 1.50) 
3 7.643 0.054 
Capture Threshold 
pulse width (ms) 
69 0.00 
(0.00) 
17 0.00 
(0.00) 
18 0.00 
(0.00) 
210 0.00 
(0.00 - 0.50) 
3 0.994 0.803 
Output Amplitude 
(V) 
65 0.00 
(-1.20 - 0.50) 
17 0.00 
(0.00 - 1.38) 
18 0.00^°& 
(-1.40 - 0.00) 
210 0.00 
(-3.00 - 2.00) 
3 9.345 0.025* 
Output pulse width 
(ms) 
65 0.00 
(0.00 - 0.35) 
16 0.00 
(0.00) 
18 0.00 
(0.00) 
210 0.00 
(0.00 - 0.10) 
3 2.279 0.516 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
* significant result; ^ significant compared to low dose (out of scan) group; ° significant compared to <20Gy group& significant 
compared to control group
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F.4.1 Calculations for capture threshold amplitude significance in 
relation to estimated maximum dose to heart (Pacemaker) 
 
 Bonferroni Adjustment:  
New α = previous α/number of tests performed (where α = significance level) 
α=0.05/3 
New significance level α = 0.017 
Table F8: Comparison of output amplitude(V) significance to greater than 
20Gy radiation therapy group 
  n= U Z r p value 
Radiation Therapy Group 
>20Gy 18     
Low dose 65 416.5 -2.775 0.30 0.006* 
<20Gy 17 97.5 -2.622 0.27 0.009* 
Control Group Control 210 1344.5 -2.784 0.18 0.005* 
Key: U = Mann-Whitney U value; r = effect size 
*significant result at α=0.017
 -326- 
 
Table F9: Change in pacemaker parameters in relation to estimated maximum dose to heart (Pacemaker) – chi square 
analysis 
 Radiation Therapy Group Control Group  
Low dose 
(out of scan) 
<20Gy ≥20Gy Control 
χ2 Cramer’s V p value n= n= n= n= 
Yes No Yes No Yes No Yes No 
Capture Threshold 
Amplitude (V) 21 46 9 8 12 6 105 102 10.728 0.186 0.013* 
Output Amplitude (V) 10 55 2 15 5 13 46 164 2.690 0.093 0.442 
Events 2# 39 0# 11 0# 12 0# 128 - - - 
#cells containing less than 5 
*significant result 
- test could not be performed due to small numbers 
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F.5  Radiation Therapy treatment intent 
Table F10: Change in pacemaker parameters in relation to radiation therapy treatment intent - Kruskall Wallis 
analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
Curative Palliative Control 
df χ2 p value n= Median (Range) 
n= Median 
(Range)  
Median 
(Range) 
Battery (V) 28 0.00  
(-0.05 - 0.03) 
31 0.00  
(-0.03 - 0.01) 
89 0.00  
(-0.03 - 0.06) 
2 1.194 0.550 
Signal Amplitude (mV) 42 0.00  
(-4.48 - 4.40) 
43 0.00  
(-3.20 - 3.10) 
184 0.00  
(-11.6 - 8.0) 
2 1.186 0.553 
Impedance (Ω) 49 -5.00  
(-193.0 - 90.0) 
53 0.00  
(-100.0 - 50.0) 
210 -0.50  
(-232.0 - 287.0) 
2 0.051 0.975 
Capture Threshold Amplitude 
(V) 
51 0.00  
(-0.50 - 0.50) 
51 0.00  
(-0.68 - 0.38) 
207 0.00  
(-0.63 - 1.50) 
2 3.037 0.219 
Capture Threshold pulse 
width (ms) 
51 0.00  
(0.00) 
53 0.00  
(0.00) 
210 0.00  
(0.00 - 0.50) 
2 0.994 0.608 
Output Amplitude (V) 47 0.00  
(-1.40 - 0.50) 
53 0.00  
(-0.50 - 1.38) 
210 0.00  
(-3.00 - 2.00) 
2 0.993 0.609 
Output pulse width (ms) 46 0.00  
(0.00 - 0.35) 
53 0.00  
(0.00) 
210 0.00  
(0.00 - 0.10) 
2 4.281 0.118 
Key: V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table F11: Change in pacemaker parameters in relation to radiation therapy treatment intent – chi square analysis 
 Radiation Therapy Group Control Group  
Curative Palliative Control 
χ2 Cramer’s V p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude (V) 20 31 22 29 105 102 2.655 0.093 0.265 
Output Amplitude (V) 9 38 8 45 46 164 1.259 0.064 0.533 
Events 1# 28 1# 34 0# 128 - - - 
# - cells containing less than 5 
 
- test could not be performed due to small numbers 
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F.6 Radiation Therapy technique (pacemaker) 
Table F12: Change in pacemaker parameters in relation to radiation therapy technique - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
3D-CRT IMRT Control 
df χ2 p value n= Median (Range) 
n= Median 
(Range) 
n= Median (Range) 
Battery (V) 56 0.00 
(-0.05 0.03) 
3 0.01 
(0.00 - 0.02) 
89 0.00  
(-0.03 - 0.06) 
2 5.466 0.065 
Signal Amplitude (mV) 79 0.00 
(-3.20- 4.40) 
6 -0.10 
(-4.48 - 0.70) 
184 0.00  
(-11.6 - 8.0) 
2 1.236 0.539 
Impedance (Ω) 96 -0.50 
(-193.0 - 90.0) 
6 -18.50 
(-53.0 - 48.0) 
210 -0.50 
(-232.0 - 287.0) 
2 1.414 0.493 
Capture Threshold 
Amplitude (V) 
96 0.00 
(-0.68 - 0.50) 
6 0.00 
(-0.25 - 0.13) 
207 0.00  
(-0.63 - 1.50) 
2 3.372 0.185 
Capture Threshold pulse 
width (ms) 
98 0.00 
(0.00) 
6 0.00 
(0.00) 
210 0.00  
(0.00 - 0.50) 
2 0.994 0.608 
Output Amplitude (V) 94 0.00 
(-1.40 - 1.38) 
6 0.00 
(-0.25 - 0.13) 
210 0.00  
(-3.00 - 2.00) 
2 0.904 0.636 
Output pulse width (ms) 93 0.00 
(0.00 - 0.35) 
6 0.00 
(0.00) 
210 0.00  
(0.00 - 0.10) 
2 0.820 0.664 
Key: 3D-CRT = three dimensional conformal radiation therapy; IMRT = intensity modulated radiation therapy; V=Volts; mV = 
millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table F13: Change in pacemaker parameters in relation to radiation therapy technique – chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
3D-CRT IMRT Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude (V) 39 57 3# 3# 105 102 - - - 
Output Amplitude (V) 15 79 2# 4# 46 164 - - - 
Events 2# 59 0# 3# 0# 128 - - - 
Key: 3D-CRT = three dimensional conformal radiation therapy; IMRT = intensity modulated radiation therapy; χ2 = chi-square value 
#  cells containing less than 5 
 
- test could not be performed due to small numbers 
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F.7 Previous radiation therapy exposure (pacemaker) 
Table F14: Change in pacemaker parameters in relation to previous radiation therapy exposure - Kruskall Wallis 
analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group    
Yes No Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
Battery (V) 8 0.00 
(-0.05 - 0.01) 
51 0.00 
(-0.03 - 0.03) 
89 0.00  
(-0.03 - 0.06) 
2 2.463 0.292 
Signal Amplitude 
(mV) 
9 0.00 
(-3.20 - 0.00) 
76 0.00 
(-4.48 - 4.40) 
184 0.00 
(-11.6 - 8.0) 
2 0.953 0.621 
Impedance (Ω) 12 -1.00 
(-36.0 - 25.0) 
90 -3.50 
(-193.0 - 90.0) 
210 -0.50 
(-232.0 - 287.0) 
2 0.080 0.961 
Capture Threshold 
Amplitude (V) 
12 0.00 
(-0.25 - 0.25) 
90 0.00 
(-0.68 - 0.50) 
207 0.00 
(-0.63 - 1.50) 
2 3.832 0.147 
Capture Threshold 
pulse width (ms) 
12 0.00 
(0.00) 
92 0.00 
(0.00) 
210 0.00 
(0.00 - 0.50) 
2 0.994 0.608 
Output Amplitude (V) 12 0.00 
(-0.32 - 0.00) 
88 0.00 
(-1.40 - 1.38) 
210 0.00 
(-3.00 - 2.00) 
2 1.306 0.521 
Output pulse width 
(ms) 
12 0.00 
(0.00) 
87 0.00 
(0.00 - 0.35) 
210 0.00 
(0.00 - 0.10) 
2 1.054 0.590 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table F15: Change in pacemaker parameters in relation to previous radiation therapy exposure – chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
Yes No Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude 
(V) 4
# 8 38 52 105 102 - - - 
Output Amplitude (V) 1# 11 16 72 46 164 - - - 
Events 0# 8 2# 54 0# 128 - - - 
Key: χ2 = chi-square value 
# cells containing less than 5 
 
- test could not be performed due to small numbers 
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F.8 Pacemaker lead type 
Table F16: Change in pacemaker parameters in relation pacemaker lead type- Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
RV Lead RA Lead RV Lead RA Lead 
df χ2 p value n= Median (Range) 
n= Median 
(Range) 
n= Median 
(Range) 
n= Median  
(Range) 
Battery (V) 57 0.00 
(-0.05 - 0.03) 
2 0.00 
(0.00) 
89 0.00 
(-0.03 - 0.06) 
0 NA 3 1.827 0.598 
Signal Amplitude 
(mV) 
47 0.00 
(-4.48 - 4.40) 
38 0.00 
(-2.50 - 4.20) 
105 0.00 
(-11.60 -8.00) 
79 0.00 
(-2.60 - 2.20) 
3 0.926 0.569 
Impedance (Ω) 60 0.00 
(-193.0 - 90.0) 
42 -4.50 
(-90.0 - 86.0) 
128 0.00 
(-201.0 - 210.0) 
82 -1.50 
(-232.0 - 287.0) 
3 4.239 0.988 
Capture Threshold 
Amplitude (V) 
61 0.00 
(-0.68 - 0.50) 
41 0.00 
(-0.50 - 0.25) 
128 0.00 
(-0.63 - 0.75) 
79 0.00 
(-0.60 - 1.50) 
3 4.607 0.227 
Capture Threshold 
pulse width (ms) 
61 0.00 
(0.00) 
43 0.00 
(0.00) 
128 0.00 
(0.00 - 0.05) 
82 0.00 
(0.00 - 0.05) 
3 1.835 0.766 
Output Amplitude 
(V) 
59 0.000.00 
(-1.40 - 1.38) 
41 0.00 
(-1.20 - 0.40) 
128 0.00 
(-3.00 - 1.13) 
82 0.00 
(-2.00 - 2.00) 
3 2.481 0.399 
Output pulse width 
(ms) 
58 0.00 
(0.00 - 0.35) 
41 0.00 
(0.00) 
128 0.00 
(0.00 - 0.10) 
82 0.00 
(0.00) 
3 6.770 0.283 
Key: RV = Right ventricle; RA = Right Atrium; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = 
chi-square value
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Table F17: Change in pacemaker parameters in relation to pacemaker lead type – chi square analysis 
 Radiation Therapy Group Control Group    
RV Lead RA Lead RV Lead RA Lead 
χ2 Cramer’s V 
p 
value n= n= n= n= 
Yes No Yes No    No 
Capture Threshold Amplitude 
(V) 28 33 14 27 70 58 35 44 5.968 0.139 0.113 
Output Amplitude (V) 13 46 4# 37 34 94 12 70 - - - 
Events 2# 60 0# 2# 0# 128 2# 190 - - - 
Key: RV = right ventricle; RA = right atrium;; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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Appendix G: Statistical Analysis of Case Control ICD Observational Study 
G.1 Treatment Energy (ICD) 
Table G1: Change in ICD parameters in relation to radiation therapy treatment energy - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
RT - 6MV±MeV/MeV 
only RT - 18MV±6MV Control df χ2 p value n= Median   
(Range) 
n= Median  
(Range) 
n= Median  
(Range) 
Battery (V) 11 -0.01 
(-0.04 - 0.00) 
3 -0.01 
(-0.05 - 0.02) 
30 -0.05 
(-0.24 - 0.00) 
2 3.529 0.171 
Signal Amplitude (mV) 15 0.00 
(-3.80 - 5.90) 
6 -0.25 
(-1.30 - 1.40) 
42 0.00 
(-2.70 - 7.80) 
2 0.545 0.761 
Impedance (Ω) 16 -6.50 
(-80.00 - 264.00) 
6 -5.00 
(-32.00 - 21.00) 
44 0.00 
(-272.00 - 72.00) 
2 1.409 0.494 
Capture Threshold 
Amplitude (V) 
11 0.00 
(-0.20 - 0.50) 
6 0.00 
(-0.25 - 0.20) 
42 0.00 
(-1.00 - 0.50) 
2 0.316 0.854 
Capture Threshold pulse 
width (ms) 
11 0.00 
(0.00) 
6 0.00 
(-0.10 - 0.00) 
42 0.00 
(-0.3 - 0.60) 
2 1.711 0.425 
Output Amplitude (V) 16 0.00 
(0.00) 
5 -0.10 
(-1.00 - 0.00) 
44 0.00 
(-1.00 - 0.30) 
2 9.465 0.009* 
Output pulse width (ms) 16 0.00 
(-0.60 - 0.10) 
5 0.00 
(0.00) 
44 0.00 
(0.00 - 0.06) 
2 1.819 0.403 
Key: MV = photons; MeV = electrons; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-
square value 
*significant result
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Table G2: Change in ICD parameters in relation radiation therapy treatment energy – Chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
RT - 6MV±MeV/MeV 
only RT - 18MV±6MV 
Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude 
(V) 
5 6 2# 4# 15 27 - - - 
Output Amplitude (V) 0# 16 3# 2# 7 37 - - - 
Events 1# 15 2# 4# 0# 44 - - - 
Key = MV = photons; MeV = electrons; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.2 Measured maximum TLD dose to ICDs 
Table G3: Change in ICD parameters in relation to measured maximum TLD dose to ICD - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
<1Gy ≥1Gy Expected high 
dose 
Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range 
Battery (V) 11 -0.01 
(-0.18 - 0.02) 
2 -0.01 
(-0.01 - 0.00) 
1 -0.02 
(-0.02) 
30 -0.05 
(-0.24 - 0.00) 
3 4.182 0.242 
Signal Amplitude 
(mV) 
15 0.00 
(-3.80 - 4.00) 
3 -0.80 
(-1.20 - 5.90) 
3 1.10 
(-2.30 - 3.70) 
42 0.00 
(-2.70 - 7.80) 
3 0.460 0.928 
Impedance (Ω) 16 -9.00 
(-80.00 - 
264.00) 
3 0.00 
(-41.00 - 
140.00) 
3 -5.00 
(-76.00 -
 -3.00) 
44 0.00 
(-272.00 - 
72.00) 
3 2.296 0.513 
Capture Threshold 
Amplitude (V) 
11 0.00 
(-0.25 - 0.20) 
3 0.10 
(0.00 - 0.40) 
3 -0.10 
(-0.20 - 0.50) 
42 0.00 
(-1.00 - 0.50) 
3 3.230 0.357 
Capture Threshold 
pulse width (ms) 
11 0.00 
(-0.10 - 0.00) 
3 0.0 
(0.00) 
3 0.00 
(0.00) 
42 0.00 
(-0.3 - 0.60) 
3 1.030 0.794 
Output Amplitude 
(V) 
15 0.00 
(-0.50 - 0.00) 
3 0.00 
(0.00) 
3 0.00 
(0.00) 
44 0.00 
(-1.00 - 0.30) 
3 1.538 0.674 
Output pulse 
width (ms) 
15 0.00 
(-0.60 - 0.00) 
3 0.00 
(0.00) 
3 0.00 
(0.00) 
44 0.00 
(0.00 - 0.06) 
3 1.874 0.599 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table G4: Change in ICD parameters in relation to measured TLD accumulated dose to ICD – chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control 
Group 
 
<1Gy ≥1Gy Expected 
high dose 
Control 
χ2 Cramer’s V 
p value n= n= n= n= 
Yes No Yes No Yes No Yes No 
Capture Threshold Amplitude 
(V) 
2# 9 2# 1# 3# 0# 15 27 - - - 
Output Amplitude (V) 3# 12 0# 3# 0# 3# 7 37 - - - 
Events 3# 13 0# 3# 0# 3# 0# 44 - - - 
Key: Gy = Gray; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.3 Estimated maximum dose to ICD leads 
Table G5: Change in ICD parameters in relation to estimated maximum dose to ICD leads - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
Low dose (out of scan) ≥25Gy Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
Battery (V) 9 -0.10 
(-0.18 - 0.00) 
5 -0.01 
(-0.05 - 0.02) 
30 -0.05 
(-0.24 - 0.00) 
2 3.557 0.169 
Signal Amplitude (mV) 14 0.55 
(-3.80 - 4.00) 
7 -0.50 
(-2.30 - 5.90) 
42 0.00 
(-2.70 - 7.80) 
2 1.227 0.542 
Impedance (Ω) 15 -10.00 
(-80.00 - 264.00) 
7 0.00 
(-76.00 - 140.00) 
44 0.00 
(-272.00 - 
72.00) 
2 2.304 0.316 
Capture Threshold 
Amplitude (V) 
10 0.00 
(-0.25 - 0.00) 
7 0.10 
(0.00 - 0.50) 
42 0.00 
(-1.00 - 0.50) 
2 7.752 0.021* 
Capture Threshold 
pulse width (ms) 
10 0.00 
(-0.10 - 0.00) 
7 0.00 
(0.00) 
42 0.00 
(-0.3 - 0.60) 
2 1.112 0.573 
Output Amplitude (V) 14 0.00 
(-0.10 - 0.00) 
7 0.00 
(-1.00 - 0.00) 
44 0.00 
(-1.00 - 0.30) 
2 0.419 0.811 
Output pulse width (ms) 14 0.00 
(-0.60 - 0.00) 
7 0.00 
(0.00) 
44 0.00 
(0.00 - 0.06) 
2 1.935 0.380 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table G6: Change in ICD parameters in relation to estimated maximum dose to ICD leads – Chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control 
Group 
 
Low dose (out of 
scan) 
≥25Gy Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude 
(V) 
3# 7 4# 3# 15 27 - - - 
Output Amplitude (V) 2# 12 1# 6 7 37 - - - 
Events 3# 12 0# 7 0# 44 - - - 
Key: Gy = Gray; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.3.1 Calculations for capture threshold amplitude significance in 
relation to estimated maximum dose to leads (ICD) 
 
 Bonferroni Adjustment:  
New α = previous α/number of tests performed (where α = significance level) 
α=0.05/2 
New significance level α = 0.025 
Table G7: Comparison of capture threshold amplitude (V) significance to 
greater than 20Gy RT Group 
  n= U Z r p value 
Radiation Therapy Group 
>25Gy 7     
Low dose 10 10.5 -2.677 0.65 0.007* 
Control Group Control 42 82.5 -2.101 0.30 0.036 
Key: U = Mann-Whitney U value; r = effect size 
*significant result at α=0.025 
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G.4 Estimated maximum dose to heart (ICD) 
Table G8: Change in ICD parameters in relation to estimated maximum dose to heart (ICD) - Kruskall Wallis analysis 
 Radiation Therapy Group Control Group  
Change 
(check 2 - check 1) 
Low dose  
(out of scan) 
≥20Gy Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
Battery (V) 11 -0.10 
(-0.18 - 0.02) 
3 -0.01 
(-0.05 - 0.00) 
30 -0.05 
(-0.24 - 0.00) 
2 3.535 0.171 
Signal Amplitude 
(mV) 
17 0.00 
(-3.80 - 4.00) 
4 -0.40 
(-1.20 - 5.90) 
42 0.00 
(-2.70 - 7.80) 
2 0.313 0.855 
Impedance (Ω) 18 -9.00 
(-80.00 - 264.00) 
4 5.00 
(-41.00 - 140.00) 
44 0.00 
(-272.00 - 72.00) 
2 2.402 0.301 
Capture Threshold 
Amplitude (V) 
13 0.00 
(-0.25 - 0.50) 
4 0.05 
(0.00 - 0.40) 
42 0.00 
(-1.00 - 0.50) 
2 2.305 0.316 
Capture Threshold 
pulse width (ms) 
13 0.00 
(-0.10 - 0.00) 
4 0.00 
(0.00) 
42 0.00 
(-0.3 - 0.60) 
2 0.905 0.636 
Output Amplitude 
(V) 
17 0.00 
(-0.50 - 0.00) 
4 0.00 
(-1.00 - 0.00) 
44 0.00 
(-1.00 - 0.30) 
2 0.972 0.615 
Output pulse width 
(ms) 
17 0.00 
(-0.60 - 0.10) 
4 0.00 
(0.00) 
44 0.00 
(0.00 - 0.06) 
2 1.772 0.412 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table G9: Change in ICD parameters in relation to estimated maximum dose to heart (ICD) – chi square analysis 
 Radiation Therapy Group Control Group  
Low dose 
(out of scan) 
≥20Gy Control 
χ2 Cramer’s V p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold 
Amplitude (V) 5 8 2# 2# 15 27 - - - 
Output Amplitude (V) 2# 15 1# 3# 7 37 - - - 
Events 3# 15 0# 4# 0# 44 - - - 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.5 Radiation Therapy treatment intent (ICD) 
Table G10: Change in ICD parameters in relation to radiation therapy treatment intent - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
Curative Palliative Control 
df χ2 p value n= Median (Range) 
n= Median 
(Range)  
Median 
(Range) 
Battery (V) 8 -0.10 
(-0.05 - 0.02) 
6 -0.10 
(-0.18 - 0.00) 
30 -0.05 
(-0.24 - 0.00) 
2 3.955 0.138 
Signal Amplitude (mV) 12 -0.25 
(-2.30 - 5.90) 
9 0.00 
(-3.80 - 4.00) 
42 0.00 
(-2.70 - 7.80) 
2 0.387 0.824 
Impedance (Ω) 12 -4.00 
(-76.00 - 140.00) 
10 -14.00 
(-80.00 - 264.00) 
44 0.00 
(-272.00 - 72.00) 
2 1.375 0.503 
Capture Threshold Amplitude 
(V) 
12 0.00 
(-0.25 - 0.50) 
5 0.00 
(0.00) 
42 0.00 
(-1.00 - 0.50) 
2 0.154 0.926 
Capture Threshold pulse 
width (ms) 
12 0.00 
(-0.10 - 0.00) 
5 0.00 
(0.00) 
42 0.00 
(-0.3 - 0.60) 
2 0.962 0.618 
Output Amplitude (V) 11 0.00 
(-0.10 - 0.00) 
10 0.00 
(0.00) 
44 0.00 
(-1.00 - 0.30) 
2 2.979 0.225 
Output pulse width (ms) 11 0.00 
(0.00) 
10 0.00 
(-0.60 - 0.00) 
44 0.00 
(0.00 - 0.06) 
2 2.307 0.316 
Key: V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table G11: Change in ICD parameters in relation to radiation therapy treatment intent – chi square analysis 
 Radiation Therapy Group Control Group  
Curative Palliative Control 
χ2 Cramer’s V p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude (V) 7 5 0# 5 15 27 - - - 
Output Amplitude (V) 3# 8 0# 10 7 37 - - - 
Events 2# 10 1# 9 0# 44 - - - 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.6 Radiation Therapy technique (ICD) 
Table G12: Change in ICD parameters in relation to radiation therapy technique - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
3D-CRT IMRT Control 
df χ2 p value n= Median (Range) 
n= Median 
(Range) 
n= Median (Range) 
Battery (V) 13 -0.10 
(-0.18 - 0.02) 
1 -0.20 
(-0.20) 
30 -0.05 
(-0.24 - 0.00) 
2 3.851 0.146 
Signal Amplitude (mV) 18 0.00 
(-3.80 - 5.90) 
3 1.10 
(-2.30 - 3.70) 
42 0.00 
(-2.70 - 7.80) 
2 0.272 0.873 
Impedance (Ω) 19 -8.00 
(-80.0 - 264.0) 
3 -5.00 
(-76.0 - -3.0) 
44 0.00 
(-272.00 - 72.00) 
2 2.045 0.360 
Capture Threshold 
Amplitude (V) 
14 0.00 
(-0.25 - 0.40) 
3 -0.10 
(-0.20 - 0.50) 
42 0.00 
(-1.00 - 0.50) 
2 0.598 0.742 
Capture Threshold pulse 
width (ms) 
14 0.00 
(0.00) 
3 0.00 
(0.00) 
42 0.00 
(-0.3 - 0.60) 
2 0.855 0.652 
Output Amplitude (V) 18 0.00 
(-1.00 - 0.00) 
3 0.00 
(0.00) 
44 0.00 
(-1.00 - 0.30) 
2 0.878 0.645 
Output pulse width (ms) 18 0.00 
(-0.60 - 0.10) 
3 0.00 
(0.00) 
44 0.00 
(0.00 - 0.06) 
2 1.729 0.421 
Key: 3D-CRT = three dimensional conformal radiation therapy; IMRT = intensity modulated radiation therapy; V=Volts; mV = 
millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table G13: Change in ICD parameters in relation to radiation therapy technique – chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
3D-CRT IMRT Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude (V) 4# 10 3# 0# 15 27 - - - 
Output Amplitude (V) 3# 15 0# 3# 7 37 - - - 
Events 3# 16 0# 3# 0# 44 - - - 
Key: 3D-CRT = three dimensional conformal radiation therapy; IMRT = intensity modulated radiation therapy; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.7 Previous radiation therapy exposure (ICD) 
Table G14: Change in ICD parameters in relation to previous radiation therapy exposure - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group    
Yes No Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
Battery (V) 3 -0.01 
(-0.04 - 0.00) 
11 -0.10 
(-0.18 - 0.02) 
30 -0.05 
(-0.24 - 0.00) 
2 3.500 0.174 
Signal Amplitude 
(mV) 
4 -0.90 
(-3.80 - 1.40) 
17 0.00 
(-2.30 - 5.90) 
42 0.00 
(-2.70 - 7.80) 
2 2.536 0.281 
Impedance (Ω) 4 -12.00 
(-80.00 - 56.00) 
18 -6.50 
(-80.00 - 
264.00) 
44 0.00 
(-272.00 - 72.00) 
2 1.376 0.503 
Capture Threshold 
Amplitude (V) 
2 0.00 
(0.00) 
15 0.00 
(-0.25 - 0.50) 
42 0.00 
(-1.00 - 0.50) 
2 0.089 0.957 
Capture Threshold 
pulse width (ms) 
2 0.00 
(0.00) 
15 0.00 
(-0.10 - 0.00) 
42 0.00 
(-0.3 - 0.60) 
2 0.813 0.666 
Output Amplitude (V) 4 0.00 
(0.00) 
17 0.00 
(-1.00 - 0.00) 
44 0.00 
(-1.00 - 0.30) 
2 1.072 0.585 
Output pulse width 
(ms) 
4 0.00 
(-0.60 - 0.00) 
17 0.00 
(-0.20 - 0.10) 
44 0.00 
(0.00 - 0.06) 
2 4.257 0.119 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table G15: Change in ICD parameters in relation to previous radiation therapy exposure – chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
Yes No Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude 
(V) 0
# 2# 7 8 15 27 - - - 
Output Amplitude (V) 0# 4# 3# 14 7 37 - - - 
Events 1# 3# 2# 16 0# 44 - - - 
Key: χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.8 ICD lead type 
Table G16: Change in ICD parameters in relation ICD lead type- Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
RV Lead RA Lead LV Lead RV Lead RA Lead LV Lead 
df χ2 p value n= Median (Range) 
n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
n= Median  
(Range) 
n= Median  
(Range) 
Battery (V)                
Signal Amplitude 
(mV) 
15 -0.50 
(-3.80 - 
5.90) 
6 0.75 
(-0.80 - 
1.60) 
- - 29 0.00 
(-2.70 - 
6.10) 
11 0.00 
(-1.70 - 
7.80) 
- - 3 1.794 0.616 
Impedance (Ω) 15 -3.00 
(-80.00 - 
264.00) 
6 -12.50 
(-40.00 - 
21.00) 
1 -8.00 
(-8.00) 
30 0.00 
(-272.00 
- 72.00) 
12 6.50 
(-30.00 - 
55.00) 
2 -4.00 
(-8.00-
0.00) 
5 2.337 0.801 
Capture 
Threshold 
Amplitude (V) 
12 0.00 
(-0.25 - 
0.50) 
5 0.00 
(-0.20 - 
0.40) 
- - 30 0.00 
(-1.00 - 
0.50) 
10 0.00 
(-0.50 - 
0.20) 
2 0.10 
(0.00 - 
0.02) 
4 1.895 0.755 
Capture 
Threshold pulse 
width (ms) 
12 0.00 
(-0.10 - 
0.00) 
5 0.00 
(0.00) 
- - 30 0.00 
(0.00 - 
0.60) 
10 0.00 
(-0.30 - 
0.00) 
2 -0.15 
(-0.30 - 
0.00) 
4 9.651 0.047* 
Output Amplitude 
(V) 
14 0.00 
(-1.00 - 
0.00) 
6 0.00 
(0.00) 
1 0.00 
(0.00) 
30 0.00 
(-1.00 - 
0.10) 
12 0.00 
(-0.50 - 
0.30) 
2 0.00 
(0.00) 
5 2.580 0.764 
Output pulse 
width (ms) 
14 0.00 
(0.00 - 
0.10) 
6 0.00 
(-0.60 - 
0.00) 
1 -0.20 
(-0.20) 
30 0.00 
(0.00 - 
0.60) 
12 0.00 
(0.00) 
2 0.00 
(0.00) 
5 16.802 0.005* 
Key: RV = Right ventricle; RA = Right Atrium; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = 
chi-square value 
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Table G17: Change in ICD parameters in relation to ICD lead type – chi square analysis 
 Radiation Therapy Group Control Group     
RV Lead RA Lead LV Lead RV Lead RA Lead LV Lead 
χ2 Cramer’s V 
p 
value n= n= n= n= n= n= 
Yes No Yes No Yes No Yes No Yes No Yes No 
Capture Threshold 
Amplitude (V) 
4# 8 3# 2# - - 11 19 3# 7 1# 1# - - - 
Output Amplitude (V) 3# 11 0# 6 0# 1# 5 25 2# 10 0# 2# - - - 
Events                
Key: RV = right ventricle; RA = right atrium;; χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
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G.9 Magnet used during radiation therapy exposure (ICD) 
Table G18: Change in ICD parameters in relation to magnet use during radiation therapy exposure - Kruskall Wallis analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group    
Yes No Control 
df χ2 p value n= Median 
(Range) 
n= Median 
(Range) 
n= Median 
(Range) 
Battery (V) 3 0.00 
(-0.02 - 0.02) 
11 -0.01 
(-0.18 - 0.00) 
30 -0.05 
(-0.24 - 0.00) 
2 3.500 0.174 
Signal Amplitude (mV) 4 -0.50 
(-2.30 - 4.00) 
17 0.00 
(-3.80 - 5.90) 
42 0.00 
(-2.70 - 7.80) 
2 2.536 0.281 
Impedance (Ω) 4 0.00 
(-76.00 - 264.00) 
18 -8.00 
(-80.00 - 
140.00) 
44 0.00 
(-272.00 - 72.00) 
2 1.376 0.503 
Capture Threshold 
Amplitude (V) 
2 0.00 
(-0.25 - 0.50) 
15 0.00 
(-0.20 - 0.40) 
42 0.00 
(-1.00 - 0.50) 
2 0.089 0.957 
Capture Threshold pulse 
width (ms) 
2 0.00 
(0.00) 
15 0.00 
(-0.10 - 0.00) 
42 0.00 
(-0.3 - 0.60) 
2 0.813 0.666 
Output Amplitude (V) 4 0.00 
(-0.50 - 0.00) 
17 0.00 
(-0.10 - 0.00) 
44 0.00 
(-1.00 - 0.30) 
2 1.072 0.585 
Output pulse width (ms) 4 0.00 
(0.00) 
17 0.00 
(-0.60 - 0.10) 
44 0.00 
(0.00 - 0.06) 
2 4.257 0.119 
Key: Gy = Gray; V=Volts; mV = millivolts; Ω = Ohm; ms = milliseconds; df = degree of freedom; χ2 = chi-square value 
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Table G19: Change in ICD parameters in relation to magnet use during radiation therapy exposure – chi square analysis 
Change 
(check 2 - check 1) 
Radiation Therapy Group Control Group  
Yes No Control 
χ2 Cramer’s V 
p value n= n= n= 
Yes No Yes No Yes No 
Capture Threshold Amplitude (V) 3# 2# 4# 8 15 27 - - - 
Output Amplitude (V) 1# 4# 2# 14 7 37 - - - 
Events 0# 5 3# 14 0# 44 - - - 
Key: χ2 = chi-square value 
#  cells containing less than 5 
- test could not be performed due to small numbers 
 
